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Summary
The objective of this thesis Is to determine the role of specific PKC isotypes 
during B cell development and transformation. B cell generation systems were 
validated both in vitro and in vivo, by coculturing haematopoietic progenitor cells 
(HPCs) on the calvanial cell line, 0P9, or by adoptively transferring HPCs into 
recombinase-activating gene 1 -deficient (RAG-TD mice, respectively. In both 
cases, mature B cells were generated as determined by analysing surface B 
cell marker expression. Coupling of these in vitro and in vivo B cell generation 
systems with a retroviral gene transfer technique, plasmids-encoding PKC 
mutants in the retroviral vector MIEV were stably expressed in foetal liver (FL)~ 
derived HPCs from wild type mice and cultured to assess the ability of individual 
PKC isoforms to modulate the development or transformation of B cells. Of 
note, expression of a plasmid-encoding dominant negative PKCa (PKCa-KR) in 
HPCs and placement in B cell generation system in vitro or in vivo resulted in 
the generation of a population of cells that displayed an enhanced proliferative 
capacity. Analysis of PKCa-KR-expressing cells in vitro revealed that these 
cells incorporated BrdU significantly more than the MIEV control, and 
unexpectedly upregulated cell cycle regulators, p21'"^ '^  ^ and p27‘"''^ 'k Of surprise, 
PKCa-KR-expressing cells phenotypically resemble human B cell chronic 
lymphocytic leukaemia (CLL) cells. Expression of constitutively active PKCa, 
PKCa-CAT, or dominant negative PKC^, PKC^-KR in HPCs caused significant 
decrease in cell number.
CLL is characterised by the accumulation of long-lived phenotypically mature B 
cells with the distinctive phenotype: CD19'^', CD5^, CD23'', IgM^™, which are 
deficient in apoptosis and have undergone cell cycle arrest in the Gq/G i phase. 
Closer analysis of PKCa-KR-expressing cells uncovered that these cells 
undergo cell cycle arrest in the absence of growth factors and stroma and 
consistent with their ability to escape growth factor withdrawal-induced 
apoptosis, exhibited elevated levels of Bel-2 and Mcl-1 expression. Upon 
stimulation with IL-7, PKCa-KR-expressing cells showed explosive proliferation,
suggesting that IL-7 is a proliferation factor for these cells. In accordance with 
this, IL-7R expression was upregulated in these cells, which may contribute to 
the increased sensitivity to IL-7. Mice injected with wildtype PKCa-KR-HPCs 
bore solid intraperitonial tumours at the injection site and the cells from both 
tumour and spleen showed CLL-like phenotype. Interestingly, splenocytes from 
these mice were cycling whereas the tumour cells were arrested at the Go/G^ 
stage, probably reflecting the two phases of this disease, a quiescent stage and 
an extensive proliferative stage, respectively. The expansion of the leukaemic 
cells was halted when they were cultured on 0P9-D L1, 0P 9 cells with ectopic 
expression of Notch ligand, DL1, suggesting that Notch signalling mediates 
tumour suppression in CLL cells.
As PI3K and ERK-MAPK pathways have been implicated in mediating the 
survival of human CLL cells, cellular and molecular mechanisms that govern the 
initiation and maintenance of CLL were investigated. MIEV- and PKCa-KR- 
expressing cells were treated with pharmacological inhibitors, LY294002 and 
U0126, against PI3K- and ERK-MAPK- mediated pathways respectively, and 
the amount of apoptosis was analysed by Annexin V staining. MIEV-expressing 
cells increased apoptosis followingLY294002 treatment, in agreement with AKT 
phosphorylation in MIEV-expressing cells, whereas this inhibitor also induced 
apoptosis in PKCa-KR-expressing cells although AKT phosphorylation was not 
detected in these cells. Analysis of ERK phosphorylation in MIEV- and PKCa- 
KR-expressing cells revealed that while ERK1 and 2 remained just weakly 
phosphorylated in MIEV-expressing cells throughout the culture period, ERK1 
was phosphorylated during the early stage of PKCa-KR-HPCs culture and both 
ERK1 and 2 were constitutively phosphorylated in longer cultured PKCa-KR- 
expressing cells. However, neither MIEV- nor PKCa-KR-expressing cells were 
affected upon treatment with U0126 compared with DMSO treated controls. In 
contrast, a cell line derived from PKCa-KR-expressing cells, M-1, underwent 
apoptosis in the presence of U0126, however, phosphorylation in ERK1 or 2 
was not detected in this cell line. Collectively, these studies suggest that PI3K-
111
and ERK-MAPK signalling pathways are differentially-regulated to induce 
survival during the progression of CLL cells.
In an effort to identify the developmental stage at which B lineage cells are 
susceptible to transformation, RAG-T^'-derived HPCs were retrovirally infected 
with either vector control, MIEV, or PKCa-KR and then placed into B cell 
generation systems in vitro or in vivo. RAG-T^' mice lack the ability to generate 
mature B lymphocytes because they are blocked at the late pro-B cell stage due 
to an inability to initiate recombination at the immunoglobulin heavy chain gene 
locus. Therefore, the onset of leukaemiagenesis in these HPCs suggests that 
CLL originates from an early B lineage cell or HPC population. Of interest, flow 
cytometric analysis of the cells from either the in vitro HPC-0P9 cocultures or 
the lymph node (LN) of the reconstituted RAG-T^ mice in vivo, revealed that a 
similar population of CLL-like cells (CD23L CD5’"'CD19^') was generated from 
RAG-T^' mouse-derived HPCs as observed from wildtype mouse-derived HPCs. 
Hence, these results suggest that PKCa-mediated development of CLL occurs 
at a very early stage of B ceil development, and challenges current dogma 
indicating that CLL is commonly considered to arise from an outgrowth of a 
mature subset of B lymphocytes.
Overall, this thesis identifies a unique oncogenic trigger for the development of 
a CLL-like disease resulting from the subversion of PKCa signalling.
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Chapter 1 : 
Introduction
1.1 The humoral immune system
The innate and adaptive immune systems together provide a remarkably 
effective defence system. A specific immune response, such as the production 
of antibodies against a particular pathogen, is known as an adaptive immune 
response, which confers lifelong protective immunity to re-infection with the 
same pathogen in many cases. Innate immunity, on the other hand, provides a 
front line of host defence through effector mechanisms that engage the 
pathogen directly, act immediately, and are unaltered in their ability to resist a 
subsequent challenge with either the same or a different pathogen. Many 
infections are handled successfully by the innate immune system and cause no 
disease; others that cannot be resolved by innate immunity trigger an adaptive 
immune response and are then overcome successfully, followed by lasting 
immunological memory (Janeway et al, 2001).
Adaptive immunity is triggered when the numbers of a pathogen exceed the 
threshold dose of antigen required for an adaptive response and thereby an 
infection eludes the innate defence mechanisms. Several days are required 
for antigen-specific T cells and B cells to locate their specific foreign antigen, 
proliferate, and differentiate into armed effector cells. Adaptive immunity f
mainly consists of CD8^ T cell-mediated immunity and B cell-mediated humoral 
immunity. The production of antibody usually requires the action of CD4’" 
helper T cells that are specific for a peptide fragment of the antigen recognised 
by the B cell. The B cell then proliferates and differentiates, first at the T to B 
zone boundary in secondary lymphoid tissues and later in the germinal centre 
(GC), where somatic hypermutation diversifies the B-cell receptors expressed 
by a clone of B cells. GD4^ helper T cells also direct both the production of 
antibody by B cells and the isotype that determines the effector function 
(Janeway et al, 2001).
The humoral immune response to infection involves the production of antibody 
by plasma cells derived from B lymphocytes, binding of this antibody to the 
pathogen, and subsequent elimination of the pathogen. Antibodies contribute
to immunity in three main ways, neutralisation, opsonisation and complement 
activation. Neutralisation is a process by which antibody binding to pathogen, 
such as viruses and intracellular bacteria, can prevent their binding to specific 
molecules on the cell surface, thus preventing entry into the host cells. 
Opsonisation is the process that results in antibodies coating the pathogen and 
being recognised as foreign by phagocytotic cells. The phagocytotic cells then 
bind to the antibody constant C region by Fc receptors, thus facilitating 
pathogen phagocytosis. Antibodies binding to the surface of a pathogen can 
also activate the complement system, which results in complement proteins 
being bound to the pathogen surface. This enhances opsonisation of the 
pathogen by phagocytes that bind to the pathogen-complement complex via 
complement receptors or even lyses certain microorganisms directly by forming 
pores in their membranes (Janeway et al, 2001).
1.2 B cell development
B cells consist of three different populations, B-1 a, B-1 b and B-2. The B-1 a/B- 
1 b/B-2 nomenclature is based predominantly on surface phenotypic criteria, 
expression of IgM and/or IgD and/or CD5; B-1 a cells are IgM^', igD'° ‘^, CDS" ;^ B- 
1b cells are IgM*"', lgD'° ‘^, CD5'°^'; B-2 cells are lgM'°, IgD*"', CDS' (Hayakawa and 
Hardy, 2000). In this thesis, B cell describes B-2 cells unless otherwise stated.
1.2.1 B-2 cell development
The development of B cells from committed progenitors into differentiated 
plasma cells is a multistep process, involving the ordered expression of various 
genes. Mouse B cell development can be divided into several stages based 
on the rearrangement status of the immunoglobulin (Ig) genes and the 
expression of specific cell markers. Currently, two nomenclatures are used to 
define the B cell developmental stages: the Hardy (Philadelphia) (Hardy et al, 
1991, Hardy and Hayakawa, 2001) and the Rolink/Melchers (Basel) (Osmond et 
al, 1998) classification (Table 1.1). In this thesis, the Hardy nomenclature is 
used. The surface developmental markers are shown in Figure 1.1.
Fraction A B/C O' D E F
Hardy
(Philadelphia) pre-pro-B pro-B Early pre-B Late pre-B immature-B Mature-B
Rolink (Basel) pro-B Pre-BI Transitionalpre-Bl Large-pre-Bli Small pre-BlI Immature-B iransmonal- Mature-B
BCR expression C|0 Pre-BCR* Pre-BCR* BCR*
IgH locus Germllne D-Jrearranging
V-DJ
rearranging VDJ VDJ
IgL locus Germllne Germllne Germllne Germllne V-Jrearranging VJ
Table 1.1 Names for B cell stages and Ig rearrangement status
Modified from Annu. Rev. Immunol. (2001); 19: 595-621.
Figure 1.1 Diagram of B lineage development In mouse
B cell development from CLP to B cell committed stages is delineated. 
Concomitant expression of cell surface markers and B-lineage genes are shown. 
Relative expression levels are indicated by line thickness. Abbreviation 
definitions are included in the text. TdT, terminal deoxynucleotidyl transferase.
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In the mouse, B cells are generated from pluripotent haematopoietic stem cells 
(HSCs) in the liver during foetal development and in the bone marrow (BM) after 
birth. A population of Lin' IL-7R+ Thy-1' Sca-1'° c-kit'° cells was discovered as a 
common lymphoid progenitor (CLP) subset that is a lymphoid-restricted (T, B 
and NK) progenitor cell (Kondo et al, 1997). Following the CLP stage, the very 
early B lineage is recognised by expression of B220 (CD45R) and lack of CD19 
(Li et al, 1996). At the next, pro-B cell stage, the cells start to rearrange D 
(diversity) to J (joining) gene segments on both alleles of the immunoglobulin 
(Ig) heavy (H) chain loci and express CD19 and the disulphide-linked Iga and 
Igp (CD79a and CD79b) heterodimers on the surface as invariant signal- 
transducing subunits together with calnexin, a chaperone protein (Nagata et al,
1997). Subsequently, the cells begin rearranging Vh (variable) to DhJh on 
individual alleles and express p.H chain in the cytoplasm (cp) (Benschop and 
Cambier, 1999). V(D)J recombination is initiated by recognising recombination 
signal sequences which flank V, D and J segments by recombination-activating 
gene (RAG) 1 and 2, expressing only in lymphocytes (Notarangelo et al, 1999). 
Progression to the early-pre-B cell stage is accompanied by surface expression 
of pre-B cell receptor (BCR), which is formed by pH chain and surrogate light 
(SL) chain; VpreB and X5, associated with Iga and !g(3. The cells 
down regulate GD117 and GD43, and upregulate GD25 and GD24. Among 
cells expressing VDJh/DJh recombined alleles, when the VDJn-recombined 
allele is functional, the second IgH allele is no longer available for to DJ^ 
rearrangements and thereby this pH chain from the first IgH allele is expressed 
on the cell surface as a pre-BGR, a process known as allelic exclusion 
(Melchers et al, 1999). In 2-4 % of cells carrying two productively VhDJh- 
rearranged IgH chain loci, however, only one of these can pair with SL chain 
and therefore allelic exclusion is maintained at the level of pre-BGR expression 
(ten Boekel et al, 1998). Due to the induction of proliferation by surface 
expression of pre-BGR, the cells divide several times and differentiate into small 
late-pre-B cells (Rolink et al, 2000), which rearrange V ^ J l  ( k  and X) at the light 
(L) chain locus (Hardy and Hayakawa, 2001). When this is accomplished, the 
cells express the newly synthesised IgL chain together with pH chain as a BGR;
IgM, and progress to the immature-B cell stage. During progression from 
immature to mature B cells, there is a checkpoint to scrutinise their BCR. 
Encounter of immature B cells with antigen capable of cross-linking their BCR 
leads to one of three results; i) clonal deletion by high-affinity interactions; ii) 
anergy; iii) revision of their BGR to eliminate self-reactivity by editing. Unless 
the BGR is auto-reactive, the cells can leave the BM and migrate to peripheral 
lymphoid organs, where they differentiate into mature B cells expressing levels 
of IgD that exceed IgM (Havran et al, 1984), GD23 and GD21/35 (Hardy and 
Hayakawa, 2001).
In the peripheral organs, such as lymph nodes (LN) and spleen, mature but 
naïve B cells encounter an antigen, and most of them are activated in T cell 
dependent way. Antigen-activated B cells transform into larger B blasts, some 
differentiate short-living, IgM producing plasma cells for first-line defence and 
other B cells migrate to the primary B cell follicle and differentiate into GG B 
cells (MacLennan, 1994). GG B cells undergo somatic hypermutation, which is 
a process by which randomised mutations are introduced into the Ig gene 
region (Diaz and Gasali, 2002). GG cells with unfavourable mutations do not 
bind to the antigen with high affinity, which results in apoptosis. The positively 
selected GG B cells activate T cells to express GD40 ligand (GD40L) and 
secrete IL-4 and IL-10, which in turn induces the expansion and class switching 
of GG B cells (Sagaert and De Wolf-Peeters, 2003). After accomplishing 
affinity maturation and isotype switching, GG B cells may differentiate into either 
post GG B cells, such as plasma cells producing antibodies or memory B cells. 
The interaction of GD27 and GD40L with T cells is an important interaction in 
directing GG B cells to become memory cells (Liu and Banchereau, 1997).
1,2.2 B-1 cell development
B-1 cells were originally described as a type of distinctive foetal B cell 
developed in the mouse, different from B-2 cells generated in adult BM. B-1 
cells reside in the peritoneal cavity, pleural cavities and spleen. B-1 cells 
present In the peritoneal cavity express GDI 1b, however, this is not applicable
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to B-1 cells present in spleen (Berland and Wortis, 2002). B-1 cells develop de
novo and persist thereafter by self-renewal, while B-2 cells develop de novo and 
continue to enter the mature B-2 pool (Kantor and Herzenberg, 1993, Kantor et 
al, 1992). B-1 cells produce most of natural IgM, which is weakly autoreactive 
and reactive with many pathogen-associated carbohydrate antigens (Boes et al, 
1998, Hayakawa et al, 1999, Hayakawa et al, 1984), and contribute significantly 
to IgA producing plasma cells in the lamina propria of the gut (de Waard et al, 
1998, Kroese et al, 1993).
Regarding B-1 cell origin, there are two models available, the layered model 
and single-lineage model. The single-lineage model proposes that B-1 and B- 
2 cells derive from different, committed precursors and therefore represent two 
different lineages. The B-1 lineage is considered to be predominantly from 
foetal and the B-2 lineage from adult origin because only foetal liver (FL) could 
reconstitute mice with both the B-1 and B-2 cells, whereas adult BM could not 
generate B-1 cells (Kantor and Herzenberg, 1993). Alternatively the layered 
model is an induced-differentiation model, proposing that the B-1 lineage is a 
consequence of antigen-driven differentiation and selection (Berland and Wortis, 
2002). The decision to differentiate into the B-1 cells rather than B-2 cells 
reflects different responses of mature B cells to stimulation with the different 
types of antigens, therefore, when the cells have encountered repetitive 
antigens during neonatal life, these cells with BCR that recognises these 
antigens differentiate into the B-1 lineage. On the contrary, cells that have 
encountered exogenous antigens during adult life become B-2 cells and their 
BCR recognises these antigens (Herzenberg and Tung, 2006). Based on this 
hypothesis, B-2 cells can be converted into B-1 cells when they are stimulated 
via BCR in certain conditions (Herzenberg, 2000). However, a recent study 
has shown that B-1 and B-2 progenitors can be physically separated from each 
other (Montecino-Rodriguez et ai, 2006), as GDI 38 and major histocompatibility 
(MHG) class II molecule expression distinguishes the B-1 a, B-1b and B-2 cell 
progenitors during early B cell development (Tung et al, 2006). Therefore,
functionally distinct B cells appear to be divided into separate developmental 
lineages rather than induced by differentiation.
1.3 Early B cell development and transcription factors
B cell development requires the coordinate expression of a series of 
transcription factors to regulate sets of genes in each differentiation stage (Fig. 
1.2).
PU.1, a member of Ets transcription factor family, is crucial in the early stages 
of haematopoietic cell specification and essential for B cell development (Scott 
et al, 1997, Scott et al, 1994). Low concentrations of PU.1 induce B cell 
development, whereas high levels of PU .1 promote macrophage differentiation 
by suppressing the B cell fate (DeKoter and Singh, 2000). DeKoter et al., 
showed that PU.1 directly activates JL-7Ra (DeKoter et al, 2002), thereby 
functioning as a regulator in early B cell development.
Differentiation of CLPs into pro-B cells critically depends on three transcription 
factors, E2A, early B cell factor (EBF) and Pax5 (Busslinger, 2004, Hagman and 
Lukin, 2005). E2A encodes the basic helix-loop-helix proteins E l 2 and E47 
produced by alternative splicing (Busslinger, 2004). Both proteins are 
essential for pro-B cell development (Bain et al, 1997, Zhuang et al, 1998).
E2A as well as EBF synergistically regulate the transcription of many B cell 
specific genes including A5 (Sigvardsson, 2000, Sigvardsson et al, 1997),
VpreB (G\s\er and Sigvardsson, 2002), Iga (mb-1) (Sigvardsson et al, 2002), 
RAG-1 and HAG-2  (Goebel et al, 2001, Hsu et al, 2003, Romanow et al, 2000). 
Both E2A- and EBF-null mice result in very early blockade in B cell 
development (Bain et al, 1994, Lin and GrosschedI, 1995).
Studies in Pax5'^' mice showed that B cell development is arrested at an early 
pro-B cell stage (Urbanek et al, 1994) and pro-B cells from these mice can 
generate both myeloid and T lineage cells (Nutt et al, 1999, Rolink et al, 1999). 
These studies indicate that Pax5 (also known as B cell specific activator protein
Figure 1.2 Regulation of early B cell development
Multi-lineage precursor can adopt either myeloid or lymphoid cell fate 
depending on the level of PU.1 expression. CLPs develop into T cell lineage 
upon stimulation of Notch 1 signalling or else adopt a default B lineage. E2A 
and EBF facilitate B lineage commitment and Pax5 functions in pro-B cell to 
pre-B cell progression by suppressing alternative cell fates. Abbreviation 
definitions are included in the text. CMP, common myeloid progenitor.
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(BSAP) (Adams et al, 1992)) is the key transcription factor in B cell commitment, 
as it suppresses alternative lineage cell fates early in development. Pax5 
target genes encode essential components of the preBCR/BCR signalling 
pathway, including Iga (mb-1) (Nutt et al, 1999, Nutt et al, 1997), G D I9 (Kozmik 
et al, 1992, Nutt et al, 1998) and the adaptor protein B cell linker protein (BLNK) 
(also called SLP-65 or B cell-restricted adaptor protein (BASH)) (Schebesta et 
al, 2002).
1.4 BCR signalling
Signals propagated through BGR are fundamental not only for the development, 
cellular selection, maturation and survival of B cells but are also imperative for 
antibody production (Gauld et al, 2002b). The BGR is a multiprotein structure 
containing membrane Ig, the disulfide-linked Iga and Igp heterodimer, which is 
noncovalently associated with membrane Ig (Kurosaki, 1997). All BGR signal 
transduction is mediated through immunoreceptor tyrosine-based activation 
motifs (ITAMs) of this heterodimer (Papavasiliou et ai, 1995, Teh and 
Neuberger, 1997). Both Iga and Igp contain a single ITAM composed of two 
tyrosine residues (Kurosaki, 1997). BGR signalling is initiated upon ligand 
binding, which induces receptor aggregation and subsequent phosphorylation of 
the ITAM (Fig. 1.3). Phosphorylation of these tyrosine resides by the Src- 
family protein tyrosine kinases, such as Lyn, Fyn, BIk or Lck, residing in 
proximity of BGR, is essential for the recruitment (Dal Porto et al, 2004) and 
activation of spleen tyrosine kinase (Syk) that binds to phosphorylated ITAMs 
with its tandem Src homology (SH) 2 domains (Rowley et al, 1995). BLNK, a 
scaffold protein containing an SH2 domain and over five defined tyrosine 
phosphorylation sites (Ghiu et al, 2002), is rapidly phosphorylated by Syk and 
serves as the primary docking site of the SH2 domain of Phospholipase G 
(PLG) y2 (Fu et al, 1998, Ishîai et al, 1999). Phosphorylated BLNK brings 
PLGy2 into the close proximity of the activated Syk in the membrane, thereby 
facilitating tyrosine phosphorylation of PLGy2 by Syk (Ishiai et al, 1999). 
Membrane-localised Bruton’s tyrosine kinase (Btk), a Tec family protein tyrosine 
kinase, which is recruited to plasma membrane (PM) by interaction between its
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Figure 1.3 BCR signal transduction cascade
BCR signalling is initiated upon ligand-induced BCR aggregation. Signals are 
propagated by Src-famlly protein tyrosine kinase-mediated phosphorylation of 
ITAM on the Iga and lg(3, thereby recruiting and activating Syk, which leads to 
phosphorylate BLNK and in turn recruits PLCy2. PLCy2 is then 
phosphorylated by proximal Syk. PLCy2 is further phosphorylated by Btk, fully 
activated and generate second messenger IP3 and DAG, resulting in PKC 
activation. Grb/Sos also associates with phosphorylated BLNK and can 
activate Ras-MAPK family pathway. Abbreviation definitions are included in 
the text.
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pleckstrin homology (PH) domain and phosphatidylinositol-3,4,5-triphosphate; 
[PI(3,4,5)Pg], (PIP3), further phosphorylates tyrosine residues on PLCy2 , 
resulting in full activation of PLCy2 (Hashimoto et al, 1999, Takata and Kurosaki, 
1996) (Fig. 1.3). PIP3 is generated by phosphorylation of the ubiquitous PM 
lipid, phophatidylinositol-4,5-bisphosphate; [PI(4,5)Pg], (PIP2) by 
phophatidylinositol-3-kinase (PI3K) (Marshall et al, 2000). Activated PLCy2 
hydolyses PIPg to produce soluble inositol-1,4,5-triphosphate (IP3) and 
membrane-anchored diacylglycerol (DAG) (Marshall et al, 2000). IP3 leads to 
elevation of cytosolic [Ca^^j levels by activating release from the endoplasmic 
reticulum (ER) through IPg-gated-Ca^^ channels, which results in activation of 
transcription factors, such as NFk-B by protein kinase 0  (PKC) 
p [Saijo, 2002 #344], while DAG activates many PKC isoforms (See Section 
1 .5.2.1) (Guo et al, 2004). Phosphorylated BLNK also associates with Vav, a 
guanine nucleotide exchange factor of Rho-family, Grb2/Son of sevenless 
(SOS), while leads to the activation of p38 and c-Jun amino-terminal kinases 
(JNKs)-mitogen activated protein kinase (MAPK), and Ras, which results In the 
activation of extracellular signal-regulated kinase (ERK)-MAPK (Dal Porto et al, 
2004) (Fig. 1.3).
1.5 Signalling molecules in B ceil development
A number of molecules interact at or near the BCR and play essential roles in B 
cell function, however, signals from these molecules also influence stages of B 
cell development.
1.5.1 The roles of Btk and BLNK in development
Btk is involved in B cell development, and its dysfunction leads to severe 
immunodeficiencies. Naturally occurring mutations in the PH domain of Btk 
are responsible for X-linked agammaglobulinaemia (XLA) in humans, an 
inherited X chromosome-linked humoral Immunodeficiency disease (Tsukada et 
al, 1993, Vetrie et al, 1993), which is characterised by an almost complete 
arrest of B cell differentiation at the pre-B cell stage (Conley et al, 2000) (Fig.
1.4). Afflicted males have an extremely low level of mature circulating B cells
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Figure 1.4 The arrest of differentiation by gene disruption in mouse
The stages at which developmental arrest occurs in various knockout models 
are shown.
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and severe hypogammaglobulinaemia of all types of circulating Igs due to 
severe deficiency of peripheral mature B cells (Conley et al, 2000). A related 
deficiency in mice is called X-linked immunodeficiency {xid) and shares many 
features with human XLA although xid  mice have a less dramatic decrease in 
the number of peripheral B cells (Rawlings et al, 1993, Thomas et ai, 1993).
The phenotype of Btk' '^ mice is similar to xid, including reduced numbers of 
mature B cells, severe B-1 cell deficiency, serum IgM and IgGg deficiency 
(Kerner et al, 1995, Khan et at, 1995).
BLNK null mice have a striking block at pro-B cell to pre-B cell transition, but the 
block is leaky (Hayashi et al, 2000, Jumaa et al, 1999, Pappu et al, 1999, Xu et 
al, 2000), and thereby the deficiency is not as severe as that observed in 
humans which resembles XLA (Minegishi et al, 1999). BLNK is rapidly 
phosphorylated by Syk after BCR cross-linking, Indicating that BLNK belongs to 
the same signal transduction pathway in B cell development, such as Syk and 
Btk. Indeed, the B cells present in BLNK'^‘ mice are phenotypically immature 
and a decrease in serum level of IgM and IgGg is observed, suggesting a 
blockade in development before pre-B cell stage, which is similar as observed 
in Syk'^' mice (Cheng et al, 1995, Turner et al, 1995), PLCy2'^' mice (Wang et al,
2000) and Btk' '^ mice (Kerner et al, 1995, Khan et al, 1995) (Fig. 1.4), although 
the phenotype of BLNK'^' mice is not as severe as that of Btk' '^ mice. Of 
interest, an enlarged pre-B cell compartment is noted due to an enhanced 
proliferative capacity in a pre-BCR and IL-7 dependent way, indicating that 
BLNK limits pre-B cell expansion to promote differentiation, and acts as a |
tumour suppressor (Flemming et al, 2003).
1.5.2 PLCy pathway
PLCy2, the predominant isoform in B cells (Carpenter and Ji, 1999), contains a 
PH domain, two SH2 domain and an SH3 domain (Kurosaki et al, 2000).
PLCy2 is activated by Syk and Btk and cleaves PIPg to generate DAG and IP3 
as described in Section 1.4. IP3 binds IP3 receptors located in the ER, leading 
to Ca^^ release from internal stores (Takata et al, 1995). Cytosolic Ca^^
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elevation leads to the activation of downstream signalling molecules including 
calcineurin, calmodulin-activated serine/threonine phosphatase and classical 
protein kinase C (PKC) (a, p, y) (Harnett et al, 2005, Kurosaki et al, 2000). A 
lipid second messenger, DAG, activates all phorbol ester-sensitive isoforms of 
PKC (a, |3, y, Ô, s, 0) (Guo et ai, 2004).
1.5.2.1 PKGs
PKC is a family of serine/threonine protein kinases that are differentially 
regulated by Ca^+, phospholipids, and DAG. This family of proteins are 
ubiquitously expressed and have differential cellular localization (Tan and 
Parker, 2003). The PKC family isotypes consist of up to ten members and are 
divided into three subfamilies depending on differences in their structures and 
cofactor requirement (Fig. 1.5). Classical PKC (cPKC) isoforms (a, (3I/[3II, y) 
are regulated by both Ca^^ and DAG; novel PKC (nPKC) isoforms (ô, e, q, 0) are 
regulated by DAG but not by Ca^^, and; atypical PKC (aPKC) isoforms (^, i/X) 
do not require either Ca^+ or DAG (Tan and Parker, 2003). cPKCs are 
composed of a regulatory domains: C l and C2 domains; and a catalytic 
domains; C3 and C4, while nPKCs and aPKCs lack C2 domain within their 
regulatory domain (Tan and Parker, 2003).
1.5.2.1.1 The roles of PKCp in development and B cell survival
PKCp-deficient mice exhibit a loss of peritonea! B-1 cells, slightly reduced 
numbers of splenic B-2 cells and decreased serum levels of IgM and IgGg, 
indicating that PKCp is important for B cell development (Leitges et al, 1996). 
However, the frequency and absolute number of pre-B and mature B cells in the 
BM of PKCp'^' mice is essentially identical to those of wildtype mice (Leitges et 
al, 1996), suggesting that PKCp is not absolutely required for B cell maturation. 
Although it is less severe, the phenotype of these mice is similar to that seen in 
xid  in Btk' '^ mice (Kerner et al, 1995, Khan et al, 1995), which is consistent with 
that there is a functional link between Btk and PKCp (Harnett et al, 2005). In 
supporting this view, Btk (Bajpai et al, 2000, Petro et al, 2000) and PKCp (Saijo 
et al, 2002, Su et al, 2002) are both shown to be essential for nuclear factor
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Figure 1.5 Structure of the PKC family
PKC are grouped into three subclasses based on regulatory domain 
composition, which dictates the cofactor-dependence. A regulatory domain 
comprises two basic modules, C l and C2 domain. The C l domain is a 
tandem repeat for cPKCs and nPKCs, but not for aPKCs. This domain mediates 
DAG/phorbol-ester-binding and contains autoinhibitory pseudosubstrate 
sequence in its N-terminus. C2 domain mediates Ca^^'-regulated phospholipid 
binding in cPKCs. All kinases have a conserved kinase domain in the C- 
terminus: C3 domain for ATP-binding and C4 domain for substrate-binding 
kinase core. Catalytic domain activity is highly regulated by phosphorylation 
and cofactor binding.
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kappa B (NF-k B) in response to BCR engagement. Successful activation of 
NF-k B and hence transcription of the NF-k B dependent genes requires 
activation of hcB kinase (IKK) and subsequent phosphorylation and degradation 
of inhibitory protein, Ik B (Karin and Ben-Neriah, 2000). It is known that NF-k B 
controls the expression of Bcl-xL and Bcl-2 (Karin and Lin, 2002), and thus, 
mature B cells derived from PKC(3’ '^ mice fail to upregulate Bcl-xL in response to 
BCR stimulation (Saijo et al, 2002), similar as observed in Btk' '^ B cells 
(Anderson et al, 1996). Taken together, these findings suggest that PKCj3 
regulates NF-k B pathway in response to BCR engagement and thereby acts to 
promote mature B cell survival.
1.5.2.1.2 The roles of PKCô in B cell tolerance and survival
PKCÔ' '^ mouse studies showed that PKCô functions as a negative regulator in 
activated B cells. PKCô'^' mice exhibit expansion of the B cell population, 
infiltration of B cells in many organs, elevated antibody production, and are 
prone to autoimmunity (Mecklenbrauker et al, 2002 , Miyamoto et al, 2002). Of 
note, PKCô* '^ mice develop autoreactive antibodies against DNA and nuclear 
proteins, thereby displaying an autoimmune phenotype (Mecklenbrauker et al, 
2002, Miyamoto et al, 2002), which is associated with a specific loss of self 
antigen-induced B cell tolerance. In contrast with PKC(3'^ ' mice, PKCô"^‘ mice 
do not develop an immunodeficiency resulting of decreased proliferation of B 
cells, suggesting that PKCô plays a role in negatively regulating the proliferation 
and survival of B cells. Indeed, recent studies demonstrated that PKCô 
regulates peripheral B cell survival by nuclear translocation following by 
phosphorylation of histone H2 B at serine 14 (Mecklenbrauker et al, 2004), 
which has been shown to be associated with cell death (Ajiro, 2000, Cheung et 
al, 2003). Interestingly, this nuclear accumulation of PKCô is prevented by B 
cell activating factor (BAFF), a member of TNF family, indicating that the 
existence of BAFF-dependent PKCô-mediated nuclear signalling on B cell 
survival (Mecklenbrauker et al, 2004).
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1.5.2.1.3 The roles of PKCÇ in B cell survival and proliferation
PKC^ has been postulated to play roles in the survival and proliferation of B 
cells. The relative number and phenotype of splenic B cells in PKC^'^' mice is 
similar to wildtype mice, however the loss of PKC^ leads to a temporal delay of 
B cell development in secondary lymphoid organs, increased spontaneous 
apoptosis and impaired BCR-dependent proliferation (Leitges et al, 2001, Martin 
et al, 2002). The impairment of BCR signalling correlates with decrease in 
ERK-MAPK activation, but not related to NF-kB or activating protein-1 (AP-1) 
complex (Martin et al, 2002). However, NF-icB-dependent genes, such as IkB 
and IL-6 , seem to be regulated by PKC^ (Leitges et al, 2001), suggesting that 
PKCÇ is Important for promoting B cell survival.
1.5.2.1.4 The role of PKCe in B cell survival
PKCe have been postulated to play roles in survival and proliferation of B cells. 
PKCe is highly expressed in B lineage cells (Ting et al, 2002), promotes the 
activation of NF-kB via NF-icB-activating kinase, a kinase that phosphorylates 
and activates IKK (Tojima et al, 2000), also suggesting PKCe plays a role of B 
cell survival.
1.5.3 PI3K pathway
PISKs phosphorylate membrane phosphatidyiinositol lipids on the 3-position of 
the inositol ring to generate the lipids, phosphatidylinositol-3-phosphate; [PI(3)P], 
phosphatidylinositol-3,4-bisphosphate; [PI(3,4)Pg], or PIP3; described in Section
1.4 (Marshall et al, 2000) (Fig. 1.6).
The PI3Ks are divided into four classes; U, Is, H and III on the basis of other 
structural characteristics and substrate specificity (Koyasu, 2003).
Each type of PI3K contains a C2 domain, which acts to bind phospholipids, and 
a catalytic domain (Koyasu, 2003). Class I and II PI3K, but not class III PI3K, 
contain a Ras binding domain at the N terminal. Class 1^  family members are 
heterodimers comprising of a regulatory subunit and a catalytic subunit. Class 
Ia enzymes have the regulatory subunits: p85a, p55a, and p50a, products of
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Figure 1.6 Phosphoinositide signalling pathways
The structure of the membrane phospholipid, phosphatidyiinositol and the sites 
of phosphorylation/dephosphorylation are illustrated (top).
The metabolism of phosphoinositides Is shown (bottom). Solid lines: 
Phosphorylation reactions, dotted lines: dephosphorylation reactions. SHIP, 
SH2 domain-containing polyinositol phosphatase; PTEN, phosphatase and 
tensin homolog.
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alternative splicing, p85f3 and p55y, and catalytic subunits: p110a, p110p, 
p110Ô (Koyasu, 2003). Class \q has only one catalytic member p110y that 
interacts with a p101 regulatory subunit. Class II has three members, PI3K- 
C2a, PI3K-C2(3 and PI3K-C2y (Koyasu, 2003). Class III is a mammalian 
ortholog of a Saccharomyces cerevisae Vsp34p, and has not been well 
characterised (Koyasu, 2003).
1.5.3.1 The roles of PI3K in development and B cell survival
The phenotypes of two kinds of PI3K knockout mice: mice lacking p85a 
regulatory domain of class 1^  and mice lacking p110ô catalytic domain of class 
show a reduction in the number of mature B cells, decreased serum Ig level, 
reduced B cell proliferative responses, developmental block at pro-B cell stage 
and reduced numbers of B-1 cells (Clayton et al, 2002, Fruman et al, 1999, Jou 
et al, 2002 , Okkenhaug et al, 2002 , Suzuki et al, 1999), which is nearly identical 
to the phenotype of Btk' '^ mice (Kerner et al, 1995, Khan et al, 1995) (Fig. 1.4). 
As suggested in other knockout model for BLNK, PKCp, PLCy2 , PI3K also has 
a critical role during B cell development and proliferation.
1.5.3.2 The roles of AKT in development and B cell survival
AKT, also known as protein kinase B (PKB), is a serine/threonine kinase with a 
PH domain that allows the recruitment of AKT to the PM by binding to PI(3 ,4)P2 
and PIP3 (Marshall et al, 2000) and consists of three isoforms, AKT1, AKT2 and 
AKT3 (Kandel and Hay, 1999). Activation of AKT requires phosphorylation on 
Thr 308 and Ser 473 (Gold et al, 1999). Thr 308 is phosphorylated by 
phosphoinositide-dependent kinase-1 (PDK1), a serine/threonine kinase, while 
the kinase that phosphorylates Ser 473 is unidentified. AKT is a major 
downstream target of the PI3K pathway and promotes various cell responses, 
such as cell division, survival, suppression of apoptosis and proliferation 
(Fruman, 2004). The pro-survival functions of AKT are exerted by 
phosphorylating bcl-2 family member, Bad (del Peso et al, 1997) and caspase-9 
(Cardone et al, 1998), whose pro-apoptotic activities are inhibited by 
phosphorylation. AKT also helps to retain Bax in the cytoplasm, preventing it
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from translocating to the mitochondria and thereby promoting survival (Tsuruta 
et al, 2002). NF-kB is known to have a pro-survival function in B cells (Ghosh 
et al, 1998) and it has been shown that AKT regulates NF-kB through 
phosphorylation and degradation of IkB (Ozes et al, 1999, Romashkova and 
Makarov, 1999), supporting the notion that AKT is an important mediator of B 
cell survival.
1.5.4 MARK pathway
MAPKs, a group of serine/threonine kinases, are activated by a wide range of 
extracellular stimuli and are able to mediate a wide range of cellular functions.
In general, ERK modules are activated in response to growth factors and 
phorbol esters, while p38 and JNK modules are more responsive to stress 
stimuli (Roux and Blenis, 2004). To date, five groups of MAPKs, have been 
identified in mammals: ERK1 and ERK2 , JNK1, JNK 2, and JNK 3, p38 
isoforms a, (3, y, and Ô, ERK3 and ERK4, and ERK5 (Roux and Blenis, 2004). 
Although each MARK has unique characteristics, each family is composed of a 
set of three evolutionarily conserved kinases: a MAPK, a MAPK kinase 
(MAPKK) and a MAPKK kinase (MAPKKK). MAPKKK activation leads to the 
phosphorylation and activation of a MAPKK, which in turn stimulates MAPK 
activity through dual phosphorylation on threonine and tyrosine residues (Roux 
and Blenis, 2004). The MAPK family is subdivided into three modules: ERK1/2 
module, known as the classical mitogen cascade, consisting A-Raf, B-Raf and 
Raf-1 as MAPKKKs, MEK1 and MEK2 as MAPKKs, and ERK1 and ERK2 as 
MAPKs; p38 MAPK module, MEKK 1-4 and several other molecules as 
MAPKKKs, MEK3 and MEK6 as MAPKKs, four isoforms of p38 as MAPKs, and; 
JNK module, MEKK 1-4 and several other molecules as MAPKKKs, MEK4 and 
MEK7 as MAPKKs, three isoforms of JNK as MAPK (Roux and Blenis, 2004) 
(Fig. 1.7).
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Figure 1.7 MAPK cascades
MAPK cascades are illustrated. Each family is composed of three levels of 
kinases: a MAPK; a MAPKK and; a MAPKKK. The MAPK family is subdivided 
into three modules: ERK1/2 module; p38 MAPK module and; JNK module. 
Abbreviation definitions are included in the text. TAO, thousand-and-one 
amino acid; ASK1, MAP3K5.
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1.5.5 The roles of p21'^ ®^ in B cell development and survival
fî/AS encodes a 21 kDa guanosine triphosphate (GTP)-binding protein, 
consisting of H-ras, K-ras and N-ras (Campbell et al, 1998). p21 '^ ®^ is normally 
equilibrated between a GTP-bound active state and guanosine diphosphate 
(GDP)-bound inactive state. BCR ligation recruits adapter proteins, such as 
Grb-2, and subsequently Grb-2 binds Sos, a guanine nucleotide exchange 
factor, which stimulates p21'^ ®^  by exchanging GDP for GTP. GTP bound 
activates the serine/threonine protein kinase, Raf-1, which in turn 
stimulates MEK1 and 2. Subsequently, the activated MEK phosphorylate 
ERK on the threonine-glutamate-tyrosine (TEY) motif of the activation loop 
(Campbell et al, 1998). Studies using a transgenic (Tg) mouse model 
expressing dominant negative form of p2 l'^^^ p2 -|H-RasNi7^ which is expressed 
under the regulation of the Ig intronic heavy chain enhancer (E|^) and Ick 
proximal promoter, revealed that p2 l'^^®-mediated Raf signals are essential for B 
cell differentiation since Tg mice expressing high levels of p21^ '^ ®^'^ ^^  displayed 
a developmental block of pro-B and pre-B cells in the BM (Iritani et al, 1997). 
Moreover, expression of constitutively active p21"^^\ p2 -|Ha-Rasvi2^ which is 
expressed under the regulation of Eg, and H chain V region promoter in RAG'^' 
mice, whose B cells are blocked at the pro-B cell stage due to an inability to 
initiate Ig gene rearrangement (Mombaerts et al, 1992, Shinkai et al, 1992), 
resulted in promotion of X5 and germline ic locus transcripts and upregulation of 
surface markers associated with more mature stages of B cell development, 
such as CD23 and CD21 ( Shaw et al, 1999a, Shaw et al, 1999b). This 
suggests that p2l'^^^ is involved in early B cell development and B cell survival.
1.5.6 ERK-MAPK
ERK1 and ERK2 are 43 and 41 kDa protein and are 83 % identical at the amino 
acid level (Chen et al, 2001). There are two activity levels in both ERKs, the 
phosphorylated form with high activity and unphosphorylated form with low 
activity (Chen et al, 2001). Activated ERK can phosphorylate membrane 
proteins, such as Syk and calnexin, and nuclear proteins, such as NF-AT, Elk-1, 
c-Fos and c-Jun, and cytoskeletal proteins, such as paxillin (Chen et al, 2001).
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ERK-mediated biological responses seem to depend on the kinetics of ERK 
activation, subcellular compartmentalization of activated ERK; localised either 
cytosol or nucleus, Its substrate targeting and interplays between cell types 
(Harding et al, 2005, Harnett et al, 2005, Kolch, 2005, Murphy et al, 2002). For 
example, the terminal differentiation of PC12 neuronal cells correlates with 
sustained activation of ERK and its translocation into the nucleus, while ERK 
mainly remain in the cytosol upon proliferative signals of the cells (Marshall,
1995). Moreover, ERK in mature B cells can stimulate proliferation, however, 
BCR-dependent activation of ERK is associated with apoptosis in immature B 
cells (Gauld et al, 2002a, Lee and Koretzky, 1998).
1.6 PKCa
1.6.1 Biological functions of PKCa
The cPKC, PKCa Is expressed in wide range of tissues and predominantly in T 
cells among lymphocytes (Iwamoto et al, 1992, Nakashima, 2002). It has been 
reported that this enzyme promotes a wide variety of biological functions such 
as proliferation (Iwamoto et al, 1992, Mandil et al, 2001, Ways et al, 1995), cell 
cycle control (Besson and Yong, 2000, Detjen et al, 2000, Frey et al, 2000), 
apoptosis/cell survival (Jiffar et al, 2004, Leirdal and Sioud, 1999), and cell 
adhesion (Ng et al, 1999) (Fig. 1,8). However, PKCa^ mice had no overt 
abnormalities in external characteristics, viability and fertility other than showing 
enhanced signalling capacity upon insulin stimulation (Leitges et al, 2002). In 
addition, PKCa has been shown to be involved in cellular differentiation. For 
instance, it provides signals for macrophage formation from macrophage 
colony-forming cells (Pierce et al, 1998), pro-platelet formation in 
megakaryocytes (Rojnuckarin and Kaushansky, 2001) and functions as a 
mediator of both differentiation and allelic exclusion in developing thymocytes 
(Michie et al, 2001).
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Figure 1.8 Signal transduction pathways In biological functions of PKCa
Biological functions involving PKCa encompass cell survival/proliferation, cell 
cycle and cell motility. PP2A is a negative regulator of PKCa.
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1.6.2 The activation of PKCa
The generation of a mature, functional PKCa is regulated by three mechanisms: 
cofactor binding; phosphorylation, and; intracellular localisation. PKC 
cofactors comprise DAG, Ca^^ and phosphatidylserine (PS). DAG serves as 
an anchor to recruit PKC to the membrane and increases the affinity of c/nPKC 
for PS, anionic membrane phospholipid, upon its binding to C l domain. Ca '^"
binding to C2 domain also increases the affinity of cPKC for acidic lipids. PS 
binding to C2 domain is accompanied by a conformational change, releasing its 
pseudo-substrate region from the substrate-binding site in the catalytic domain 
(Newton, 1995). PKC activity is also regulated by the phosphorylation of three 
conserved residues in its kinase domain, with the unphosphorylated precursor 
being inactive (Dutil and Newton, 2000). Previous work using mutagenesis 
analysis has identified three phosphorylation sites in PKCa catalytic domain 
noted as the actlvation-loop site (Thr-497), the autophosphorylation site (Thr- 
638), and the hydrophobic C-terminal site (Ser-657) (Parekh et al, 2000) (Fig.
1.9). Phosphorylation at both the Thr 638 in turn motif and the Thr 497 in the 
activation motif is essential for full activation of PKCa (Bornancin and Parker, 
1996, Cazaubon et al, 1994). PDK1 initiates the maturation of cPKC by 
phosphorylating the residue at the activation loop, which promotes 
autophosphorylation at the turn motif and the hydrophobic motif (Dutil et al,
1998). Then, a conformational change occurs, which enables the 
pseudosubstrate to block the active site, and the enzyme is only activated and 
maintained at the membrane in response to second messengers (Dutil and 
Newton, 2000). Mutational analyses showed that phosphorylation at the turn 
motif and the hydrophobic motif contribute to phosphatase-resistance and 
thermal stability although the phosphorylation of hydrophobic motif is not 
necessary for full activation of PKCa (Bornancin and Parker, 1996, Bornancin 
and Parker, 1997). Of note, dephosphorylation of these residues is critical to 
control PKC signalling, which is mediated by protein phosphatase 2A (PP2A) 
(Hansra et al, 1996).
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Figure 1.9 PKCa structure
PKCa (bovine illustrated here) protein comprises amino acid (aa) at the position 
of 2 to 672. The aa numbers shown indicate phosphorylation sites in PKCa, 
T497 in activation loop, T638 in turn motif and S657 in hydrophobic motif.
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A number of proteins regulate the intracellular localisation of PKC isoforms at 
different maturation stages. Scaffolding proteins, such as A Kinase Anchoring 
Protein (AKAP) family members (Klauck et al, 1996), Receptor for Activated C 
Kinases (RACKs) (Schechtman and Mochly-Rosen, 2001) and Proteins that 
Interact with C Kinases (PICKs) (Staudinger et al, 1995, Wang et al, 2003), 
contribute PKC to be in proximity of substrates, which is important for the 
precise targeting of PKCa.
1.6.3 PKCa and proliferation
PKCa has been related to proliferation. Indeed, overexpression of PKCa in 
human U87 glioma cells (Mandil et al, 2001) and PKCa-transfected human 
MCF-7 breast cancer cells (Ways et al, 1995) results in enhanced proliferation 
in vitro. Raf-1 is phosphorylated in a PKCa dependent manner (Kolch et al, 
1993), which leads to activation of ERK-MAPK cascade, thereby causing cell 
proliferation (Buitrago et al, 2003, Schônwasser et al, 1998). Additionally, 
PKCa has been implicated in the activation of NF-kB in Jurkat cells upon 
TCR/CD28 stimulation (Trushin et al, 2003), suggesting that PKCa in involved 
in T cell proliferation. In vivo, thymocytes from 3 month old Tg mice 
overexpressing wiidtype PKCa under the CD2 promoter displayed a higher 
proliferation rate and increased IL-2 production in response to anti-CD3 
antibody stimulation in the absence of co-stimulation (Iwamoto et al, 1992). 
However, at 16 months, PKCa-overexpressing Tg mice showed increased 
PKCa expression but decreased proliferation during aging, thereby, the duration 
and timing of PKCa activation may have a profound effect on proliferation 
(Ohkusu et al, 1997).
1.6.4 The Impact of PKCa on cell cycle regulation
Increasing evidence implicates PKCa is in the control of cell cycle progression 
and survival. Stable expression of constitutively active PKCa in N1H3T3 cells 
upregulates cyclin D1 and E and cycled faster compared to control cells (Soh 
and Weinstein, 2003). PKCa activation in glioma cells also promotes cell cycle 
progression concomitant with upregulated p21'^ ^^ '^  (Besson and Yong, 2000),
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which implies that PKCa-mediated cell cycle progression is counter-intuitive, as 
it involves the upregulation of p21™^'\ a cyclin dependent kinase (CDK) inhibitor.
However, several reports indicate that PKCa can function as an inhibitory factor 
in cell cycle regulation. In intestinal epithelial cells, PKCa activation leads to 
cell cycle withdrawal into Go, which accompanies downregulation of cyclin D 
and upregulation of and p27 \  CDK inhibitors (Frey et al, 2000).
Similarly, PKCa activation results in growth arrest in the G  ^ phase, by inducing 
p2 iwaf-i expression (Detjen et al, 2000). Hence, PKCa may act as growth 
stimulator/inhibitor depending on the cell system.
1.6.5 The impact of PKCa on survival and apoptosis
The loss of PKCa activity generally correlates with the induction of apoptosis.
In COS cells, dominant negative PKCa expression induced apoptosis (Whelan 
and Parker, 1998) and the inhibition of PKCa expression by ribozyme which can 
cleave specific mRNAs, triggered apoptosis with a reduction in Bcl-xL (Leirdal 
and Sioud, 1999). However, depending on cell types, PKCa appears to 
function as a pro-apoptotic factor (Okuda et al, 1999). Indeed, PKCa 
phosphorylates the anti-apoptotic protein, Bcl-2 (Ruvolo et al, 1998), the anti- 
apoptotic action of PKCa appears to be mediated via increasing 
phosphorylation/expression level of Bcl-2 (Blackburn et al, 1998, Jiffar et al,
2004) and/or Bcl-xL (Leirdal and Sioud, 1999). Cumulative evidence suggests 
that the activation and phosphorylation of PKCa (Boudreau et al, 2002, Hansra 
et al, 1996) and Bcl-2 (Ruvolo et al, 1998) are regulated by okadaic acid- 
sensitive PP2A. Moreover, overexpression of PKCa suppresses mitochondrial 
PP2A activity, thus maintaining constitutively phosphorylated Bcl-2 (Jiffar et al,
2004). In support of this finding, PKCa and Bcl-2 can colocalise at the 
mitochondrial membrane in myeloid leukaemia derived HL60 cells (Ruvolo et al, 
1998). This colocalisation may involve PICK1, which targets PKCa for 
anchoring at mitochondria (Wang et al, 2003).
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1.6.6 PKCa and cell adhesion
PKCa is involved in the regulation of cell morphology and cell motility. Cells 
overexpressing PKCa exhibited anchorage-independent growth and 
morphologic alterations (Ways et al, 1995, Zeng et al, 2002). Moreover, PKCa 
plays a pivotal role in focal adhesion formation and have been shown to be 
associated with adhesion molecules including [3 integrins (Ng et al, 1999), 
syndecan-4, transmembrane heparan sulphate proteoglycans (Lim et al, 2003), 
and fascin, an actin-bundling component (Anilkumar et al, 2003). PKCa is 
shown to interact with syndecan-4 directly (Lim et al, 2003) and PKCa activation 
is necessary for a5|31 integrin-mediated focal adhesion formation via syndecan- 
4 (Mostafavi-Pour et al, 2003). Recent studies showed that PKCa 
phosphorylates and activates p115 Rho guanine nucleotide exchange factors 
(GEFs) (Holinstat et al, 2003), and the integrin and syndecan-4-mediated focal 
adhesion is Rho-dependent (Saoncella et al, 1999), therefore, PKCa appears to 
contribute toward focal adhesion formation via two pathways, by the 
phosphorylation of syndecan-4 and Rho.
A naturaiiy occurring mutant of PKCa, PKCa^^®'^®, has been identified in a 
subpopulation of human tumours, and the mutation is located in the V3 hinge 
region separating the catalytic domain and the regulatory domain (Fig. 1.9).
The mutant has lost the ability of selective targeting to cell-cell contact (Vallentin 
et al, 2001) and exhibits aberrant translocation (Alvaro et at, 1997).
1.6.7 PKCa and cancer
It is perhaps unsurprising that dysregulation of PKCa has been implicated in a 
tumourigenicity. Indeed, PKCa-transfected breast cancer cells exhibit 
anchorage-independent growth, morphologic alterations, increased metastatic 
capacity in nude mice, and formation of mammary carcinomas in isografts 
model (Ways et al, 1995, Zeng et al, 2002). Treatment with antisense 
oligonucleotides for PKCa inhibited human lung carcinoma cells to proliferate 
and form colonies in soft agar, and it also reduced tumour formation in these 
cell inoculated nude mice (Wang et al, 1999). However, as described in
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Section 1.6.4, PKCa appears to have opposing effects on the cell cycle 
regulation depending on types of cells. Of interest, Zhu et aL, propose that 
PKCa functions as anti-tumourigenic factor in the progression of endocrine 
tumours because PKCa'^ ^®' '^^  mutant has been found in more invasive tumours. 
As this mutant has lost the membrane translocating ability, it fails to mediate 
several anti-tumourigenic signais (Zhu et al, 2005). Considering this, inhibition 
of PKCa activity may resuit in promoting tumourigenicity within cancer cells.
1.7 Chronic lymphocytic leukaemia (CLL)
1.7.1 Overall clinical symptoms
CLL is the most common leukaemia in the Western world, with increasing 
frequency in industrialised countries (Rozman and Montserrat, 1995), and 
mainly affects the aging population (Chiorazzi and Ferrarini, 2003). CLL is 
represented by a proliferation of B lymphocytes that express B cell markers, 
CD19 or CD20, CD5, CD23, and low levels of CD79b, CD22 and surface Igs 
that are monoclonal with regard to expression of either ic or X. (Batata and Shen, 
1992, Dighiero, 2005, Matutes et al, 1994, Moreau et al, 1997). These 
characteristics are generaliy adequate for a precise diagnosis of CLL (Dighiero, 
2005). Whereas some patients with CLL have an indolent course and die after 
many years from unrelated causes, other patients progress very rapidly and 
succumb within a few years from this currently incurable leukaemia (Chiorazzi 
and Ferrarini, 2003).
While a central cytogenetic abnormality has not been identified (Chiorazzi and 
Ferrarini, 2003), recent progress in the identification of molecular and cellular 
markers, particularly, the mutational profile of Ig genes (Damie et al, 1999, 
Hamblin et al, 1999) and some cytogenetic abnormalities (Dohner et al, 2000), 
may allow a prediction of disease progression in patients with CLL.
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1.7.2 Clinical staging and prognostic markers
One third of CLL patients never require treatment and have a long survival; in 
another third, an initial indolent phase is followed by disease progression; the 
remaining third exhibit an aggressive disease at the onset and need immediate 
treatment (Dighiero, 2005). The Rai (Rai et al, 1975) and Binet (Binet et ai, 
1981) staging systems have allowed CLL patients to be categorised into three 
prognostic groups. Both staging systems are based on the extent of 
lymphoadenopathy, splenomegaly, and hepatomegaly on physical exam and on 
the degree of anaemia and thrombocytopenia in peripheral cell counts (Hallek,
2005). However, neither the Rai nor the Binet staging system are sufficient to 
predict which individuals will develop progressive disease among patients 
diagnosed with good prognosis (Dighiero, 2005, Hallek, 2005). In order to 
develop risk-adapted therapeutic strategies, additional parameters have been 
identified allowing a more accurate prediction of clinical course of CLL at initial 
diagnosis. As shown in Tablel .2 (Hallek, 2005), cytogenetic abnormalities, the 
IgVn mutational profile and cytoplasmic ZAP-70 expression can help predict 
disease activity.
1.7.2.1 Chromosomal aberrations
Chromosomal abnormalities are detected in over 80 % of CLL cases.
Although there is not a decisive cytogenetic alteration to characterise CLL, 
predominant cytogenetic abnormalities can be linked prognosis. Dohner et a!., 
analysed 325 cases by fluorescence in situ hybridization (FISH) and linked 
genomic aberrations to prognostic indicator (Dohner et al, 2000). The most 
frequent aberration was deletion 13q14 (55 %), followed by deletion 11q22-q23 
(18 %), trisomy 12q13 (16 %), deletion 17p13 (7 %) and deletion 6q21 (7 %). 
They also demonstrated that the presence of 17p or 11q deletion is associated 
with reduced survival probability, whereas the 13q is associated with favourable 
prognosis (Dohner et al, 2000).
Throughout the molecular characterization of the critical region affected by 
deletions of 11q22-23, ATM  (ataxia telangiectasia mutated), which is a kinase
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P aram eter
Aberrations in chromosomes 13 (13q ),11(11q ) and 17 (17p)
Expression of cytoplasmic ZAP-70 
Expression of surface CD38 
Lymphocyte doubling time 
Serum p2-microglobulin concentration 
Serum levels of soluble CD23 
Serum thymidine kinase activity
Mutational profiles of the IgVn gene region_________________________
Table 1.2 Additional parameters for predicting the prognosis of CLL
Adapted from Hallec, M (2005); Hematology (Am Soc Hematol Educ Program): 
285-291.
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implicated in p53 activation (Pettitt, 2001), appears to be a tumour suppressor 
gene candidate (Stilgenbauer et al, 2002). However, ATM  mutations were only 
found less than 25 % of CLL cases with 11q deletion (Schaffner et al, 1999) and 
its mutations occurred in normal cells in CLL patients as well as leukaemic cells 
from the same patients (Bullrich et al, 1999). Therefore, ATM  may not be a 
causative gene for CLL. Yet, of interest, all ATM  mutant CLL cells showed an 
absence of somatic hypermutation indicating that loss of AT/Wfunction during 
B cell maturation may lead to tumourigenesis at pre-germinal stage by a defect 
in p53 damage response and repair of chromosomal breaks (Stankovic et al, 
2002). The discovery of the p53 tumour suppressor gene located in 17p13 
and assessment of its importance in the disease progression promoted 
investigations from a molecular genetic angle. Based on intensive reports, 
frequencies of p53 mutation in CLL range from 7 % to 15 % (Stilgenbauer et al,
2002). As p53 is important in the regulation of cell cycle arrest and cell death 
upon response to DNA damage (Levine et al, 1991), the presence of p53 
mutations correlates with poor prognosis and poor response to therapy 
(Cordone et al, 1998, Dohner et al, 1995, Lin et al, 2002).
1.7.2.2 IgVn mutational profile
The widely confirmed method to determine to obtain patients' prognosis is 
based on the incidence of somatic mutations in the IgV^ gene. gene 
sequences with differences of s2 % from the most similar germline gene were 
considered the ‘mutated’ subgroup, and <2 % differences were considered the 
‘unmutated’ subgroup (Chiorazzi and Ferrarini, 2003). DamIe etal., and 
Hamblin et aL, associated IgVy gene mutation status with clinical course and 
survival in CLL (Damie et al, 1999, Hamblin et al, 1999). The overall studies 
showed that patients bearing unmutated IgV^ genes result in more severe and 
poorer clinical outcome compared to those with mutated IgVn genes (Hamblin et 
al, 2002, Krôber et al, 2002, Lin et al, 2002, Oscier et al, 2002).
The mutation status of the IgV^ region genes is correlated with the presence of 
genomic aberrations (Krôber et al, 2002, Oscier et al, 1997). Although overall
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incidence of aberrations is not different between the mutated and unmutated 
subgroup, the unmutated subgroup are more likely to express the poor 
prognostic cytogenetic abnormalities, such as 17p deletion and 11 q deletion, 
whereas those of the mutated subgroup were more likely to express the 
favourable aberrations, such as 13q deletion 13q14 deletion as a single 
abnormalities (Krôber et al, 2002).
1.7.2.3 CD38 expression
Damie et al., subdivided CLL into two categories based on IgV^ gene mutation 
status and CD38 expression (Damie et al, 1999). In some cases, patients with 
unmutated IgV^ genes displayed higher percentage of CD38+ CLL cells (s 
30 %), whereas in other cases, patients with mutated IgV^ genes exhibited 
lower percentage of CD38+ cells (Damie et al, 1999). This suggests that an 
inverse correlation exists between disease aggressiveness and higher 
percentages of CD38^ CLL celis, however, other studies failed to find a strong 
correlation (Damie et al, 1999, Hamblin et al, 2002, Krôber et al, 2002, 
Thunberg et al, 2001), which makes CD38 inadequate for surrogate marker for 
the IgVn gene mutational status.
1.7.2.4 Cytosolic ZAP-70 expression
ZAP-70, 70 kDa zeta associated protein, is a cytoplasmic tyrosine kinase 
essential for T cell receptor signal transduction. ZAP-70 was thought to be a 
key element in T and natural killer (NK) cells and be absent in normal B cells. 
However, recently it has shown that ZAP-70 is expressed in normal human 
splenic and tonsillar B cells (Nolz et al, 2005), and a subset of normal BM- 
derived B cells (Crespo et al, 2006). Murine studies show that ZAP-70 is 
expressed in most of the developmental stages, such as pro-B cell, pre-B cell 
and immature B cell stage (Meade et al, 2004, Schweighoffer et al, 2003) and 
the kinase is important for allelic exclusion at the IgH locus (Schweighoffer et al,
2003). This protein tyrosine kinase has emerged as a potential prognostic 
marker in CLL following gene expression profiling which compared unmutated 
CLL and mutated CLL cells (Rosenwald et al, 2001). In some studies, high
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levels of ZAP-70 protein are detectable in the majority of cases of unmutated 
subgroup (Crespo et al, 2003, Wiestner et al, 2003), although there is more 
variation between clinical treatments in the group of mutated CLL patients with 
ZAP-70 expression (Crespo et ai, 2003, Orchard et al, 2005, Rassenti et al, 
2004, Wiestner et al, 2003). Other groups tested the correlation between ZAP- 
70 and mutational status, but there was discordance between ZAP-70 and IgV^ 
gene mutation status depending on the presence or absence of additional 
genetic high-risk features (Krôber et al, 2006, Orchard et al, 2004). ZAP-70 is 
not a complete surrogate for IgV^ gene, however, as it can be an independent 
prognostic marker in CLL to add supplemental information to that of mutational 
status.
In vitro studies demonstrated that the level of Syk phosphorylation (Chen et al, 
2002) and [Ca^^j flux upon IgM cross-linking is greater in ZAP-70 positive CLL 
cells, suggesting that ZAP-70 is involved in the signal transduction initiated by 
BCR in CLL cells. This implies that ZAP-70 allows more effective IgM 
signalling in CLL ceils and thereby contributes to the more aggressive course 
observed in ZAP-70 positive CLL cells, mostly consisting of unmutated 
subgroups.
1.7.3 Immunophenotype
Surface membrane phenotypic studies suggest that all CLL cells resemble 
memory cells which are antigen-experienced and activated (Damie et al, 2002, 
Klein et al, 2001, Rosenwald et al, 2001 ). Apart from low density of surface Ig, 
the markers on CLL cells are different from those on normal B cells and other B 
cell malignancies (Hamblin and Oscier, 1997), in that they overexpress CD23, 
CD5, CD25 and CD71, and underexpress CD22, FcyRllb, CD79b (Chiorazzi 
and Ferrarini, 2003, Damie et al, 2002).
CD5 and CD23 are present on virtually all CLL cells, but absent from most B 
cell lymphomas, which make them CLL specific markers (Hamblin and Oscier, 
1997). CD23, low affinity Fee receptor, is cleaved into soluble fragments
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(sCD23) displaying pleiotropic biological activities (Schwarzmeier et al, 2005). 
The CD23 protein and gene expression are abnormally regulated in CLL cells 
(Fournier et al, 1992). The serum level of sCD23 is elevated in some CLL 
patients and parallels to aggressiveness of the disease (Reinisch et al, 1994, 
Sarfati et al, 1996). A recent finding indicates that an anomalous 
overexpression of Notch2 in CLL cells leads to the upregulation of CD23 
(Hubmann et ai, 2002). Of interest, expression of a constitutively active form 
of Notch2 in developing B cells promotes development of B-1 cells while it 
results in a block of B-2 B cells at the pre-B cell stage (Witt et al. 2003). 
Although the regulatory mechanisms controlling Notch2 signalling in CLL cells 
are unknown, overexpression of CD23 may be a consequence of Notch2 
signalling.
1.7.4 BCR molecule
Although 50-70 % of CLL cells have undergone somatic mutations of genes 
(Dighiero, 2005), CLL cells use predominantly V ^ l, and Vh4 family genes in 
a distribution that is different from that reported for normal peripheral CD5^ B 
cells (Fais et al, 1998). The most frequently used genes within these families 
are V^l -69, Vh3-07, 3-23, Vh 3-21 and Vh4-34 (Chiorazzi et al, 2005). Of
interest, the Vh3-21 gene is associated with aggressive disease, even when it is 
expressed in a mutated form (Tobin et al, 2003, Tobin et al, 2002).
It is established that signals delivered through the BCR can have different 
consequences depending on the stage of maturation of the cells, and thus BCR 
ligation results in apoptosis for immature B cells, whereas BCR engagement 
leads to proliferation for mature B cells (Carey et al, 2000). Previously, Zupo 
et aL, reported that anti-IgM treatment of CD38'" CLL cells causes apoptosis 
(Zupo et al, 1996), whereas surface IgD appeared not involved in apoptosis 
(Zupo et al, 2000). However, the results of IgM ligation varied from survival to 
apoptosis depending on the investigators (Bernal et al, 2001, Nédellec et al,
2005). Altogether, fine balance between the signals delivered through the 
BCR may dictate survival of CLL cells.
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1.7.5 Possible mechanisms involved In evasion of apoptosis
Recent studies reported that in vitro apoptosis of CLL celis is prevented by 
exposure to lL-4 (Dancescu et al, 1992, Panayiotidis et al, 1993, Zupo et al, 
2000) and/or stimulation via surface CD40 (Bernal et al, 2001, Fluckiger et al,
1992, Granziero et al, 2001 ). This inhibition of apoptosis may occur at 
particular site in lymphoid organs, such as the psuedofolficules, where CLL cells 
interact with T cells, resulting in substantial inhibition of the apoptosis and 
proliferation of the leukaemic cells (Ghia et al, 2002, Granziero et al, 2001).
CD5 appears to contribute to survival of CLL cells because CDS stimulation 
increased viability of CLL cells by upregulating Mcl-1, which is PKC-dependent 
manner (Perez-Chacon et al, 2006).
The microenvironment of CLL cells such as the presence of circulating nurse­
like cells (NLCs) (Burger et al, 2000, Tsukada et al, 2002), BM stromal cells 
(Deaglio et al, 2005, Lagneaux et al, 1998) and follicular dendritic cells (DCs) 
(Pedersen et al, 2002) appear to be critical cellular components to confer 
prolonged viability to CLL cells. NLCs, derived CLL patient blood, and BM 
stromal cells can prevent apoptosis of CLL cells in vitro, mediated by the 
upregulation of anti-apoptotic factors, including Bcl-2, Mcl-1, and/or survivin 
(Granziero et al, 2001, Hanada et al, 1993, Kitada et al, 1998, Pedersen et al, 
2002, Schena et al, 1992),
BAFF is a key regulator of B cell homeostasis (Moore et al, 1999) and was 
recently found aberrantly expressed in CLL cells (Novak et al, 2002). A 
proliferation-inducing ligand (APRIL), another TNF-related ligand, is a stimulator 
of tumour cell growth (Hahne et al, 1998), and is also expressed in CLL cells 
(Kern et al, 2004, Novak et al, 2002). An autocrine pathway via BAFF and 
APRIL seems to play a crucial role for apoptosis resistance and enhanced CLL 
cell survival. Indeed, NLCs secrete BAFF, APRIL (Nishio et al, 2005) and 
stromal cell-derived factor (SDF-1/CXCL12) (Burger et al, 2000), a TNF family 
CXC chemokine. Additionally, CLL cells express BAFF and APRIL receptors, 
such as BAFF-R (receptor only for BAFF), B cell maturation antigen (BCMA)
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and transmembrane activator and CAML interactor (TACI) (receptors for both 
BAFF and APRIL), (He et al, 2004, Schneider, 2005) and CXCR4 (SDF-1 
receptor) (Burger et al, 1999). Soluble forms of BAFF and APRIL prevented 
spontaneous/drug-induced apoptosis (Kern et al, 2004, Novak et al, 2002) and 
SDF-1 stimulated B cell growth (Nagasawa et al, 1994), suggesting that both 
autocrine and paracrine secretion of these factors rescue CLL cells from 
apoptosis.
Despite the rarity of Bcl-2 gene translocations in CLL, upregulation of Bcl-2 
mRNA and protein expression are quite common. Indeed, 95 % of cases 
expressed Bcl-2 at higher levels than normal lymphocytes (Hanada et al, 1993). 
Relative expression of Bcl-2 and pro-apoptotic protein, Bax may also contribute 
to apoptosis resistance (Kitada et al, 1998, McConkey et al, 1996, Ringshausen 
et al, 2002). Some factors, such as cytokine effects, environmental stimuli or 
both, appear to contribute to the up-regulation of Bcl-2 protein.
Taken together, these studies underline the fact that CLL is a heterogeneous 
disease.
1.8 General aims and objectives
PKC regulates key biological functions including proliferation, differentiation and 
cell survival in various types of cells. Specific PKC isoforms, such as PKCp, ô 
and have been shown to play important role in B cell development and signal 
transduction. The aim of this project is to elucidate the role of PKC isoforms, 
especially PKCa, in B cell development and transformation.
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Chapter 2: 
Materials and Methods
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2.1 Animals and Plasmids
ICR mice were purchased from Harlan UK Ltd. and maintained at the University 
of Glasgow Central Research Facilities. ICR mice, which have an outbred 
Swiss background, aged between 6-10 weeks were used to isolate primary 
splenic cells and BM cells. R A G- 1 mi c e  (Mombaerts et al, 1992), which have 
a C57B1/6 background and lack both T and B cells due to inability of V(D)J 
recombination, were bred and maintained in-house. Timed-pregnant mice 
were generated, and liver and thymus were extracted from foetuses at day 14 of 
gestation. All animals were maintained in accordance with local and home 
office regulations.
The dominant negative PKC isoforms (PKC-KR) were generated by introducing 
a point mutation at the lysine in the adenosine triphosphate (ATP) binding 
domain; PKCa, PKCa-KR (K"""R); PKCÔ, PKCÔ-KR ( I f  R); and PKC;, PKCÇ- 
KR, (K^^^M); and introduced into the backbone plasmid pHACE (Fig. 2.1 top)
(Soh et al, 1999) derived from pcDNA3 (Invitrogen Life Technologies). The 
constitutively active PKC isoforms (PKC-CAT) were generated by deletion of 
the regulatory domain: PKCa-CAT, PKCô-CAT and PKC^-CAT, and introduced 
into the backbone plasmid pHANE (Fig. 2.1 bottom) derived from pcDNA3 (Soh 
et al, 1999). The original wildtype PKCa construct is expressed in the pHACE 
backbone and the original wildtype PKCa fused with GFP (PKCa-GFP) is 
expressed in the pGFP3 backbone (Fig. 2.2 top) (pEGFP-N1 : Takara Bio 
Europe/Clontech). All the original PKC constructs were a kind gift from Dr.
Jae-Won Soh (Soh et al, 1999). Retroviral constructs were generated by 
subcloning the gene of interest (mutated PKC isoforms (see below) and 
wildtype PKCa) into the retroviral backbone (MIEV) (Fig. 2.2 bottom) at the site 
of Bgl II and Not I, which is 5 ’ of the internal-ribosomal entry site (1RES), 
allowing the bicistronic expression of the gene of interest and green fluorescent 
protein (GFP) (Fig. 2.3 and 2.4). The hemagglutinin (HA)-tag engineered onto 
the C-termina! (pHACE) or N-terminal of each PKC construct (pHANE) allowed 
confirmation of expression at the protein level utilizing an anti-HA antibody 
(Roche Diagnostics).
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2.2 Antibodies and inhibitors
Fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, allophycocyanin 
(APC)" and biotin-conjugated, and purified anti-mouse antibodies for flow 
cytometry (FCM) were purchased from BDBiosciences unless otherwise stated. 
Primary antibodies and horseradish peroxidase (HRP)- conjugated antibodies 
for Western blots were obtained from Cell Signalling Technologies unless 
otherwise stated. The list of antibodies used is supplied in the Table 2.1.
All the inhibitors were purchased from Calbiochem, Merck Biosciences. 
LY294002, [2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one], is a selective 
PI3K inhibitor (ICso=1.4 fjM) and acts on the ATP-binding site of the enzyme. 
Wortmannin, a fungal metabolite, is an irreversible, covalent inhibitor of PI3K 
(ICso=5 nM). U0126, [1,4-Diamino-2,3-dicyano-1,4~bis(2~ 
aminophenyithio)butadiene], is a specific inhibitor of MEK1 (ICso=72 nM) and 
MEK2 (IC5o=58 nM). PD98059, [2’-amino-3’-methoxyflavone], inhibits MEK1 
(IC5o=4 jvM) more potently than MEK2 (ICso=50 ^M). SB 203580, [4-(4- 
Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1 H-imidazole], is an 
inhibitor of p38 MAP kinase (IC5q=34 nM in vitro, 600 nM in cells). Rottlerin is a 
nPKC inhibitor that selectively inhibits PKCô (ICso=3-6 fjM) and PKC0.
Rottlerin also inhibits PKCa, PKCp and PKCy, but significantly reduced potency 
(ICso=80-100 jjM ). Chelerylthrine, naturally-occurring alkaloid, is an inhibitor of 
PKC (lCso=660 nM) and acts on the catalytic domain of PKC.
2.3 Primers and PGR conditions
Primers were ordered from MWG Biotech AG at the scale of 0.2 jl/M or 0.05 /vM 
for GC rich primers. Gene specific primers and conditions used for PCR are 
supplied in Table 2.2. Gene specific primer pairs were designed using the 
OLIGO program (Molecular Biology Insight Inc.), ensuring that no hairpin 
formation could occur within primers and no binding occurred between primer 
pairs. All the primers are designed for mouse genes.
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2.4 Tissue culture
All cell culture reagents were purchased from Invitrogen Life Technologies 
unless otherwise stated. All procedures carried out in a under laminarspace 
flow hood to maintain sterile conditions.
2.4.1 Cell lines
2.4.1.1 GP+E.86 retroviral packaging lines
GP+E.86 (gag-pol and env) retroviral packaging line was used for retroviral 
gene transfer. These cells were generated by co-transfection of the plasmid 
containing the gag and po/genes derived from Moloney murine leukaemia virus 
(MMLV) and the plasmid containing the env gene derived from the helper virus 
into NIH-3T3 cells (Markowitz et al, 1988, Grady et al, 2004). These cells were 
cultured in complete media (High Glucose-DME media containing 10 % foetal 
bovine serum (PBS) (Cambrex), 100 U/ml penicillin, 100 pg/ml streptomycin, 2 
mM glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 50 pM p- 
mercaptoethanol (p-ME) and 10 pg/ml gentamicin) at 37°C in a humidified 
incubator containing 5 % (v/v) COg in air.
2.4.1.2 PT-67 retroviral packaging lines
The PT-67 cell Line was obtained from Takara Bio Europe/Clontech. The cell 
line is an NIH-3T3-based packaging line expressing the 10A1 viral envelope. 
Virus packaged from PT-67 cells can enter cells via two different surface 
molecules, the amphotropic retrovirus receptor and the GALV receptor (Miller 
and Chen, 1996). These cells were maintained in complete media at 37°C in a 
humidified incubator containing 5% (v/v) COg in air.
2.4.1.3 0P9 cells
Simple coculture of embryonic stem cells with the established stromal cell lines, 
such as ST2 (Nisitani et ai, 1994), PA6 (Kodama et al, 1984) and RP0.10 
(Gutierrez-Ramos and Palacios, 1992), without exogenous growth factors 
exclusively give rise to macrophages (Nakano et al, 1994). Therefore, Nakano 
et al. established a stromal cell line, 0P9, from new born calvaria of B6C3F2-
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op/op mice (Nakano et ai, 1994) which lack functional M-CSF (macrophase 
colony-stimulating factor) due to a mutation generating stop codon in the coding 
sequence of the M-CSF gene (Yoshida et al, 1990). The coculture of 
embryonic stem (ES) cells with 0P 9 cells supports the development of erythroid, 
myeloid, and B cell lineages (Nakano et al, 1994), but ES cells could give rise to 
B cells more dominantly when lL-7 and p-ME were added to the culture 
(Nakano, 1995). Under this condition, 0P9 cells were fully supportive of B cell 
development from ES cells and therefore, they were utilised to generate B cells 
in vitro. 0P9 cells were cultured in complete media at 37°C in a humidified 
incubator containing 5 % (v/v) COg in air.
2.4.1.4 0P9-DL1 cells
0P9 cells expressing the Notch ligand Delta-likel (0P9-DL1) were established 
by retroviral transduction of the Notch ligand, DL1. This cell line loses its 
ability to support B lymphopoiesis, but gains the capacity to induce T cell 
differentiation (Schmitt and Zûhiga-Pflücker, 2002). The cells were cultured in 
0P9-DL1 media (a-MEM media containing 20 % FBS, 100 U/ml penicillin, 100 
pg/ml streptomycin) at 37°C in a humidified incubator containing 5 % (v/v) COg 
in air.
2.4.2 Primary cell preparation
2.4.2.1 Foetal Liver cells
Haematopoietic progenitor cell (HPC)-enriched-foetal liver (FL) cells were 
extracted from ICR or RAG-T^‘ foetuses at day 14 of gestation and prepared by 
carrying out a CD24 (heat-stable Ag) antibody/complement-mediated cell lysis 
(Carlyle and Zûhiga-Pflücker, 1998). Briefly, FL single cell suspensions were 
prepared by crushing FL and filtered in 70pm nylon mesh (BioDesign) followed 
by a wash in complete medium (450 g, 6 min, 4°C). Then, the cells were 
incubated at 37°C for 30 min in medium with anti-CD24 antibody (final 
concentration; 100 pg/10^ cells) and 1/10 dilution of 1 mL Low-Tox rabbit 
complement (Cedar Lane). After complement-mediated lysis, viable CD24'°^’- 
HPCs were recovered by discontinuous density gradient centrifugation over
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Lympholyte-Mamma! (Cedar Lane) at 600 g for 15 min at room temperature 
(RT) (Fig. 2.5). Viable cells were removed from interphase of Lymphoiyte and 
medium, and washed in complete medium by centrifugation (450 g, 6 min, 4°C) 
once before the subsequent use. A representative FCM plots of a pre­
antibody/complement mediated cell lysis and post-antibody/complement 
mediated cell lysis is shown in Figure 2.5.
2.4.2.2 Foetal thymocytes
Foetal thymocytes (FT) were extracted from ICR foetuses at day 14 of gestation. 
A single cell suspension was prepared by crushing the thymuses through a 
70pm nylon mesh, in phosphate buffered saline (PBS). The cells were washed 
in complete medium by centrifugation (450 g, 6 min, 4°C) once before 
subsequent culture.
2.4.2.3 BM cells
Femurs were taken from 6-10 week old ICR mice and BM cells were flushed out 
of the femurs using a 18 gauge needle. Then, CD24 antibody/complement- 
mediated cell lysis was carried out and subsequently viable cells were 
recovered by discontinuous density gradient centrifugation as described in 
Section 2.4.2.1.
2.4.2.4 Splenocytes
Splenocytes were extracted from a spleen of 6-10 week old ICR mice. A 
single cell suspension was prepared by crushing a spleen in PBS and passing 
through a 70pm nylon mesh in PBS. The resultant suspension was 
centrifuged (300 g, 6 min, 4°C), and the pellet was resuspended in PBS. Red 
and dead cells were removed by discontinuous density gradient centrifugation 
and viable cells were collected described in Section 2.4.2.1.
2.4.3 Purification of CD19"  ^Splenocytes
Ali procedures were performed at 4°C. A single cell suspension was 
resuspended in 5 ml ice-cold MACS buffer (PBS, 2 mM
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Ethylenediaminetetraacetic acid (EDTA)) and counted by Trypan blue exclusion, 
and pelleted by centrifugation (300 g, 6 min). The cells were then 
resuspended in ice-cold MACS buffer (5 X 10^ cells/ml) and incubated for 10 
min with biotinylated anti-CDI 9 antibody (1 pg/10  ^cells). These cells were 
washed in MACS buffer to remove primary antibody by centrifugation (300 g, 6 
min) and resuspended in ice-cold MACS buffer (90^1/1 X 10^ cells) and 
incubated for 15 min with MACS Streptavidin (SA) micro beads (10 pi/I X 10^ 
cells) (Miltenyi Biotech). Labelled cells were washed in MACS buffer to 
remove unbound beads by centrifugation (300 g, 6 min), and resuspended in 3 
ml ice-cold MACS buffer and applied to a LS-type positive selection magnetic 
column (Miltenyi Biotec) attached to the separator in a strong magnetic field.
The column was washed with 3 ml ice-cold MACS buffer three times. The 
column was removed from the separator and flushed out in 5 ml ice-cold MACS 
buffer by applying the plunger, and purified cells (CD19^) were collected in the 
eluent. The cells were centrifuged (450 g, 6 min), resuspended in complete 
media at 37°C in a humidified incubator. Typical FCM plots before CD19^ 
purification and after are shown in Figure 2.6. The population of CD19'' cells is 
nearly 1.8 times (from 55 % to 98 %) more concentrated in the post MACS 
sample.
2.4.4 Generation of retroviral packaging lines
A retrovirus vector is a powerful tool to introduce a nonviral gene into mitotic 
cells in vitro and in vivo. An integration of the retroviral insert into the genome 
requires active cell division (Miller et al, 1990). Of importance, retrovirus- 
mediated gene transfer leads to stable proviral integration in the target 
chromosomal DNA and its application is broad-ranging because many cells, 
including most primary cells, express viral receptors on the surface (Cepko and 
Pear, 2003). The retroviral vectors utilised in these studies have had all of the 
genes encoding virion structural proteins {gag, pol, env) removed to create 
space for inserted genes, and disable the retrovirus from replicating by itself. 
However, these vectors retain the efficiency of infection, therefore they are used 
in laboratory experiments (Cepko and Pear, 2003). To produce infectious viral
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particles from a replication-incompetent retrovirus vector, retrovirus-packaging 
cells are utilised. These cells express gag, pol and env, thus supplying all of 
the viral proteins by trans that are necessary for encapsidation of vector RNA 
into virions and for subsequent infection, reverse transcription, and integration 
of the vector into the genomic DNA of infected cells (Cepko and Pear, 2003).
In order to obtain packaging lines that produce higher viral titer, generally two 
packaging cell lines with different tropism, such as ecotropic and amphotropic, 
are employed. This is because the overexpression of env in a packaging cell 
line leads to binding and blocking of the cognate receptor, such that packaging 
cells can not be infected with a virus of the same tropism. One packaging cell 
line is transiently transfected with a vector DNA for transient production of virus 
and the produced virus is used to obtain stable virus producing lines. The 
virus from the stable packaging line is exploited for the further infection.
Retroviral constructs were engineered by subcloning the gene of interest into 
the retroviral vector (MIEV) as described in section 2.1 (Michie et al, 2001).
The day before transfection, 5X10" ^  PT-67 retroviral packaging cells were 
plated out into a 6 well-plate per well in complete medium. The retroviral 
vectors were transfected into the PT-67 cells using Effectene as per 
manufacturers instructions (Qiagen), utilising 0.4 (jg DNA. The medium was 
replaced after 24 h and the transfected cells were cultured in complete medium 
until usage as a viral source. After 24 h, the supernatant from the transfected 
PT-67 was collected and filter-sterilised using a 0.45/vm filter membrane 
(Millipore UK Ltd.) attached to a 10 mL syringe (BDBiosciences) to ensure that 
there was no carry over of PT-67 cells. 1 X 1 0 ^  GP+E.86 retroviral packaging 
cells, which were plated 1 day before in complete medium, were spin-infected 
with supernatants from transfected PT-67 supplemented with 5 ^g/ml polybrene 
(Sigma-Aldrich) by centrifugation at 600 g for 45 min at RT and then placed in 
culture for 48 h.
Retrovirally-transduced GP+E.86 packaging cells were trypsinised and then 
resuspended in sterile sorting buffer (Hank’s Balanced Salt Solution (HBSS),
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without phenol red, plus 1 % Bovine Serum Albumin (BSA)), and sorted on the 
basis of GFP expression using a FAGSAria cell sorter (BDBiosciences) and 
FACSDiva software (BDBiosciences). After 2-3 weeks, the GP+E.86 
packaging cells were resorted to a purity of >98 % GFP^, thus establishing 
stable retroviral packaging cell lines. The established cell lines were 
maintained in complete media at 37°C in a humidified incubator containing 5 % 
(v/v) COg in air.
2.4.5 Retroviral infection of HPCs
The retroviral GP+E.86 cell lines were seeded at 1 X 10^ cells per 10 cm^ dish 
and incubated with ^0 pg/ml mitomycin 0  (Sigma-Aldrich) for 2-3 h at 37°G, 1 
day before retroviral infection of primary cells, washing cells in complete 
medium 5 times post mitomycin G treatment. Single cell suspensions of viable 
HPGs isolated from either FL, FT or BM were cocultured with the mitomycin G- 
treated retroviral packaging line in FL-0P9 medium (complete medium 
supplemented with 3 % FBS), and 5 pg/ml polybrene, and IL-6, IL-7 and stem 
cell factor (SGF) (10 ng/ml of each) for 24-48 h prior to being placed either in an 
in vitro B cell generation system as described in Section 2.4.7 or adoptively 
transferred into RAG-T^' mice as described in Section 2.4.8.
2.4.6 Retrovirus infection of CD19^ splenocytes
The retroviral packaging lines were seeded and mitomycin G treated as 
described in Section 2.4.5. 1 X 1 0 ^  GD19'' splenocytes were prepared as
described in Section 2.4.3 and placed on the packaging line with 50 pg/ml E.
Co//derived lipopolysaccharide (LPS) (Sigma-Aldrich) for 48 h in complete 
media with IL-7 (10 ng/ml) in order to enhance retrovirus incorporation into the 
unproliferative mature GD19  ^ B cells (McMahon et al, 1995). After the infection, 
the cells were washed in complete medium once and further cultured in an in 
vitro B cell generation system as described in Section 2.4.7.
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2.4.7 B cell generation system in vitro
HPCs were cocultured on 60 % confluent layer of OP9 cells in the FL-0P9 
medium together with 10 ng/ml IL-6, IL-7 and SCF until day 5 of coculture. 
Thereafter, FL-OP9 media was supplemented with IL-7 alone (10 ng/ml). 0P9 
layers were replenished every 4-5 days and HPCs were cocultured until FCM 
analysis at the indicated time points (Fig. 2.7).
2.4.8 In vivo adoptive transfer
Retroviraliy infected/non-infected HPCs from ICR/RAG-T^’ mice (from Section 
2.4.2.1) were centrifuged over Lympholyte-Mammal to ensure that dead cells 
and non-lymphoid cells were removed. The resultant cells were washed in 
PBS and resuspended in PBS at the concentration of 1 X 10^ cells/ml. 1 X 10^ 
3 X 10®, 1 X 10® cells were injected intra-peritoneally (i.p.) into neonatal RAG-T 
mice as indicated in figure legends. The mice were sacrificed by cervical 
dislocation 2-6 wk post-injection and the BM, spleen, LN and tumours if present, 
were harvested. A single cell suspension was obtained by crushing organs in 
PBS and by passing through a 70^m nylon mesh in PBS (Fig. 2.8).
2.4.9 Purification of GFP^ cells from ICR-PKCa-KR-FL injected mice
GFP^ spleen/LN cells from PKCotKR-injected mice were obtained as described 
in Section 2.4.8, and purified by magnetic bead IgD negative-selection as 
described below.
All procedures were performed at 4°C. A single cell suspension was 
resuspended in 5 ml ice-cold MACS buffer counted by Trypan blue exclusion, 
and pelleted by centrifugation (300 g, 6 min). The cells were then 
resuspended in ice-cold MACS buffer (5 X 10^ cells/ml) and incubated for 10 
min with biotinylated anti-lgD antibody (1 j.il/10^ cells). These cells were 
washed in MACS buffer to remove primary antibody by centrifugation (300 g, 6 
min) and resuspended in ice-cold MACS buffer (90|il/1 X 10^ cells) and 
incubated for 15 min with MACS SA micro beads (1 fig/1 X 10^ cells).
Labelled cells were washed in MACS buffer to remove unbound beads by
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centrifugation (300 g, 6 min), resuspended in 10 ml ice-cold MACS buffer and 
applied to a CS-type negative selection magnetic column (Miltenyi Biotec) in a 
separator with strong magnetic field. Purified cells (IgD ) were eluted from the 
column upon removing the column from the magnet by washing with 50 ml ice- 
cold MACS buffer. Next, IgD' cells were positively selected as described in 
Section 2.4.3, except using anti-CD23 antibody. In brief, the cells were 
incubated for 10 min with biotinylated anti-CD23 antibody (1(ig/10^ cells), 
centrifuged in MACS buffer to remove primary antibody, resuspended in ice- 
cold MACS buffer (90|il/1 X 10^ cells) and incubated for 15 min with MACS SA 
micro beads (1 fal/10^ cells). The purified cells (IgD', CD23+) were collected in 
the eluent using LS-type positive selection magnetic column. The cells were 
washed in medium and used for further experiments.
2.4.10 Generation of M-1 cells
Retroviraliy PKCa-KR infected HPCs were cocultured with 0P 9 up to day 21 in 
the presence of lL-7 as described in Section 2.4.7. Next, the cultured PKCa- 
KR infected HPCs were transferred to a new tissue culture dish and cultured in 
the FL/0P9 medium in the presence of lL-7 and in the absence of 0P9 for 
further 7 days. Every 2-3 days, medium was replenished. At day 30, cells 
were washed in medium by centrifugation (450 g, 6 min, 4 X ) , transferred to a 
new tissue culture and cultured for further 28 days without IL-7. Cells were 
prepared and stained with anti-CD5 antibody (diluted 1/200) in 500 p\ sorting 
buffer for 20 min on ice and washed twice in sorting buffer prior to sorting.
GFP’*’ CD5'° cells were sorted using a FACSAria and analysed with FACSDiva 
software; sorted cells were 99 % pure, as determined by post-sort analysis.
The CD5'° cells that are able to survive without 0P 9 or IL-7 were selected and 
used for further experiments as the M-1 cell.
2.5 Flow Cytometry
2.5.1 Surface marker analysis
Cells were removed by gentle pipetting, washed in FACS buffer (HBSS 
supplemented with 1 % BSA and 0.05 % sodium azide) and then incubated with
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anti"CD16/CD32 antibody (diluted 1/200) to block Fc receptors, and non­
specific binding. After cells were washed in FACS buffer once by 
centrifugation (300 g, 1 min, RT), the appropriate antibodies (diluted 1/300) 
were added, as indicated in the text, and incubated for 30 min at 4°C. When 
biotin-conjugated antibodies were used, the cells were incubated with SA-APC 
(diluted 1/300) for 20 min at 4°C. The cells were then washed twice in FACS 
buffer, resuspended in FACS buffer, and filtered through a 70jLvm nylon mesh 
just before FCM analysis. Propidium iodide (PI) at final concentration of 25 
jL/g/ml was added prior to analysis to discriminate dead cells. FCM was 
performed using a FACSCalibur flow cytometer (BDBiosiences). CellQuest 
software (BDBiosciences) was used to acquire the cells and FlowJo software 
(Tree Star) was employed to analyse the data. All data shown were live and 
size gated based on forward scatter (FSC) and side scatter (SSC) and lack of 
PI uptake.
2.5.2 Intracellular marker analysis
Cells were washed once in FACS buffer and fixed using the Cytofix/Cytoperm 
(BDBiosciences) solution by incubating for 20 min at 4°C, and were then 
washed in BDPerm/Washsolution (BDBiosciences) twice. Then, the cells were 
stained with fluorochrome-conjugated antibody (diluted 1/300), washed twice in 
the wash solution and analysed with a FACSCalibur flow cytometer. If a 
secondary antibody required, such as anti-rat IgG-PE antibody (diluted 1/200), 
cells were subsequently incubated with it for 20 min at 4°C, and then washed, 
and analysed with a FACSCalibur flow cytometer. CellQuest software was 
used to acquire the data and FlowJo software was employed to analyse the 
data. All data shown were size discriminated based on FSC and SSC.
2.5.3 FCM analysis of cell cycle and DNA content using PI
Cellular DNA content was detected by carrying out PI staining. Cells were 
lysed with 100 p\ of 0.2 % Triton X-100-PBS solution and incubated for 10 min 
on ice. The lysed cells were treated with 0.5 % (w/v) RNase to remove RNA, 
followed by the addition of PI to a final concentration of 50 pg/m\ (Vindelov et ai,
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1983). PI incorporation was analysed using a FACSCalibur flow cytometer 
with activated doublet discriminator module. The acquired data were analysed 
using the FlowJo software package. A figure showing basic cell cycle FCM 
analysis pattern is shown in Figure 2.9.
2.5.4 Measurement of DNA synthesis by BrdU incorporation
5-Bromo-2’-deoxyuridine (BrdU) is an analogue of the DNA precursor thymidine 
and is incorporated into newly synthesized DNA by cells entering and 
progressing through the S (DNA synthesis) phase of the cell cycle. Staining 
BrdU labelled cells with anti-BrdU antibody enables the FCM analysis, which 
allows enumeration of cells that are actively synthesizing DNA.
Cell samples were removed from the 0P9 cell line two days prior to analysis 
and the dead cells were removed by discontinuous density centrifugation. The 
resultant cells were resuspended in complete media either in the absence or 
presence of IL-7 (10 ng/ml) at a concentration of 2 X 10® cells/ well. 50 pM  
BrdU was added 23 h prior to cell harvesting, at which time the cells were 
washed once in PBS and then fixed using the Cytofix/Cytoperm. To expose 
incorporated BrdU, cells were washed in BDPerm/Wash solution and treated 
with DNase at the final concentration of 300 pg/m\ for 1 h at 37°C and then 
stained with anti-BrdU-APC antibody (diluted 1/300) for 20 min at 4°C. Cells 
were then resuspended in 7-amino-actinomycin D (7-AAD) to stain DNA, 
washed in the BDPerm/Wash solution and the samples were acquired on a 
FACSCalibur flow cytometer using the CELLQuest software package. All data 
shown were live and size gated by discrimination based on FSC and SSC. 
FlowJo software package was used to analyse the data.
2.5.5 Detection of apoptosis by Annexin V
Retroviraliy infected HPCs were cocultured with 0P 9 for 16 days. Thereafter, 1 
X 10® cells were plated on a 0P9 cell layer in a 6 well-plate and incubated in 
the absence or presence of pharmacological inhibitors (1 ^M, 3 pW\, pW\ 
LY294002, PI3K inhibitor; 0.2 ^M, 2 pW\, Chelerythrine, total PKC inhibitor; 2 ^M,
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20 pU, Rottlerin, PKCô/0 inhibitor; IpM , lOpiM, U0126, MEK1/2 inhibitor; 0.5 pW\, 
5 pW\, SB203580, p38 MAPK inhibitor) for 24 h at 37°C in a 5 % (v/v) COg 
atmosphere. The cells were removed from 0P9 layer by gentle pipetting, 
washed twice in ice-cold PBS, resuspended in 1 X Annexin V Binding Buffer 
(BDBiosciences) at the concentration of 1 X 10® cells/ml. 5 pi Annexin V-PE 
and 7-AAD were added to the cell suspension (100 p\, 1 X 10®), and incubated 
for 15 min at RT in the dark. 400 p\ of binding buffer was added to the sample 
and analysed by FCM. The samples were acquired on a FACSCalibur flow 
cytometer using the CELLQuest software package. FlowJo software package 
was used to analyse the data.
2.5.6 Cell number counting by flow cytometry
The retrovirally-infected HPCs were seeded in the following conditions: in the 
absence of 0P 9 and in the presence of IL-7, and in the absence of both 0P9 
cells and IL-7. The cells were cultured for up to three weeks. During this 
period, the cultures were sampled and analysed by FCM for the cell number, by 
collecting each for the same period of the time.
2.6 Western blotting
2.6.1 Cell stimulation and whole cell lysate preparation
Cell samples were removed from the 0P 9 cell line and either treated with 
phorbol ester (20 or 200 nM 12-0-tetradecanoylphorboI-13-acetate (TPA); Cell 
Signalling Technology) for 30 minutes or vehicle (DMSO). Then, cell samples 
were washed in ice-cold PBS twice and resuspended in ice-cold lysis buffer (50 
mM Tris-HCI (pH=7.4), 150 mM NaCl, 1 mM EDTA, and 0.5 % (v/v) Triton X- 
100 supplemented with Complete Protease Inhibitor Cocktail (Roche 
Diagnostics)). After vortexing, the cells were solubilised for 30 min on ice 
before centrifugation of lysates at 10,000 g for 1 min. The resulting 
supernatant (whole cell lysate) was then collected and the protein concentration 
was determined by Bradford method (Bradford, 1976) using Coomassie Plus 
(Pierce). The samples were stored at -20°C before being used for Western 
blot analysis.
54
2.6.2 Sodium dodecyl sulphate-polyacylamide gel electrophoresis (SDS- 
PAGE) and transfer
Whole cell lysates (4 protein per lane) were resolved on the Xcell SureLock 
Mini-Cell kit with NuPAGE Novex high-performance pre-cast Bis-Tris gels and 
NuPAGE buffers and reagents (all supplied by Invitrogen). Lysates were 
diluted in lysis buffer to a constant final volume and the appropriate volume of 4 
X NuPAGE LDS sample buffer (10 % (w/v) Glycerol, 1.7 % (w/v) Tris-Base,
1.7 % (w/v) Tris-HCI, 2.0 % (w/v) lithium dodecyl sulfate (LDL), 0.15 % (w/v) 
EDTA, 0.019 % Serva Blue G250 and 0.063 % Phenol Red (pH=8.5)) and 10 X 
NuPAGE reducing agent was added prior to heating samples to 70°C for 10 min. 
Samples were resolved using NuPAGE Bis-Tris gels (10 %) with NuPAGE 
MOPS running buffer (50 mM 3-(N-morpholino) propane sulfonic acid (MOPS), 
50 mM Tris-Base, 3.5 mM SDS and 1.0 mM EDTA (pH=7.7); supplemented with 
NuPAGE antioxidant) at 150 V for 75 min following the manufacturers 
instructions. Polyvinyliden difluoride (PVDF) membrane (GH healthcare) was 
activated by immersing in methanol for 5 min and used. The gel was then 
transferred onto the PVDF membrane using NuPAGE transfer buffer (25 mM 
Bicine, 25 mM Bis-Tris, 1.0 mM EDTA, 50 pM  Chlorobutanol (pH=7.2); 
supplemented with 20 % (v/v) methanol) at 30 V for 70 min.
2.6.3 Western Blot Analysis
Following transfer, PVDF membranes were washed once in Tris buffered saline 
(TBS; 0.5 M NaCI and 20 mM Tris pH=7.5) with 0.1 % (v/v) Tween-20 
(TBS/Tween) and blocked for 1 h in TBS/Tween with 5 % non-fat milk. 
Membranes were then incubated with the appropriate primary detection 
antibody overnight at 4°C. All antibodies were diluted in TBS/Tween with 
either 5 % non-fat milk. Following incubation with primary antibody, PVDF 
membranes were washed ( 3 X 1 0  min) with TBS/Tween and incubated in the 
appropriate HRP-conjugated secondary antibody for 1 h at RT. PVDF 
membranes were then washed ( 6 X 1 0  min) with TBS/Tween and protein 
bands were visualised using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce). PVDF membranes were incubated in a mixture of equal
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volumes of Enhanced Chemiluminescence (ECL) solution A (2.5 mM luminol,
0.4 mM p-coumaric acid and 100 mM Tris pH=8.5) and ECL solution B (0.002 % 
hydrogen peroxide and 100 mM Tris pH=8.5) for 1 min before exposing 
membranes to Kodak X-Ray film.
2.6.4 Stripping Western blots
PVDF membranes were sometimes stripped and re-probed with a new primary 
antibody. Membranes were stripped at RT for 5 min in warm Restore Western 
Blot Stripping Buffer (Pierce). PVDF membranes were washed thoroughly in 
TBS/Tween and checked for residual signal before re-starting the Western 
blotting protocol.
2.7 In vitro protein kinase assay
2.7.1 ELISA-based assay
Retroviraliy infected cells were washed in ice-cold PBS twice and resuspended 
in ice-cold sample preparation buffer (30 mM Tris-HCI (pH=7.0), 15 mM NaCI, 5 
mM EGTA, 2.6 mM EDTA, 25 mM |3-ME, and 0.05 % (v/v) Triton X-100 
supplemented with Complete Protease Inhibitor Cocktail, Roche Diagnostics), 
and incubated on ice for 30 min. All the reagents were purchased from Sigma- 
Aldrich unless otherwise stated. Lysates were sonicated for 5 sec five times 
and then centrifuged at 15,000 X g for 60 min at 4°C. The supernatant was 
then collected and the protein concentration was determined using Bradford 
method. Protein (10 pg) per well was assayed per sample in triplicate. The 
PKC ELISA uses a synthetic PKC substrate and a monoclonal antibody that 
recognises the phosphorylated form of the peptide. In accordance with the 
protocol of the manufacturer (Merck Biosciences), 108 p\ of component mixture 
was added to each well of a 96 well-plate and preincubated at 25°C for 5 min. 
The component mixture was prepared by combining the following components: 
12 p\ PKC reaction buffer (250 mM Tris-HCI (pH=7.0), 30 mM MgCL, 5 mM 
EDTA, 10 mM EGTA, and 50 mM (3-ME), 12 ji/l 2 mM ATP, 12 p\ 500 pg/m\ PS, 
12 ^1 20 mM CaClg and 72 p\ distilled water. The negative control for the 
assay contained an equal volume of distilled water instead of PS and CaClg
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solution. A 12 jUl kinase sample was added to each well and mixed. Next 100 
p\ reaction mixture was transferred to each pseudosubstrate-coated well; the 
plate was incubated at 25°C for 20 min; and 100 p\ 20 % H2S04was added to 
each well to stop the reaction. The wells were washed with PBS five times and 
the liquid was removed from each well by inverting and blotting on paper towel. 
Biotinylated antibody to phosphorylated PKC/PKA pseudosubstrate (2B9) (100 
jvl) was added to each well and incubated at 25°C for 60 min. After washing 
five times, 100 p\ peroxidase-conjugated SA was added to each well and 
incubated at 25°C for 60 min. After additional washes, 100 p\ substrate solution 
(1 tablet of o-Phenylenediamine in 12 ml hydrogen peroxide) was added to 
each well and allowed to develop until there was a medium bright yellow colour 
(3-5 min) at 25°C. The reaction was stopped by adding 100 p\ 20 % H2SO4 to 
each well. The optical density (OD) value was measured at 490 nm 
wavelength. The PKC activity for each dominant negative PKC sample was 
analysed in triplicate and expressed as a ratio against the value of the control 
(MIEV).
2.7.2 ®^P-based assay
The kinase samples were prepared as described in Section 2.7.1. PKC activity 
was measured based upon the PKC catalysed transfer of the y-phosphate 
group of adenosine-5’-triphosphate to a peptide which is specific for PKC 
according to the manufacturer’s protocol (GE Healthcare). 25 \i\ kinase 
sample and 25 pi component mixture (3 mM Calcium acetate, 75 ng/ml La- 
phosphatidyl-L-serine, 6 pg/ml phorbol 12-myristate 13-cetate, 225 pM 
substrate peptide, 7.5 mM dithiothreitol, 50 mM Tris/HCl (pH=7.5) containing 
0.05 %(w/v) sodium azide) were mixed, and the reaction was started by adding 
0.2 pCi Mg^^ [®^P]ATP. The samples were incubated at 37°C for 15 min and 
stopped by adding 10 pi stop reagent (300 mM orthophosphoric acid containing 
carmosine red) to terminate the reaction. 35 pi terminated reaction mixture was 
transferred on to the centre of individual paper discs and allowed to air dry for 5 
min. The discs were washed in 5 % (v/v) acetic acid for 5 min to remove 
leftover radioactivity, and then the discs were individually transferred to
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scintillation vial using forceps. 10 mi scintillation cocktail (GE Healthcare) was 
added to each vial and the activity was counted for 60 sec in a scintillation 
counter appropriate for Data expressed as percentage of MIEV counts.
2.8 PCR
2.8.1 Genomic DNA extraction
Cells were pel letted by centrifugation (450 g, 6 min, 4°C) and resuspended in 
200 pi PBS. Genomic DNA was isolated using the Easy-DNA kit (Invitrogen 
Life Technologies) and then dissolved in DNase-free water.
2.8.2 Total RNA extraction
Cell pellets collected from HPC-0P9 cocultures at day 0, 3, 8 and 14 were 
homogenised using QIAshredder spin column (Qiagen). Total RNA was 
isolated from homogenised cells using the RNA-Easy RNA purification 
procedure (Qiagen) followed by DNase I (Qiagen) treatment to digest residual 
genomic DNA, and dissolved in RNase-free water.
2.8.3 RT-PCR/genomic PCR
cDNA was prepared from 1 pg RNA using oligo(dT)is primers and first strand 
cDNA synthesis kit (Roche Diagnostic). First, RNA and primer mixture was 
incubated at 70°C for 10 min and chilled on ice immediately. Then, the 
following component mixture; 10 mM Tris (pH=8.3), 50 mM KCI, 5 mM MgClg, 1 
mM dNTP, 60 units RNase inhibitor, 20 units avian myeloblastosis virus (AMV) 
reverse transcriptase (all the reagents were from Roche Diagnostic) was added 
to the mixture, and incubated at 42°C for 1 h. Following the incubation, the 
reaction was heated at 90°C for 5 min to denature the AMV reverse 
transcriptase, followed by cooling the reaction to 4°C. Semi-quantitative PCR 
reactions were performed using the same serially diluted cDNA batches shown 
for (32m. Subsequent PCR analysis was performed using titrations of cDNA in 
a 1/3 dilution series in dHgO. Reverse transcription-PCR (RT-PCR) reactions 
carried out in the absence of AMV were included as negative controls.
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100 ng each cDNA/genomic DNA sample was amplified in Pfu reaction buffer 
(20 mM Tris-HCI (pH=8.8), 10 mM (NH4)S04 , 10 mM KCI, 0.1 % Triton X-100,
0.1 mg/m! BSA) with DNA polymerase mixture. Tag-Pfu polymerase (Tag 
polymerase to Pfu polymerase (6:1), (Fermentas Life Sciences)), using a 
Master cycler personal (Eppendorf). PCR was performed for 15-20 sec at 
94°C, 30 sec at 57 to 62°C (depending on primer Tm ’s) (Table 2.2), and 20 sec- 
2 min 30 sec at 72°C for 32 cycles, with a hot start at 94°C for 2 min and a final 
extension at 72°C for 6 min. Products were separated by 1 % agarose gel 
electrophoresis in a TAE (0.48 % (w/v) Tris-Base buffer, 0.11 % (w/v) Acetic 
acid and 0.29 % (w/v) EDTA) filled tank and visualized using ethidium bromide 
staining. 1 Kb ladder (Fermentas life Sciences) was run along side of the 
samples to detect the size. All PCR products correspond to the expected 
molecular sizes (Table 2.2).
2.9 Statistical analysis
Statistical comparisons of the values were carried out by two-tailed Student’s t- 
test with an option of equal variances. The results are expressed as the mean 
standard error of the mean (SEM). Statistical significance was defined as 
p<0.05.
2.10 Supplier’s addresses
Supplier’s address was supplied in table 2.3.
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Table 2.1 Antibodies
D e sc rip tio n
re ac tive
spe c ie s C lone Form at iso typ e Use M anu fa c tu re r
CD2 mouse RM 2-5 PE conjugated Rat(SD)lgG2b, K FGM BDBiosciences
CD4 mouse RM4-5 PE conjugated Rat(DA)igG2a, k FGM BDBiosciences
CDS mouse 53-7.3 ARG conjugated Rat(LOU/W s1/M) igG2a, K FGM BDBiosciences
C D8a mouse 53-6.7 APG conjugated Rat(LOU/W s1/M) igG2a, k FGM BDBiosciences
CD11b mouse M1/70 PE conjugated Rat(DA) igG2b, ic PGM BDBiosciences
CD16/CD32 mouse 2.4G2 Purified Rat(sprague- Dawiey)igG2b, i< Blocking BDBiosciences
CD19 mouse 103 PE-, APG-, Biotinylated
Rat(Lewis) igG2a, 
ic
F G M /
MAGS BDBiosciences
CD21/CD35 mouse 7G6 Purified Rat(SD)igG2b, k FGM BDBiosciences
CD23 mouse B3B4 PE conjugated, Biotinylated
Rat(LOU/M) 
lgG2a, 1C
F G M /
MAGS BDBiosciences
CD24 mouse J11d Purified Rat(Lewis) IgM, ic ceilpurification BDBiosciences
CD24 mouse M1/69 Biotinylated Rat(DA) lgG2b, k FGM BDBiosciences
CD25 mouse PG61 PE conjugated Rat(Outbred0 F A )igG 1 ,X FGM BDBiosciences
CD45 mouse 30-F11 PE-conjugated Rat{L0U /W s1/M ) igG2b, K FGM BDBiosciences
CD45R/B220 mouse/Human RA3-6B2 PE-conjugated
Rat(LOU) igG2a,
IC PGM BDBiosciences
GD90.2 mouse 53-2.1 PE conjugated Rat(L0U /W s1/M ) igG2a, ic FGM BDBiosciences
CD117 mouse 288 APG conjugated Rat(W istar) igG2b, 1C FGM BDBiosciences
Ly-51 (6 G 3 /B P -
1) mouse BP-1 PE conjugated
Mouse(Mus 
spretus) igG2a, ic FGM BDBiosciences
Ly-6A/E {Sca- 
1) mouse D7 PE conjugated
Rat(Lewis) igG2a,
IC FGM BDBiosciences
Ly-6G and Ly6G 
(Gr-1) mouse RB6-8G5 Biotinylated Rat igG2b, ic FGM BDBiosciences
NK1.1 mouse PK136 APG conjugated
Mouse[(G3H x 
BALB/c)F1]igG2a,
K
FGM BDBiosciences
T E R -1 1 9 / 
Eryhtroid cells mouse TER-119 Biotinylated
Rat(Wistar) 
igG2b, 1C FCM BDBiosciences
H-2K" mouse AF6-88.5 FITG conjugated Mouse (BALB/c) igG2a. ic FGM BDBiosciences
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D e sc rip tio n
re ac tive
spe c ie s C lone Fo rm a t Iso tvpe Use M anu fa c tu re r
H-2K" mouse KH114 FITG conjugated Mouse (BALB/c) igG2a, ic FGM BDBiosciences
igD“ mouse AMS9.1 Biotinylated Mouse (SLJ) ip G e u , K
FGM/ceil
purification BDBiosciences
IgM mouse ii/41 APG conjugated Rat igG2a, k FGM BDBiosciences
Ig, K  light chain mouse 187.1 PE conjugated Rat(sprague- Dawiey)igG1, k FGM BDBiosciences
Rat lgG(H+L) rat PE conjugated goat polyclonal FCM Galtag-Medsystems
HA BMG-3F10
Peroxidase
conjugated Rat igG1
FGM/W este 
rn blots Roche Diagnostics
BrdU human 3D4 APG conjugated Mouse ig G I, k FGM BDBiosciences
PKC/PKA
phosphorylated
psuedosubstrate
Ail 2B9 Biotinylated N.D. ELISA Merck Biosciences (Calbiochem)
Streptavidin - - APG conjugated - FGM BDBiosciences
phospho-(Ser) 
PKC Substrate Ail - Purified Rabbit polyclonal
W estern
blots
Geii signalling 
Technology
Phospho-PKC
(pan)
(piiSer660)
Human,
Mouse,
rabbit,
Monkey
- Purified Rabbit poiycionai W esternblots
Geii signalling 
Technology
Akt
Human,
Mouse,
Rat.
Chicken,
Drosophila
- Purified Rabbit poiycionai W esternblots
Geii signalling 
Technology
Phospho-
Akt(Thr308)
Human,
Mouse,
Rat,
Ham ster
- Purified Rabbit poiycionai W esternblots
Cell signalling 
Technology
p42/44 MAP 
Kinase
Human, 
Mouse, 
Rat, 
Hamster, 
Zebra fish
- Purified Rabbit poiycionai W esternblots
Geii signalling 
Technology
Phospho-p42/44 
MAP Kinase 
(Thr202/Tyr204)
Human,
Mouse,
Rat,
Chicken,
Hamster.
- Purified Rabbit poiycionai W esternblots
Geii signalling 
Technology
PKCa
Human, 
Mouse, 
Rat, 
Chicken, 
Dog, Frog
3 Purified Mouse igG2b W esternblots BDBiosciences
Rabbit igG 
(H+L) mouse - HRP cojugated goat poiycionai
W estern
blots
Geii signalling 
Technology
Mouse igG 
(H+L) mouse - HRP cojugated horse poiycionai
W estern
blots
Geii signalling 
Technology
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Table 2.2 PCR primers and conditions
G ene e x p e c te d  s ize  (b p ) [ M g c i j D e n a tu re A n n e a l E x te n s io n S e q u e n ce
[32m 455 2.0 mM 94°C 
15 sec
59°C 
30 sec
72 “C 
40 sec
U: 5' G G C  G TC AAC  AAT G C T G CT TO T 3' 
L: 5' C TT TO T GTG TTT CGC G C T CGC 3'
Bcl-2 323 2.3m M 94°C 
15 sec
57°C 
30 sec
72°C 
30 sec
U: 5' G G G  AG A AC A GGG TA T GA 3' 
L: 5 ’ A TC  TC T  GGG AAG TC A  CG 3'
Bcl-xL 351 2.0 mM 94°C 
15 sec
57°C 
30 sec
72°C 
25 sec
U: 5' G A A  G C A  GAG AG G  GAG ACC 3' 
L; 5' GTC C TT  GTG TA C  G C T TTC 3'
IgM, D-J 120, 700, 
1000, 1300
3.0 mM 94°C 
15 sec
62°C 
30 sec
72°C 
2.5 min
U; 5' AGG G A T G CT TG T GAA GGG ATG 
TAC TA C  TG T G 3'
L: 5' AAA  GAG GTG GAG AGG GGA TTC 
TTA  GG 3'
IgM, V-J 400, 1000, 
1300, 1600
2.8 mM 94°C 
15 sec
62°C 
30 sec
72°C 
2,5 min
U: 5' AG G  T(G /G )(A /G ) A(A /G )G  TGG 
A G (G /G ) A G T G(A7T)G G 3'
L: 5' AAA  GAG GTG GAG AGG GGA TTC  
TTA  GG 3 ’
p2iw.ii 235 2.9 mM 94°C 
20 sec
61.5°C 
30 sec
72°C 
20 sec
U: 5' GGG GTG GAG AG T GAG GAG T 3' 
L: 5' GGA GG A GGG GAG AGG AAG T 3'
Mcl-1 163 2.0 mM 94°C 
30 sec
60°C 
30 sec
72°C 
30 sec
U: 5 ’ TG G  GGG AGG ATT GTG AGT GTT 3' 
L: 5' AGG G AT GGG AGG GTG TTT G TT 3'
p27 305 2.9 mM 94°C 
20 sec
61.5°C 
30 sec
72°C 
20 sec
U: 5' GAG  GGT GGA GGG GAT GGA G 3' 
L; 5' GGG TGG GGG TG A GAT GGT G 3'
IL7R 348 2.0 mM 94°C 
15 sec
58°C 
30 sec
72"C  
40 sec
U; 5' GAG  G TG  AAA  GGG G TT GAA GG 3' 
L: 5 ’ G G A  GTG G AA AG G  GAA TG G  TT 3'
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Table 2.3 Suppliers addresses
Company Address
BD Biosciences 21 Between Towns Road, Cowley, Oxford 0X4 3LY, UK
Biodesign
c/o AMS Biotechnoiogy (Europe) Ltd. 63B Milton Park, Abingdon, Oxon, 0X14 4RX, UK
Caibiochem, Merck Biosciences 
c/o VWR international Ltd. Hunter Boulevard, Magna Park, Lutterworth, LE17 4XN, UK
Caitag-M edsystems Ltd Botyl Road, Botoiph Claydon, Buckingham, MK18 2LR, UK
Cambrex
c/o Cambrex Bio Science Nottingham Ltd.
BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 
IG F, UK
Cedar Lane 
c/o VH Bio Ltd.
Unit 11b, Station Approach, Team Valley Trading Estate, 
Tyne & Wear NE11 02F, UK
Ceii signalling Technology 73 Knowl Piece, Wiibury Way, Hitchln, Hertfordshire SG4 OTY
Eppendorf UK Ltd.
c/o Helena Biosciences Europe Ltd.
Oueensway South, Team Valley Trading Estate, Gateshead, 
Tyne&Wear, NE11 OSD, UK
Fermentas Life Sciences
c/o Helena Biosciences Europe Ltd.
Oueensway South, Team Valley Trading Estate, Gateshead, 
Tyne&Wear, NE11 OSD, UK
GE Healthcare UK Ltd.
(Formaiy Amersham Biosciences)
Pollards Wood. Nightingales Lane, Chalfont St.Giles, Bucks,
UK
Harlan UK ltd Shaw’s Farm, Blackthorne, Bicester, Oxon 0X25 1TP, UK
invitrogen Life Technologies 3 Fountain Drive, inchinnan Business Park, Paisley, UK
Kodak Ltd. Kodak House, Station Road, Heme! Hempstead, Hertfordshire, HP1 1JU, UK
Millipore UK Ltd. Units 3&5, The courtyards, Hatters lane, watford, WD18 8YH, UK
Miltenyi Biotec Aimac House, Church Lane, Bisley, Surrey GU24 9DR, UK
Molecular Biology Insight Inc 8685 US Highway 24, Cascade, CO 80809-1333, USA
MWG Biotech AG Anzingerstr. 7a, 85560 Ebersberg, Germany
PeproTech EC Ltd PeproTech House. 29 Margravine Road. London. W6 8LL,UK
Pierce
c/o Perbio Science UK Ltd.
Unit 9, Atiey Way, North Nelson industrial Estate, 
Cramiington, Northumberland, NE231WA, UK
Qiagen Ltd. OiAGEN House, Fleming Way, Crawley, West Sussex, RH10 9N0, UK
Roche Diagnostics Ltd, Beil Lane, Lewes, East Sussex, BN7 1LG, UK
Sigma-Aldrich company Ltd. Fancy Road, Poole, Dorset BH12 40H, UK
Takara Bio Europe/Clontech 2 Avenue du President Kennedy 78100 Saint-Germain-en- Laye, France
Tree Star 340 A Street Bdl //203, Ashland, OR 97520, USA
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Figure 2.1 pHACE and pHANE plasmids
pHACE is a mammalian expression vector that contains a cytomegaiovirus 
promoter (CMV), Kozak translational Initiation sequence, ATG start codon, 
EcoRI cloning site, C-terminal HA epitope tag, and stop codon. pHANE is a 
mammalian expression vector that contains a CMV promoter, Kozak 
transiational initiation sequence, ATG start codon, N-terminal HA epitope tag, 
EcoRI cloning site, and stop codon. These plasmids are derived from the 
pcDNA3 vector.
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Figure 2.2 pGFP3 and MIEV plasmids
pGFP3 is a mammalian expression vector that contains a CMV promoter, 
Kozak translational initiation sequence, ATG start codon, EcoRI and BamHI 
cloning sites and EGFP. The plasmid Is derived from the pEGFP-N1 vector. 
pMIEV is a retroviral vector that contains pgk promoter and 5 ’ 1RES which 
allows the bicistronic expression of the gene of interest and GFP.
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Figure 2.3 pMIEV-PKC-KR/PKCa and pMIEV-PKC-CAT plasmids
pMIEV-PKC-KR/PKCa expression plasmids were generated by subcloning full- 
length open reading frames of PKCa or full-length open reading frames of PKC 
isoforms with a point mutation at the ATP binding site into pMIEV. pMIEV- 
PKC-CAT expression plasmids were generated by subcloning cDNA fragments 
encoding the catalytic domains of PKC isoforms into pMIEV,
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Figure 2.4 pMIEV-PKCa-GFP and pMIEV-PKCaReg plamids
pMIEV-PKCa-GFP expression plasmid was generated by subcloning full-length 
open reading frames of PKCa fused with GFP into pMIEV digested with Bglll 
and Notl. pMIEV-PKCaReg expression plasmid was generated by subcioning 
a part of open reading frames of regulatory domain (aa 2-383) into pMIEV 
digested with Bglll and Notl.
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Figure 2.5 Summary of the generation of a CD24'°^' -HPC-enrlched 
population
FL single cell suspensions were prepared by crushing FL and filtered in 70^m 
nylon mesh. The cells were incubated with anti-CD24 antibody and rabbit 
complement to permit complement-mediated CD24^ cell lysis. Viable CD24'°- 
progenitor cells were recovered by Lympholyte-Mammal gradient centrifugation 
and CD24‘°^ ' -HPC-enrlched population was obtained. FOM plots CD24-APC 
vs. GD117-PE show typical enrichment of HPCs by analysing pre­
antibody/complement mediated cell lysis and post-antibody/complement 
mediated cell lysis (24 % to 86 % CD117^ cells). The analysis was live and 
size gated.
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Figure 2.6 Enrichment of cells utilising MACS-sorting
MACS sorting was applied for obtaining enriched population with expression of 
interested surface marker. The cells were incubated with biotinylated antibody 
(anti-CD19 in this figure). These cells were then labelled with MACS SA-micro 
beads and applied to a magnetic column to purify the population of interest. 
Typical flow cytometric plots before CD19^ purification and after are presented. 
The analysis was live and size gated.
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Figure 2.7 in vitro B cell generation system
HPCs were prepared from d14 gestation FL and were cocultured on 0P9 cells 
with growth factors. 0P9 layers were replenished every 4-5 days and HPCs 
were cocultured until FCM analysis.
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Figure 2.8 In vivo B cell generation system
HPCs from ICR/RAG-r^' mice were injected i.p. into neonatal R A G -1 m ice .
The mice were sacrificed by cervical dislocation at 2-6 weeks post-injection, and 
the BM, spleen, LN were harvested. A single cell suspension was obtained by 
crushing organs in PBS and by passing through a 70/ym nylon mesh in PBS.
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Figure 2.9 FCM plot of ceil cycle analysis
Pi incorporation was analysed by FCM. The typical acquired data are shown. 
Sub-Go/Gi, apoptosing (DNA amount<2); Gq, quiescent (DMA amount=2); G ,^ 
growth and preparation of the chromosomes for replication (DNA amount=2); S, 
DNA synthesis (2<DNA amount<4); GgA mitosis preparation phase (DNA 
amount=4); M, mitosis (DNA amount=4).
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Chapter 3:
Effects of mutated and wildtype PKC isotype expression during
B cell development
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3.1 Introduction
3.1.1 PKC mutants
PKC mutagenesis is a useful tool to examine the functions of specific PKC 
domains and to identify the roles of each PKC isotype, which can be difficult to 
define due to redundancy between PKC functions (Michie et al, 2001, Soh and 
Weinstein, 2003). Therefore, the following PKC mutants were used in this 
thesis, which were constructed as described in Section 2.1 and figure legends 
for Figure 2.3 and 2.4: PKC-KR (dominant negative PKC); PKC-CAT (kinase 
active PKC); PKCa-GFP, and PKCcc-Reg. PKCa-KR and PKCÔ-KR were 
generated by K to R point mutation, and PKC^-KR were generated by K to M 
point mutation in ATP binding domain (Soh et al, 1999). PKCa-CAT, 
PKCÔ-CAT and PKC^-CAT were generated by deletion of the regulatory domain 
from the full length PKC open reading frames, which results in constitutive 
activation of PKC (Fig. 3.1 ) (Soh et al, 1999). PKCa-GFP was made by fusing 
GFP to the full length PKCa open reading frames at carboxyl-terminal. PKCa­
Reg was constructed by deletion of a part of ATP binding domain and kinase 
domain from the full length PKCa open reading frames (Figure 3.1). In order 
to understand the mechanism of each PKC isotype during B cell development 
and transformation, the PKC constructs were stably expressed in HPCs using 
retroviral gene transfer technique as described in Section 2.4.5. The plasmids 
containing the above PKC mutants were subcloned into retroviral backbone to 
allow stable expression as described in Section 2.1.
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3.2 Aims and Objectives
To assess the role of individual PKC isoforms during B cell development and 
transformation, the aims of this chapter were:
i. To validate the in vitro B cell generation system and phenotypically define 
B cell development in vitro.
ii. To validate the in vivo B cell generation system and phenotypically define 
B cell development in vivo.
ill. To develop the retroviral transfer technique, and validate the expression of 
PKC mutants at protein level, 
iv. To test the effects of PKC mutant expression during B cell development.
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3.3 Results
3.3.1 The in vitro B cell generation system supports mature B lymphocyte 
development
The calvarial stromal cell line, 0P9 is able to support erythroid, myeloid, and B 
cell lineage differentiation (Nakano et al, 1994), and thus this in vitro system is a 
useful tool to examine lineage commitment and B cell development/maturation. 
FL cells were extracted from wildtype mice at day 14 of gestation and an HPC- 
enriched population was obtained by removing CD24'^' cells with density 
gradient centrifugation as described in Section 2.4.2.1. The cells were cultured 
in the presence of 0P 9 cells and growth factors until analysis, as described in 
Section 2.4.7. To develop a model system to promote the development of B 
cells, phenotypic markers during B cell development were analysed by FCM.
B cells express different surface molecules whose expression is 
developmentally regulated (Fig. 1.1): CD43, CD117, CD19, CD24, CD25, 
CD45R, kappa light chain ( k ) ,  IgM and IgD during the course of an OP9-HPC 
coculture. As shown in Figure 3.2, a significant percentage of HPCs 
differentiated towards the B cell lineage, as determined by expression of the B 
cell markers, CD19 and CD45R, as early as day 5. Upregulation of pre-B cell 
marker, CD24 and CD25, was detected, which is compatible with 
downregulation of stem cell marker, CD117. However, CD43 downregulation, 
which is observed in vivo (Nagata et al, 1997), at large pre-B cell stage was not 
observed in our system (Fig. 3.2). HPCs expressed IgM and IgD on surface by 
day 12, and developed into mature-B cell as observed normal B cell 
development in vivo (Mârtensson et al, 2002). These results support the use 
of this OP9-FL in vitro B cell development system to analyse the impact of PKC 
mutants throughout B cell development and transformation.
3.3.2 Establishment of an in vivo B cell generation system
HPCs derived from FL of wildtype mice were prepared, and 1 X 10^, 3 X 10^ or 
1 X 1 0 ® cells were i.p. injected into RAG-T^' neonatal mice. These mice lack 
V(D)J recombination activation gene-1, hence have no mature B or T cells. B
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cell development is halted at pro-B stage, whereas T cell development is 
stopped at pre-T cell stage, since B and T cells are incapable of rearranging the 
genes encoding the IgH chains and T cell receptor p (TCRp) chain respectively 
(Mombaerts et al, 1992). ICR mice have an outbred Swiss background, 
therefore, express H-2K'’ type MHC-I molecule, and on the other hand, RAG-T'" 
mice have a C57BI/6 background, which express H"2K*  ^type MHC-I (Fig. 3.3). 
Therefore, as expected, no H-2K^'’ cells were observed in either spleen or 
thymus from unreconstituted RAG-T^' mice (Fig. 3.3). RAG-T^' mice were 
sacrificed at 3-6 weeks from the injection, spleen cells were prepared, and the 
percentage of reconstitution was analysed by detecting surface MHC class I 
molecule, H-2K^, which is expressed on ICR mouse-derived cells. The 
reconstitution average in the spleen was around 25 % in all mice injected with 1 
X 10®, 3 X 10® or 1 X 10® cell injection (Fig. 3.4). To examine the 
reconstitution potential of injected-HPCs, the B and T cell populations were 
examined using FCM. Surface marker expression, T cell markers: CD4 vs. 
CD8, TCRp VS.CD90.2 (Thy1.2) and B cell markers: CD45R (B220) vs. IgM, 
were analysed by FCM in cells extracted from a spleen, thymus and LN of 
reconstituted mice. This analysis revealed that the reconstituted cell 
populations were different depending on the number of HPCs injected, despite 
the finding that the reconstitution efficiency appeared similar between 1X10®,  
3 X 1 0 ®  and 1 X 1 0 ® cell injections. Only B cell reconstitution was observed in 
1 X 10® MIEV-HPC injected mice (Fig. 3.5). In 3 X 10® MIEV-HPC injected 
mice, either B cell-oriented reconstitution (mouse 1) or T cell-oriented 
reconstitution (mouse 2) occurred (Fig. 3.6). Successfully, both T cells (TCRp^, 
CD90.2^, CD4^ or CD8^) and B cells (CD45R^ and lgM+) were observed in 1 X 
10® MIEV-HPC injected (Fig. 3.5), in spleen/thymus/LN and in spleen/LN, 
respectively. Taken together, 3 X 1 0 ®  MIEV-HPC injection did not provide 
reliable reconstitution of both B and T populations, whereas 1 X 1 0 ®  MIEV-HPC 
injection into RAG-T^' mice allows the robust development of both B and T cells. 
Therefore, 1 X 1 0 ®  cell injections were utilised to reconstitute B and T 
lymphocytes in mice for further examination of in vivo B cell development.
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3.3.3 Confirmation of PKC expression in GP+E.86 by HA staining
The retroviral construct utilised during these studies generates a bicistronic 
message that encodes the mutant PKC isoform coupled to GFP, thus allowing 
retrovirally-infected FIPCs to be monitored during the course of the experiment 
using cytometry by virtue of expression of GFP. In addition, all of the PKC 
mutants with the exception of PCKot-GFP are HA-tagged at either C or N 
terminus (Fig. 3.1). Therefore, direct expression of mutant PKC can be 
analysed using an anti-HA antibody. First, HA expression in the GP+E.86 
retroviral packaging cell lines expressing PKCa-KR, PKCô-KR or MIEV was 
confirmed by carrying out intracellular staining with anti-HA antibody. Both 
GP+E.86-PKCa-KR and -PKCô-KR expressed HA, 62 % and 93 %, respectively 
compared to 0.32 % in MIEV (Fig. 3.7 top and middle). In contrast, GP+E.86- 
MIEV revealed the brightest in GFP fluorescence, however, as expected, this 
cell line did not express HA (Fig. 3.7 top and middle). In accordance with the 
above results, HA expression was recognised in the lysate from GP+E.86- 
PKCa-KR, but not in GP+E.86-MIEV by Western blots (Fig. 3.7 bottom).
3.3.4 The expression of PKC mutants in the retroviral GP+E.86 packaging 
line alters the activity of PKCa
The kinase activity in GP+E.86 retroviral packaging line stably expressing 
PKCa-KR, PKCa-CAT or MIEV was examined by ELISA-based non-radioactive 
kinase assay. GP+E.86-PKCa-KR, the kinase inactive form of PKCa 
expressing GP+E.86, attenuated its PKC kinase activity by 26 % and GP+E.86- 
PKCa-CAT, the constitutively kinase activated form of PKCa expressing 
GP+E.86, elevated its PKC kinase activity by 34 % compared to GP+E.86-MIEV 
(Fig. 3.8). Therefore, this suggests that the PKCa mutants being expressed in 
these cells are functional and thus is able to alter the level of PKCa activity in 
cells.
78
3.3.5 Retroviral transfer of PKC mutants revealed that GFP^ PKCa-KR 
expressing cells exhibited growth advantage over GFP cells
PKC regulates a wide variety of cellular processes that control cell growth, 
differentiation, cell cycle and apoptosis in response to diverse stimuli (Tan and 
Parker, 2003). In order to elucidate which PKC isotype mutants can affect B 
cell development and transformation, PKC constructs were retrovirally 
introduced Into HPCs and cultured in the B cell generation system. To address 
this, HPCs from wildtype mice FL were retrovirally infected with PKC constructs; 
PKCa. PKCa-GFP, PKCa-Reg, PKCa-CAT, PKCa-KR, PKCÔ-KR, PKCÔ-CAT, 
PKC^-KR and PKC^-CAT, and empty MIEV vector control. Then, the cells 
were cultured in our in vitro B cell generation system. FCM analysis of HPC 
cultures immediately after retroviral infection revealed a GFP"^ population within 
each retroviral condition (Fig. 3.9A, day 2 MIEV 25 %, PKCa-KR 4.6 %, PKCô- 
KR 11%, PKCL-KR 3.5 %; Fig. 3.9B, day 2 PKCa-CAT 7.2 %, PKCÔ-CAT 12%, 
PKCL-CAT 16 %, Fig. 3.9C; day 2 PKCa-GFP 16% , PKCa 3.0 %, PKCa-Reg 
16 %). Of note, a greater proportion of cells were retrovirally infected in the 
MIEV control culture (Fig. 3.9A). This is likely due to the absence of a gene of 
interest in the control vector 5 ’ of GFP. As the 0P9 coculture progressed, it 
became clear that PKCa-KR-expressing (GFP^) cells displayed a growth 
advantage over the untransduced (GFP ) cells as shown by a 20-fold increase 
in the percentage of GFP'*' cells from days 2 to 14 (4.2 % vs. 98 %; Fig. 3.9A). 
This was in contrast to cocultures containing PKCa-CAT-HPCs whose GFP^ 
population was decreased from 7.2 % to 0.2 %, 36-fold loss within 12 days, 
which is not surprising considering PKCa-CAT has an enhanced kinase activity 
of PKCa, opposite to PKCa-KR (Fig. 3.9B). PKC^-KR expressing cells started 
from 3.5 % GFP^ and resulted in more than 3.2-fold decrease at day 14 (Fig. 
3.9A). This tendency for GFP'*' population to reduce as the culture progresses 
was confirmed at least three separate experiments. GFP^-PKCa-Reg- 
expressing cells also decreases 2.2-fold (Fig. 3.9C). None of the other 
constructs; PKCa-GFP, PKCa, PKCÔ-KR, PKCÔ-CAT, and PKCL-CAT and 
MIEV had any effect on proliferation during B cell development, which 
maintained a relatively constant percentage of GFP expression (Fig. 3.9A, B
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and C). The observed growth advantage of GFP^ PKCa-KR expressing cells 
was accompanied by substantial elevation in cell numbers compared with 
MIEV-cocultures, and indeed, PKCa-KR-expressing cells proliferate 1,5-times 
faster than MIEV-expressing cells (data not shown). Taken together, these 
results demonstrate that the decrease of PKCa signals leads to an increase in 
the proliferative capacity of developing B cells.
3.3.6 PKCa-KR-FL cells revealed human CLL-like phenotype in vitro
HPCs were retrovirally infected with the PKC constructs described in the Figure
3.1 and were cocultured with 0P9 cells and growth factors for 10 days. FCM 
analysis of the GFP’*' cells was carried out, utilising cell surface markers that can 
define the developmental stages of B cell maturation. More than 95 % of the 
GFP"" cocultured cells expressed the pan-B cell markers CD45R and CD19, 
establishing that the retrovirally-infected cells had committed to the B cell 
lineage as seen in non-infected cells in the Figure 3.2 (Fig. 3.10A, B and C). 
Phenotypic analysis revealed that MIEV, PKCÔ-KR, PKCô-CAT, PKCÇ-KR and 
PKC^-CAT cocultures contained similar populations of normal developing B 
cells (CD19T CD23-, IgM", CD5 ,CD45R"; Fig. 3.1 OA, 3.1 OB). Interestingly, 
cocultures expressing PKCa mutants with kinase activity, such as, PKCa, 
PKCa-GFP and PKCa-CAT, resulted in less B cell population and the B cells 
express reduced amount of IgM on surface (0.9 %, PKCa; 0.3 %, PKCa-GFP;
0 %, PKCa-CAT; Fig. 3.1 OB and 3.1 OC). PKCa-CAT-expressing cells had the 
most obvious impacts, and only 55 % became CD 19" B cells none of which 
expressed IgM on surface (Fig. 3.1 OB). PKCa-Reg expression in HPCs 
provided detrimental effects on B cell development, reducing the size of the B 
cell population and reducing the level of IgM on surface. Moreover, of surprise, 
PKCa-KR-expressing cells had upregulated CD19, CD23, CD21, a complement 
receptor (Rickert, 2005) and CD5 whilst expressing low levels of IgM and IgD by 
day 10 of coculture (Fig. 3.1 OA). Indeed, analysis of the mean fluorescence 
intensity (MFI) of key cell surface markers on B lineage cells in MIEV- 
compared with GFP" PKCa-KR populations revealed an upregulation of GDI 9 
(271 vs. 476), CD23 (1.1 vs. 14), CD21 (9.8 vs. 15) and CD5 (5.1 vs. 50)
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expression, while IgM and IgD expression were downregulated; îgM (19 vs. 2.8) 
and IgD (9.6 vs. 3.0) In GFR"" PKCa-KR-expressIng B cells. These findings 
indicate that stable expression of PKCa-KR leads to an outgrowth of cells that 
phenotypically resemble human CLL (CD19^', CDS’*', CD23^, lgM'°; Fig. 3.10A).
In addition to the established phenotype of human CLL cells in PKCa-KR- 
expressing cultures, an elevation in CD2 levels was also noted compared with 
MIEV- or PKCô-KR-expressing cultures; MFI of MIEV vs. PKCa-KR=19 vs. 204, 
thus broadening the GLL-like phenotype of the proliferating population in our in 
vitro mouse model system.
In contrast to GFP"^ PKCa-KR-expressing cells, GFP+ PKCa-CAT expression 
appeared to inhibit the progenitor cells committing to the B lineage and 
developing towards the pre-B cell stage since the level of CD19^ cells were 
significantly reduced in the culture compared to other PKG-CAT expressing 
celis (Fig. 3.1 OB). GDI 9+ CD5^ B-1 cells were not observed in these cultures. 
These findings indicate that PKGa-KR expression generates a population of 
celis that resembles GLL.
3.3.7 GFP^ cells were reconstituted in MIEV-HPC-injected RAG-T^‘ mice
The in vivo adoptive transfer system was established by transplanting 
retrovirally infected BM cells that express a gene of interest and GFP 
bicistronically, allowing injected cells to be monitored throughout the 
experiments (Pui et al, 1999). This system is a powerful tool to examine 
effects of a specific transduced gene on lymphopoiesis and transformation in a 
physiological environment. Prior to in vivo analysis on the role of PKCa-KR, a 
GFP' FIPG reconstitution potential was tested by I.p. injecting MIEV-HPGs into 
RAG-r^' mice. A correlation between percentage of GFP^ cells in HPGs pre­
injection and that of splenocytes derived from post-reconstitution of 1 X 10® 
MIEV-HPG-injected RAG-1 mice was determined by PGM analysis. Mice 
injected with 65 % GFP’*’ MIEV-HPGs were able to achieve as much as the 
average of 11 % of GFP’" cells in the spleen (Fig. 3.11, top). Two 
representative experiments from MIEV-reconstituted mice are shown in Figure
3.11 (bottom). Mouse 1 had 5.8 % and 42 % GFP'' cells in spleen and LN, 
respectively, and mouse 2 had 10 % and 42 % GFP" cells in spleen and LN, 
respectively. Both mice had an adequate number of B and T cell reconstituted 
in both spleen and LN although the orientation toward B or T cell is slightly 
different: mouse 1 had T cell orientation; 43 % GD8" T cells, 46 % GD4" T ceils 
and 3.3 % GD45R" IgM" B cells in GFP" gated LN cells, whereas mouse 2 had 
B cell orientation; 12 % GD8" T celis, 25 % GD4" T cells and 16 % GD45R" IgM" 
B cells in GFP" gated LN cells (Fig. 3.11 bottom). Taken together, it showed 
that the adoptive transfer provides successful T cell and B cell reconstitution in 
vivo, thus this system is sufficient for B celi generation system for further 
investigation for B cell development and transformation.
3.3.8 PKCa-KR-expressing ceils displayed growth advantage in vivo
To test the impact of the stable expression of PKCa-KR in vivo, retrovirally- 
infected FL-HPGs were adoptively transferred into RAG-T^' mice. Notably, 
PGM analysis of spleen and LN samples revealed an increase in the 
percentage of GFP" cells in PKGa-KR-HPG injected mice compared with MIEV- 
HPG injected mice, despite the fact that the percentage of GFP" cells in the 
PKGa-KR sample prior to injection was significantly less than that in the MIEV 
sample; prior to injection, MIEV vs. PKGa-KR=35 % (average 44.2 %) vs. 2.4 % 
(average 6.35 %), post reconstitution in spleen, MIEV vs. PKGa-KR=7.3 % 
(average 5.9 %) vs. 7.5 % (average 16 %) (Fig. 3.12, Table 3.1 and data not 
shown). This suggests that PKGa-KR expressing cells display an elevated 
proliferative potential in vivo and supports our in vitro data (Fig. 3.9A). This 
notion was supported by the finding that a reduction in the percentage of GFP" 
HPGs in the MIEV sample prior to injection resulted in a reduction in the 
percentage of GFP" cells recovered from the reconstituted spleen (Table 3.1).
3.3.9 PKCa-KR-FL cells also revealed human CLL-llke phenotype in vivo
To assess whether the population of cells observed in vitro culture (Fig. 3.10A) 
could be also generated in vivo, MIEV- or PKGa-KR-retrovirally-infected FL- 
HPGs derived from wildtype mice were injected into RAG-T^' mice and the
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lymphocyte populations of the mice were analysed from 2 weeks to 6 weeks 
post injection. The representative data of spleen cells from either PKCa-KR or 
MIEV-HPCs injected RAG-T^' mice is presented in Figure 3.13. Phenotypic 
analysis revealed that as expected, a population of mature B cells was present 
in the GFP' populations of both MIEV and PKCa-KR-injected mice (Fig. 3.13: 
GDI 9" IgM" IgD" GD23"), indicating that the HPGs derived from wildtype mice 
reconstituted RAG-T^' mice successfully as expected. PGM analysis of a 
spleen from an unreconstituted, age-matched RAG-T^' mouse (no donor) 
highlights the presence of host-derived GD45R" GDI 9" IgM' IgD' GD23' cells 
which are also present in the GFP' population of MIEV- and PKGa-KR-HPG 
donor reconstituted mice (Fig. 3.13). Mice injected with-MIEV HPGs possess a 
significant eievation in the percentage of IgM" and IgD" B lymphocytes in the 
GFP" population, confirming that this is a successful method of generating 
mature B cells in vivo (Fig. 3.13). The phenotype of splenocytes from the 
PKGa-KR HPG-injected mice resembled that of cells generated by coculture of 
PKGa-KR-HPGs with 0P9 cells in vitro (G FP\ IgM'", GD23", GD5", CD19^
IgD'"; Fig. 3.10A), representing hallmark of human GLL. Similar to that 
observed in the in vitro cocultures, analysis of the MFI of GLL cell surface 
markers on B lineage cells in MIEV- compared with PKGa-KR-GFP', GFP'" and 
GFP''' populations revealed an upregulation of GD19 and GD23 expression, 
while IgM and IgD expression was downregulated on GFP"-PKCa-KR 
expressing B lineage cells as indicated: in the order of MIEV vs. PKGa-KR, 
GFP', GFP'" and GFP"'; IgM, 31, 351, 403 vs. 74, 77, 23; IgD, 5.2, 73. 25 vs. 9.1, 
7.3, 4.5; GD23, 13, 55, 29 vs. 22, 142, 232; CD19, 91, 106, 102 vs. 101, 136, 
149. The upregulation of G D I9 and GD23 and downregulation of IgM and Ig D 
in PKGa-KR-expressing cells is concordant with the expression of GFP, thus, 
expression of PKGa-KR due to its bicistronic expression (Izon et al, 2001), but 
not in MIEV-expressing cells. Overall, subversion of PKGa causes 
transformation in developing B cells in vivo that are similar to human GLL cells 
in vitro.
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3.4 Discussion
In this chapter, it is confirmed that our in vitro and in vivo B cell generation 
systems are sufficient for anaiysing the development of mature B cells.
However, downregulation of CD43 in large pre-B cell stage and upregulation of 
CD23 in mature B ceil stage could not be observed in our in vitro B cell 
generation system under natural circumstances (Fig. 3.2). The inability of 0P9 
cells to provide optimal niches for B cell development (Tokoyoda et al, 2004) 
can be a possible explanation for these.
Cellular analyses were carried out using the B cell generation system and 
retroviral technique to investigate a role of a specific PKC isotype. These 
systems indicate that stable expression of PKCa-KR in developing B ceils 
results in the dysregulation of signalling pathways that control B cell 
differentiation and proliferation, thus driving the cells towards a CLL phenotype 
(Fig. 3.10A and 3.13). An intriguing feature of the cellular system is that B cell 
transformation is induced by the expression of a dominant negative PKGa 
molecule. This finding suggests that either PKGa kinase activity is not 
required for the generation of leukaemic cells or reduced PKG activity leads B 
cells to transform. There are reports that PKGa has a signalling role that is 
independent of its’ kinase activity, and relies on the regulatory domain behaving 
as an adapter, thus allowing protein-protein interactions resulted in subsequent 
activation of signalling pathways (Melendez et al, 2001), morphology change 
(Mandil et al, 2001), proliferation (Mandil et al, 2001) and apoptosis (Soh et al, 
2003). Yet, this seems not in the case because PKGa-Reg expression did not 
transform cells, but had rather harmful effects for B cell development. Of 
course the following possibility that it may simply be because the PKGa-Reg 
construct used contains a part of catalytic domain and may be incapable to 
translocate where the kinase should target can not be eliminated. In order to 
test whether the stable expression of the reguiatory domain of PKGa, rather 
than catalytic domain, is responsible for the outgrowth of GLL cells, HPGs will 
be retrovirally Infected with PKGa-regulatory domain only consists of PS, G1
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and C2 domains and cultured in our B cell generation system in vitro. The 
resultant cell populations will be phenotypically characterised for the CLL cell 
surface markers, such as CD19, CD23, IgM, IgD and CD5. This set of studies 
will enable us to decipher whether the transformation can occur independently 
of kinase domain. Interestingly, increased PKGa activity resulted in giving 
detrimental effects on B cells, thus, among all the mutants with PKGa activity, 
PKGa-GAT that has most enhanced PKGa activity, appeared to promote B cell 
death (Fig. 3.1 OB). Several reports showed that PKGa activation negatively 
regulate cell cycle and growth in specific cells, such as pancreatic cells (Detjen 
et al, 2000), gastric cells (Okuda et al, 1999) and intestinal epithelial cells (Frey 
et al, 2000). Therefore, B cells may be one of cells that are negatively 
modulated by PKGa activity.
While knockout mouse models have highlighted the importance of PKG|3 and 
PKG^ in controlling B cell activation, survival and proliferation (Leitges et al, 
1996, Martin et al, 2002) and PKGô in mediating B ceil tolerance 
(Mecklenbrauker et al, 2002, Miyamoto et al, 2002), none of these models 
identify specific roles for individual PKG isoforms during early B cell maturation, 
suggesting a functional redundancy may exist between PKG family members. 
Interestingly, B cells from PKGô^ mice display splenomegaly and 
lymphadenopathy due to increases in the numbers of peripheral B cells 
(Mecklenbrauker et al, 2002, Miyamoto et al, 2002), therefore it is perhaps 
surprising that HPGs expressing PKGô-KR do not display a growth advantage in 
our B cell generation systems. However, PKGô  ^ mouse-derived mature B 
cells proliferate because they are unable to undergo B cell anergy in response 
to self antigen (Mecklenbrauker et al, 2002, Miyamoto et ai, 2002). Therefore, 
lack of proliferation observed in PKGô-KR retrovirally-infected cells may be due 
to an absence of antigen in our in vitro HPG-0P9 coculture system. Previous 
findings showed that PKG^ knockout mice have abrogated BGR signalling 
results inhibition of proliferation and survival upon BGR stimulation. In PKG^'^ 
mice, the matured B cell is the target and other co-stimulation signals delivered 
by anti-IgM or anti-GD28 antibody is required to see the inhibitory effects.
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Even though decreased survival or proliferation was observed in our PKC^-KR- 
expressing cell, this appeared to happen at early stage of the development (by 
day 5; Fig. 3.9A), therefore, these results appear to differ from the observation 
from PKC^'^' mice.
The fact that PKCa-KR expression specifically transformed B cells in our 
system is perhaps unsurprising as our in vitro B cell generation system utilises 
the stromal cell line, 0P9, derived from op/op mice, which are deficient in M- 
CSF (Nakano et al, 1994). OP9 cells support haemopoiesis and 
lymphopoiesis from HPGs, but the lack of M-GSF expression contributes to the 
preferentiai development of B cells over macrophages (Nakano et al, 1994).
Our previous results suggest that expression of PKGa-KR does not trigger 
oncogenesis in developing T cells (Michie et al, 2001 ), however it remains to be 
established whether subversion of PKGa signalling can generate an oncogenic 
signal in other haematopoietic cell lineages such as NK cells, macrophages or 
granulocytes as has been established for a number of other cell types (Michie 
and Nakagawa, 2005).
Our results revealed that a GLL-like population of B cells develops on stable 
expression of PKGa-KR. Transgenic mouse with PKGa overexpression in the 
T cell lineage specifically, revealed that the T cells exhibited enhanced 
proliferation upon anti-GD3 stimulation and enhanced IL-2 production upon anti- 
GD3 and TPA stimulation (Iwamoto et al, 1992). Expression of PKGa-KR 
blocked development of T cells whereas PKGa-GAT promotes the development 
(Michie et al, 2001). Thus, PKGa expression in T cells induces proliferation 
and differentiation rather than hindrance. The studies using the PKGa^' mouse 
model show that a lack of PKGa activity does not result in enhanced 
proliferation or development of spontaneous cancers, suggesting that PKGa 
does not normaily behave as a tumour suppressor (Leitges et al, 2002).
Indeed, overexpression of PKGa in MGF-7, human breast cancer cell line, 
causes enhanced proliferation, anchorage-independent growth and morphologic 
alterations and increased tumourigenicity (Ways et al, 1995), However, there
8 6
were reports showing that overexpression of PKCa in R6 cell, rat embryo 
fibroblast cell line, inhibits cellular growth (Burger et al, 1999, Burger et al,
2000). Thus, the impact of PKCa expression appears to depend on a kind of 
cell and functions of PKCa may be regulated by more complicated way. Taken 
together, our result that subversion of PKCa causes enhanced proliferation as 
well as tumourigenicity might be expected.
One of the haiimarks of CLL is the accumulation of B cells that are arrested in 
the Gq/Gi phase of the cell cycle, due to a reluctance to undergo apoptosis 
(Bannerji and Byrd, 2000). This suggests that during the initial onset of CLL 
there is a proliferative stage, followed by cell cycle arrest. Indeed, there are 
reports that some circulating GLL cells are actually proliferating in vivo 
(Messmer et al, 2005, Quintanilla-Martinez et al, 1998). Interestingly, CLL 
cells generated from our in vitro and in vivo system are proliferating, as 
evidenced by the fact that they dominate the culture (Fig. 3.9A, 3.12 and Table 
3.1). Recently, an orange dye called Orange CMRA from Invitrogen has been 
available as a replacement of green fluorescent, GFSE (5-(and-6)- 
carboxyfluoresceindiacetate-succinimidyl ester), which is a cytoplasmic 
fluorescent to track the number of cell division. The combination of this orange 
dye and GFP will make it possible to detect the number of cell divisions in our 
cells because the fluorescent range will not overlap with GFP, which is utilised 
to track the expression of PKG construct.
In summary, a novel system has been developed that leads to the generation of 
GLL both in vitro culture and in vivo, by expressing a plasmid-encoding a 
dominant negative PKGa in HPGs. In the next chapter, this powerful system 
will be utilized to address the molecular mechanisms that mediate PKGa-driven 
transformation events.
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% GFP pre-injection ± 
SEM
% GFP in spleen post­
reconstitution ± SEM
MIEV 44.2 ± 6.75 5.94 ± 1.78
PKGa-KR 6.35 ± 1 .1 6 *** 16.1 ±5 .09  **
MIEV-diluted 1 6.35 0.22 ±0.11
MIEV-diluted II 16.8 0.72 ±0.55
Table 3.1 HPCs display a proliferative advantage upon subversion of 
PKCa signalling in vivo
The mean percentage of GFP expression is shown in MIEV- and PKGa-KR- 
HPGs prior to injection into R A G - 1 m i c e  (pre-injection; MIEV vs. PKGa-KR 
**=p < 0.05; n=7) and in the spleen of RAG-T^' mice reconstituted with 1x10® 
MIEV- or PKGa-KR-retrovirally-infected HPGs (post-reconstitution; MIEV vs. 
PKGa-KR ***=p < 0.001 ; n=8). The results shown indicate that PKGa-KR- 
expressing cells possess an enhanced proliferative capacity in vivo, as an 
increase in the percentage of GFP" cells is observed in the spleens of PKGa- 
KR-HPG injected mice compared with MIEV-HPC injected mice, despite the fact 
that the percentage of GFP" cells in the PKGa-KR sample prior to injection was 
significantly less than that in the MIEV sample. Two individual experiments are 
shown where the percentage of GFP" MIEV cells is reduced/diluted prior to 
injection and the percentage of GFP" ceils present in the spleen is further 
reduced at three weeks post injection (I: n=3; II; n=4).
Figure 3.1 Schematic representation of the structure of PKC mutants
PKCa construct contains full-length PKCa open reading frames (aa 2-672). 
PKCa-GFP construct has EGFP fused to full-length PKCa open reading frames 
at the C-terminus. PKC-KR constructs encode a full-length PKC open reading 
frames with a point mutation; lysine to arginine; PKCa (K368R) and 
PKCÔ (K376R), lysine to methionine; PKGÇ (K281M), in the G3 domain, ATP 
binding region. PKG-CAT constructs encode a truncated protein with a 
catalytic domain by deletion of the regulatory domain; PKGa (aa 326-672), 
PKGÔ (aa 334-674) and PKG^ (aa 239-592). PKGa-Reg encodes the 
regulatory domain and truncated G3 domain (aa 2-383). PKGa, PKGa-GFP, 
PKGa-Reg and PKC-KRs have HA-tag on the N terminus and PKC-CATs have 
HA-tag on the C terminus.
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Figure 3.2 The generation of mature B ceiis in vitro
Wildtype FL-derived HPCs were isolated from ICR mice at day 14 of gestation 
and HPCs were prepared as described in Section 2.4.2.1. The cells were 
cocultured on monolayer of 0P 9 cell line with growth factors, and PGM analysis 
was carried out at the indicated time point. Contour plots show the surface 
expression of GD43 vs. GDI 9, GD117 vs. GDI 9, GD24 vs. CD45R, GD25 vs. 
GD45R, K vs. IgM and vs. IgD. Data was size gated on FSG vs. SSC and live 
gated based on exclusion of PI stained cells. Percentages as indicated in 
corner of quadrants. These data are from a single experiment, representative 
of three separate experiments.
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Figure 3.3 Phenotypic analyses In cells derived from a RAG-T^ mouse
The spleen and thymus was taken from a 3-week old R A G - 1 m o u s e  and 
analysed for the expression of mouse alio- and syngeneic-MHC class I, B cell 
markers and I  cell markers; CD45R vs. IgM, CD90.2 vs. TCRp and CD4 vs. 
CDS. H-2K'^ and H-2K^ represent MHC class I for RAG-T^’ mice and for ICR 
mice, respectively. Data was size gated on FSC vs. SSC and live gated based 
on exclusion of PI stained cells. Percentages as indicated in corner of 
quadrants. These data are from a single experiment, representative of two 
separate experiments.
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Figure 3.4 Transplantation efficiency of HPCs In adoptive transfer Into 
RAG-r^* mice
Wildtype HPCs from ICR mice were i.p. injected into R A G - 1 m i c e  at the 
concentrations of 1 X 10^, 3 X 10^ and 1 X 10^ as indicated and the amount of 
reconstituted cells was analysed by PCM with H-2K^ staining, which is a surface 
marker specific to donor, ICR derived cells. The values described were the 
average (n=3-9 mice/point) ± SEM.
92
S:Cü
<D
C
g(DÛ_
m mI
1x1 QS 3x10= 1x10®
Cell number injected
Figure 3.5 Reconstitution of RAG-1  ^ mice with FL-derived HPCs
RAG-r^' mice i.p. injected with either 1 X 10^ or 1 X 10® wildtype HPCs were 
sacrificed at 6 weeks post injection and spleen, LN and thymus were extracted 
and prepared for the PCM analysis; CD45R vs. IgM, CD90.2 vs. TCR{3 and CD4 
vs. CD8. Contour plots were size gated on FSC vs. SSC and live gated based 
on exclusion of PI stained cells. Percentages as indicated in corner of 
quadrants. These data are from a single experiment, representative of three 
separate experiments.
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Figure 3.6 Reconstitution of RAG-1 mice with 3 X 1 0 ®  FL-derived HPCs
RAG-1 mice i.p. injected with 3 X 1 0 ®  MIEV-HPCs were sacrificed at 6 weeks 
post injection. Cells from spleen, LN and thymus were extracted and prepared 
for PCM analysis. The cells shown were analysed for the B and T cell 
markers; CD45R vs. IgM, CD90.2 vs. TCRp and CD4 vs. CDS. Contour plots 
were size gated on FSC vs. SSC and live gated based on exclusion of PI 
stained cells. Percentages as indicated in corner of quadrants.
94
CM
S3O
S
: O)c6
o
(03E>»
i
q qo o
o .:ICl
ÛC
ûü
: s
# 1oo
IM6| ^ d O l 800
$3O
S
SE>%
o
(Oo
oc
Qü
^ ■■■li■ -''P
H
s
qo i
CMd
ûü
e\j (OS
co Jm
CVIo 00d
d  -4-.iiQü
d w o i
o>
eo
800
Figure 3.7 Expression of PKC constructs within GP+E.86 packaging lines
The constructs containing PKC-KR mutants bicistronically express GFP, and 
are also HA-tagged at the C-terminus, therefore PKC-KR expression was 
determined by both GFP fluorescence and Intracellular staining with anti-HA 
antibody. The retroviral packaging cell line expressing vector alone (MIEV), 
PKCa-KR or PKCô-KR were examined for GFP and HA expression (top and 
middle, respectively). These data are from a single experiment, representative 
of two separate experiments. The cell lysates from GP+E.86-MIEV and - 
PKCaKR were prepared and examined HA expression by Western blots with 
antl-HA antibody (bottom). The data are from a single experiment, 
representative of two separate experiments.
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Figure 3.8 GP+E.86-PKCa-KR decreased PKC activity and GP+E.86-PKCa- 
CAT increased PKC activity
Cell lysates were prepared from GP+E.86-!\/llEV and -PKCa-KR before the 
determination of PKC activity with non-radloactive PKA kinase kit. The graph 
shows the average % kinase activity (n=3/polnt) relative to MIEV-expressing 
control cells (100%); SEM shown. *=p<0.05 a value against MIEV. These 
data are from a single experiment, representative of two separate experiments.
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Figure 3.9A Wiidtype FL-derived HPCs retrovirally-infected with PKCa-KR 
display a growth advantage over GFP and PKCa-CAT displayed a survival 
disadvantage over GFP cells
Wildtype HPCs derived FL of ICR mice were retrovirally-infected with MIEV, 
PKCa-KR, PKCÔ-KR or PKC^-KR and then cultured In our in vitro B cell 
generation system. During this period, the cultures were sampled and 
analysed by FCM for relative amounts of GFP expression, percentages as 
indicated. Histogram plots were live and size gated. These data are from a 
single experiment, representative of six separate experiments.
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Figure 3.9B WIidtype FL-derived HPCs retrovlrally-infected with PKCa-KR 
display a growth advantage over GFP and PKCa-CAT displayed a survival 
disadvantage over GFP ceils
Wildtype HPCs derived FL of ICR mice were retroviraily-infected with PKCa- 
CAT, PKCÔ-CAT or PKCÇ-CAT and then cultured in our in vitro B cell 
generation system. During this period, the cultures were sampled and 
analysed by FCM for relative amounts of GFP expression, percentages as 
indicated. Histogram plots were live and size gated. These data are from a 
single experiment, representative of five separate experiments.
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Figure 3.9C Wildtype FL-derived HPCs retrovirally-infected with PKCa-KR 
display a growth advantage over GFP and PKCa-CAT displayed a survival 
disadvantage over GFP cells
Wildtype HPCs derived FL of ICR mice were retrovirally-infected with PKCa, 
PKCa-GFP or PKCa-Reg and then cultured in our in vitro B ceil generation 
system. During this period, the cultures were sampled and analysed by FCM 
for relative amounts of GFP expression, percentages as indicated. Histogram 
plots were live and size gated. These data are from a single experiment, 
representative of three separate experiments.
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Figure 3.1 OA Stable expression of PKCa-KR in wildtype HPCs results in 
the development of CLL-like cells
Wildtype HPCs derived from ICR mice infected with MIEV, PKCa-KR, PKCô-KR 
and PKC^-KR were phenotypically characterised by FCM. The cocultures 
were harvested at day 10. Analysis of IgM vs. k , IgD vs. k , CD5 vs. CD2,
CD23 vs. CD19 and CD21 vs. CD19 expressions are shown for GFP’" gated 
cells, percentages as indicated. Contour plots were live and size gated. 
N.D.=not determined. These data are from a single experiment, representative 
of six separate experiments.
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Figure 3.1 OB Stable expression of PKCa-KR In wildtype HPCs results In 
the development of CLL-Ilke cells
Wildtype HPCs infected with PKCa-CAT, PKCÔ-CAT and PKC^CAT were 
harvested at day 14 and phenotypically characterised by FCM. Analysis of 
IgM vs. K, CD5 vs. CD2 and CD23 vs. CD19 expressions are shown for GFP^ 
gated cells, percentages as indicated. Contour plots were live and size gated. 
These data are from a single experiment, representative of five separate 
experiments.
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Figure 3.1 OC Stable expression of PKCa-KR in wildtype HPCs results In 
the development of CLL-Ilke cells
Wildtype HPCs infected with PKCa, PKCa-GFP and PKCa-Reg were harvested 
at day 14 and phenotypically characterised by FCM. Analysis of IgM vs. k ,
CDS vs. CD2 and CD23 vs. CD19 expressions are shown for GFP+ gated cells, 
percentages as indicated. Contour plots were live and size gated. These 
data are from a single experiment, representative of three separate experiments.
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Figure 3.11 GFP+ cells were detected in MIEV-HPC-reconstituted RAG-1 ' 
mice
The retroviral vector MIEV encode EGFP protein and MIEV infected cells can 
be monitored throughout the experiments by virtue of GFP. 1 X 10® HPCs from 
ICR mice were injected into RAG-T^' mice and the amount of reconstituted cells 
was analysed at 4-6 weeks post injection by FCM with H-2K^ staining, which is 
a surface marker specific to donor, ICR mice. The correlation of the GFP^ 
population in MIEV-HPCs before injection and the amount of reconstituted H- 
cells is shown. The values described were the average (n=2-4 
mice/point) ± SEM (top). RAG-T^' mice injected with 1 X 1 0 ® MIEV-HPCs were 
sacrificed at 4-6 weeks post injection. Cells from spleen and thymus prepared 
for FCM and cells shown were gated on GFP and analysed for the B and T cell 
markers; CD45R vs. IgM and CD4 and CD8. Contour plots were size gated on 
FSC vs. SSC and live gated based on exclusion of PI stained cells.
Percentages as indicated in corner of quadrants (bottom).
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Figure 3.12 GFP^ PKCa-KR-expressing cells showed enhanced 
proliferation in vivo
MIEV- and PKCa-KR-retroviraiiy-infected HPCs prior to injection into RAG-T^' 
mice (pre-injection) and splenocytes derived from RAG-1  ^ mice reconstituted 
with 1x10® MIEV- or PKCa-KR-retroviraliy-infected HPCs (post-reconstitution) 
after 4-6 weeks injection were analysed their GFP intensity by FCM. The 
results were size gated on FSC vs. SSC and live gated based on exclusion of 
PI stained cells. Representative data of more than 10 separate experiments is 
shown.
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Figure 3.13 Splenocytes from PKCa-KR-infected-HPC Injected RAG-1  ^
mouse displayed a CLL-Ilke phenotype
1 X 10® of either PKCa-KR- or MIEV-infected cells were i.p. injected into 
RAG- 1 mo us e .  Spleen cells from reconstituted mice were analysed 3 week 
after the injection. FCM was carried out on GFP , GFP'™ and GFP""' 
populations, IgM vs. CD45R, IgD vs. CD45 and CD23 vs. CD19, percentages 
as indicated. Plots were live and size gated. This is a representative 
experiment from five separate adoptive transfers.
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Chapter 4:
Subversion of PKCa signalling results in the outgrowth of a 
population of B lineage cells that have key hallmarks of CLL
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4.1 Introduction
4.1.1 The potential link between PKC and CLL
Although PKC-mediated signalling pathways are suggested to be associated 
with the survival of CLL cells, the role of individual PKC isoforms has not been 
well elucidated. Previously, it was reported that activation of PKC with phorbol 
esters and bryostatin, which structurally mimic DAG and bind to the regulatory 
domain of cPKC and nPKC, thus triggering activation of these PKC isoforms, 
decreases spontaneous and chemotherapy-induced apoptosis in CLL cells 
(Barragan et al, 2003). Moreover, the PKC activation by byrostatin 
upregulates Mcl-1 and X-linked inhibitor of apoptosis proteins (lAP) expression, 
which correlates with cell survival (Kitada et al, 1999). In accordance with this, 
treatment of CLL cells with the nPKC inhibitor, rottlerin (Ringshausen et al, 2006, 
Ringshausen et al, 2002), or the pan PKC inhibitors, bisindolylmaleimide I (BisI) 
(Barragan et al, 2002) or UCN-01, a straurosporine derivative, (Kitada et al, 
2000) induces apoptosis of CLL cells. Among all the isoforms, PKCô is 
considered as a causative molecule in CLL because this PKC isoform is 
constitutively expressed in human samples and phosphorylated on tyrosine in a 
PI3K dependent manner (Alkan et al, 2005, Ringshausen et al, 2002).
Therefore, PKCô may act as a downstream effecter in the survival of these 
leukaemic cells. In addition to PKCô, constitutive expression of PKC|3, y, and ^ 
isoforms have been observed in human CLL, and at best, a low level of PKCct 
expression was detected in CLL samples (Alkan et al, 2005). Moreover, the 
overall PKC activity in CLL appeared lower compared to acute myeloid 
leukaemia (AML) and acute lymphoblastic leukaemia (ALL) samples (Komada 
et al, 1991). This relatively low PKC activity and lack of PKCa expression in 
human CLL may have an important bearing on our CLL model that results from 
the subversion of PKCa.
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4.2 Aims and Objectives
It was interesting and surprising to find that the subversion of PKCa in HPCs 
resulted in the generation of CLL-like cells with enhanced proliferation. 
Therefore, the mechanisms that underlie this transform event both in vitro and 
in vivo were chosen to study, because to date, there are no good animal models 
available to study CLL. Therefore, to gain a deeper understanding of our CLL 
system, the aims of this chapter were:
i. To confirm the expression of PKCa-KR in retrovirally infected primary 
cells in vitro.
ii. To analyse cell cycle and proliferation level in PKCa-KR-expressing cells 
in vitro.
ill. To examine anti-apoptotic mechanisms in PKCa-KR-expressing cells in 
vitro.
iv. To test the effects of IL-7 in PKCa-KR-expressing cells in vitro.
V. To examine the expression of IgM molecules in PKCa-KR-expressing
cells in vitro.
vi. To study the cell cycle in cells generated from PKCa-KR-HPCs and 
MIEV-HPCs in vivo.
vii. To assess the signalling pathways associated with CLL survival in vitro.
viii. To identify the molecular mechanisms that are modulated by PKCa-KR to
drive oncogenesis.
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4.3 Results
4.3.1 Confirmation of PKCa-KR expression in PKCa-KR-FL ceils
Previously, PKCa-KR expression in GP+E.86-PKCa-KR packaging line was 
determined by HA staining due to a HA tag fused to C-terminus of the PKCa-KR 
construct as described in Section 3.3.3, now the intracellular HA expression in 
PKCa-KR-expressing FL cells was tested. FCM analysis revealed that 66 % of 
HA^ cells among GFP^ PKCa-KR-expressing cells, but not in GFP^ MIEV- 
expressing cells at day 16 of coculture. Of note, MIEV-expressing cells 
expressed GFP higher than PKCa-KR-expressing cells, possibly due to the lack 
of gene of interest (Fig. 4.1).
4.3.2 Attenuation of kinase activity in PKCa-KR-expressing cells at early 
stage is important for leukaemic events
The level of PKC activity was examined in PKCa-KR- and MIEV-expressing 
cells at day 10 by non-radioactive ELISA-based kinase assay. As described in 
Section 3.3.4 that showed the reduction of kinase activity in GP+E.86-PKCa-KR, 
a 50 % reduction in kinase activity was detected in PKCa-KR-expressing cells 
compared to MIEV-expressing cells at dIO culture (Fig. 4.2). A radioactive 
PKC kinase assay detecting '^^P-labelled PKC-specific substrate peptide was 
also carried out and this revealed that 33 % attenuation in the activity in dIO 
PKCa-KR-expressing cells compared to dIO MIEV-expressing cells (Fig. 4.3 
top), but surprisingly, PKC activity increased 16 % in d17 PKCa-KR-expressing 
cells relative to d17 MIEV-expressing cells (Fig. 4.3 bottom). In support of the 
decreased PKCa activity in PKCa-KR-expressing cells at day 10, Western blots 
analysis revealed a decreased level of serine phosphorylation of downstream 
substrates of PKC in lysates derived from PKCa-KR-expressing cells compared 
to MIEV-expressing cells. In addition, a reduction in the level of 
phosphorylation of PKC substrates was noted on TPA stimulation in PKCa-KR- 
expressing cells compared to MIEV (Fig. 4.4).
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A similar expression level of PKCa was found in the lysate of PKCa-KR- 
expressing cells compared to that of MIEV-expressing ceils at day 10 when they 
were probed with anti-PKCa antibody (Fig. 4.5). The same blot was stripped 
and reprobed with anti-pan-phospho-PKC antibody that can recognise PKC 
phosphorylated at a carboxyl-terminal residue homologous to serine 660 of 
PKC pll. Phosphoryl isoforms can be differentiated by virtue of size: PKCe, 
85kDa; PKCa, 82kDa; PKC|3I, (311, n and 9, 80 kDa; PKCô, 78kDa. Utilising 
this antibody, it was demonstrated that PKCa is the only phosphorylated PKC 
isoform detected within these cells, as these bands were in the same location 
as those of anti-PKCa probed blot. The level of phosphorylation was similar 
among all the samples (Fig. 4.5).
4.3.3 Growth advantage in PKCa-KR-expressing cells occurs as a result of 
explosive proliferation
A growth advantage of GFP'' PKCa-KR-expressing cells over GFP' population 
was observed as described in Section 3.3.5, therefore, PI staining was carried 
out to assess potential changes in the cell cycle. This set of analysis was 
performed on day 12 PKCa-KR- and MIEV-expressing cells as >90% of PKCa- 
KR-expressing cells were GFP'' at this stage (Fig. 3.9A). The analysis showed 
that there was no significant difference in the cell cycle pattern between PKCa- 
KR-expressing cells and MIEV-expressing cells. However, these data 
confirmed that the relative elevation in cell number in PKCa-KR-expressing 
cells was not due to an increase in apoptosis in MIEV-expressing cells (Fig. 4.6). 
To address whether the elevation in cell number in GFP+ PKCa-KR-expressing 
cells was due to an enhanced proliferation, the cells were analysed by BrdU 
incorporation to measure the level of DNA synthesis in the cell cultures. This 
set of analysis revealed that 55 % PKCa-KR-expressing cells were in the S 
phase compared with 42 % MIEV-expressing cells (Fig. 4.7). It was noted that 
PKCa-KR-expressing cells possessed an increased proliferative capacity as 
shown by their ability to incorporate 1.3 times more BrdU compared with MIEV- 
expressing cells. Taken together, these results show that in the presence of
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0P9 cells and IL-7 the subversion of PKCa signals leads to an increase in the 
proliferative capacity of B lineage cells.
4.3.4 The level of expression of cyclln-dependent kinase Inhibitors, p21'"^ ‘^  ^
and p27'"""'\ was relatively higher In PKCa-KR-expressing cells
In order to investigate the mechanism that underlies enhanced proliferative 
capacity in PKCa-KR-expressing cells, the transcript level of CDK inhibitors,
and p27’'’P'\ was examined. The mRNA was extracted from the PKCa- 
KR- and MIEV-cultures at the indicated day in the figure legend and semi- 
quantitative RT-PCR was carried out using either p21'^ ^^ "^  specific or 
specific primer pairs. Interestingly, the mRNA level of both p21'"^'’  ^ and p27 '^'"'  ^
was maintained in PKCa-KR-expressing cells throughout the culture, whereas 
those of MIEV were diminished by day 14 compared with p2m (Fig. 4.8),
4.3.5 PKCa-KR-expressing cells are able to evade apoptosis
One of the hallmarks of CLL is the accumulation of B lineage cells that are 
arrested at the Gq/Gi phase of the cell cycle and refractory to apoptosis 
(Bannerji and Byrd, 2000). To test whether PKCa-KR-expressing cells are 
able to survive in the absence of both 0P9 cells and IL-7, GFP'' ceils were 
counted by FCM after withdrawal of both factors. PKCa-KR- and MIEV- 
expressing cells were cultured in the presence of 0P 9 cells and IL-7 up to day 
12, and then 1 X 10"^  cells from each condition were cultured for 3 consecutive 
days in the absence of both OP9 cells and IL-7 and an aliquot from each culture 
was counted by FCM. The results showed that PKCa-KR-expressing cells 
were able to survive under these conditions for 3 days, while the majority of 
MIEV-expressing cells were dead after 2 days in culture, indicating that PKCa- 
KR-expressing cells are transformed and are able to evade cell death (Fig. 4.9). 
PI analysis on day 14 of culture, i.e. after 2 days in culture in the absence of 
OP9 cells and IL-7, revealed that 3.4-fold more cells were at the sub Gq/G^ 
stage in MIEV-expressing cells, representing cells that were undergoing 
apoptosis. This finding indicated that the PKCa-KR-expressing cells were able 
to evade apoptosis (Fig. 4.10). Moreover, 75 % of PKCa-KR-expressing cells
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were halted in the Gq/G i phase >2-fold higher than 35 % MIEV-expressing cells. 
When the capacity of cells to incorporate BrdU was analysed using day 14 
cultures under the same condition, 20 % of the PKCa-KR-expressing cells were 
still cycling whereas only 6.5 % of MIEV-expressing cells were cycling (Fig. 
4.11).
4.3.6 The level of Bcl-2 and IVIcl-1 transcripts in PKCa-KR-expressing cells 
is reiatively higher than In MIEV-expressing cells
To gain an understanding of the mechanism by which PKCa-KR-expressing 
cells modulate apoptotic rates, the level of mRNA expression on anti-apoptotic 
Bcl-2 family members was analysed. The results of RT-PCR showed that Bcl- 
2 and Mcl-1 transcript levels remained elevated in day 14 PKCa-KR-expressing 
cells although they were downregulated in MIEV cultures. When normalised to 
p2m expression, the expression levels of Bcl-2 and Mcl-1 were 3.7-fold and 1.5- 
fold higher than those of MIEV at day 14, respectively (Fig. 4.12). In contrast, 
the level of Bcl-xL transcripts remained unchanged in both MIEV and PKCa- 
expressing cells. Collectively, these studies provide a casual link between the 
subversion of PKCa signalling in developing B lineage cells and the generation 
of a transformed population that can escape apoptosis via a process that likely 
involves the upregulation of Bcl-2 and Mcl-1.
4.3.7 IL-7 accelerates proliferation In PKCa-KR-expressing cells
To test the effects of IL-7 on the survival and proliferation of CLL-like cells, 1 X 
lO'^day 12 PKCa-KR- and MIEV-expressing cells were cultured for further 3 
days in the absence of OP9 cells and in the presence of IL-7, and then an 
aliquot of each culture was counted by FCM as indicated in the figure legend. 
These experiments suggested that IL-7 supported survival of MIEV-expressing 
cells during the culture, as our previous results indicated that no live cells were 
left after 3 day culture in the absence of both 0P9 cells and IL-7 (Fig. 4.9). 
Indeed, 45 % of MIEV-expressing cells survived after 3 days (Fig. 4.13). 
Interestingly, this cytokine in the absence of 0P9 cells induced pronounced 
proliferation on PKCa-KR-expressing cells, and the cell number increased 4.7-
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fold after 3 days in culture, suggesting these cells may be more sensitive to IL-7 
and do not require 0P9 to proliferate (Fig. 4.13). Therefore, the level of mRNA 
expression on IL-7 receptor (IL-7R) was analysed. The results of RT-PCR 
showed that IL-7R transcript levels were elevated in both the MIEV and PKCa- 
KR compared to day 0 cultures at day 8, PKCa-KR-expressing cells further 
upregulated IL-7R at day 14 compared with MIEV cultures, resulting in a 1.9- 
fold higher expression in PKCa-KR-expressing cells at day 14. Taken together, 
our results show that IL-7 is an essential cytokine for the proliferation in PKCa- 
KR expressing cells.
4.3.8 Long-term culture, M-1 cells were established from PKCa-KR- 
expressing cells
M-1 cells were generated by culturing PKCa-KR-HPCs in the absence of 0P9 
cells and IL-7, and GFP'" CD5'° population was sorted out by cell sorter as 
described in Section 2.4.10. The sorted cells were characterised by post-sort 
FCM analysis (Fig. 4.15). The cells were >99 % GFP'' and CD45R'^. Most 
cells are CD19' and CD23'and there is the mixture of CD5'' and CDS' population 
(Fig. 4.15), suggesting M-1 cells consist of mixed oligoclonal population.
These cells were established for molecular analysis of long-term cultured CLL 
cells.
4.3.9 Recombined IgM molecules are expressed in PKCa-KR- expressing 
cells
As described in Section 3.3.6, the surface expression of IgM in PKCa-KR- 
expressing cells was reduced. Therefore, to examine the level of intracellular 
IgM expression, intracellular staining using anti-IgM antibody was carried out in 
both PKCa-KR- and MIEV-expressing cells. Confirming previous data, the 
surface IgM expression on PKCa-KR-expressing cells was only 0.33 %, which 
was 3.9-fold less than that of MIEV-expressing cells (Fig. 4.16). On the other 
hand, the percentage of intracellular IgM expression in PKCa-KR-expressing 
cells was 1.5 %, 4.5-fold higher than that of surface expression, whereas the 
percentage of intracellular IgM expression in MIEV-expressing cells was 2.5 %,
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only 1.9-fold higher than that of surface expression (Fig. 4.16), suggesting that 
IgM is synthesised in PKCa-KR expressing cells, but actively withheld within the 
cell. Molecular analysis of the IgH in the D to J locus in both MIEV and PKCa- 
KR cellular populations revealed that a similar pattern of multiple, random 
rearrangements occurred in both populations, which is similar as that of the 
control, normal B cells from spleen of a wildtype mouse (Fig. 4.17). M-1 cells 
mainly possessed 1300 bp and 120 bp bands, DhiJhi and DhiJh4« respectively, 
indicating that this cell line possibly developed from 2 clones, thus, they 
contained oligoclonal populations. DhiJhi band was brighter than the lower 
DhiJh4 band, suggesting that one clone has dominantly expanded in the culture 
in the absence of 0P 9 cells or IL-7. These results served to confirm that the 
proliferating PKCa-KR population arose from a number of distinct transformed 
progenitor cells.
4.3.10 RAG-1  ^ mice Injected PKCa-KR-HPCs bore subcutaneous tumour, 
lymphadenopathy and splenomegaly
In addition to the generation of human CLL-like populations within the spleen 
and LN of PKCa-KR-HPCs injected mice as described in Section 3.3.9, a 
subcutaneous (s.c.) tumour cell mass was also noted at the site of injection. 
These tumours were only present in PKCa-KR-HPC injected mice and 
resembled an enlarged LN (Fig. 4.18 top). PKCa-KR-HPCs injected mice 
survived no longer than 6 weeks (Fig. 4.18 bottom). This is possibly because 
of progression of tumours that seems to be early onset in this in vivo model.
The spleen from 1 X 1 0 ® PKCa-KR-HPCs injected mice was larger than that of 
1 X1 0 ® MIEV-HPCs injected mice (Fig.4.19 top). The splenomegaly in 1 X 
10® PKCa-KR-HPCs injected mice accompanied the increase of GFP+ 
population and the cellularity is 18-fold higher compared to that of 1 X 10® 
MIEV-HPCs injected mice (Fig. 4.19 bottom). Similar to spleen, 
lymphadenopathy was observed in these mice.
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4.3.11 Tumour cells also showed typical CLL phenotype
FCM analysis of the tumour mass revealed that the majority of the cells were 
GFP^ (89 %; Fig. 4.20), and phenotypicaily the cells resembled the CLL 
population observed in the spleen and LN (IgM'®, CD23+, CD5^, CD19'^', lgD'° as 
described in Section 3.3.9). It has been shown previously that the level of 
gene expression in bicistronic retroviral vectors can be directly related to the 
intensity of GFP expression (Izon et al, 2001), therefore it is interesting to note 
that the expression levels of CD23, CD19 and CDS were elevated with 
increasing GFP expression in the s.c. tumours. This was demonstrated by 
comparing the MFI for specific cell surface markers on B lineage cells in PKCa- 
KR GFP^° compared with GFP^' populations: CD19 (98.0 vs. 99.2), CD23 (90.1 
vs. 172) and CDS (23.2 vs. 66.7) (Fig. 4.20). Additionally, in agreement with 
our previous in vitro and in vivo data, IgM expression was downregulated on the 
tumour cells with increasing GFP expression levels (16.2 vs. 11.6; Fig. 4.20). 
This finding suggests that the frequency of CLL cells increases with elevating 
levels of PKCa-KR expression in vivo.
4.3.12 Tumour cells are halted at Gq/G  ^ phase of cell cycle ex vivo
As enhanced proliferation was observed in PKCa-KR-expressing cells in vitro 
as described in Section 4.3.3 and in vivo (Fig. 3.12 and Table 3.1), the cell cycle 
profile was analysed by PI staining in in vivo samples. To obtain a most 
homogenous population of mature B cells or GFPVCD23'^-PKCa-KR expressing 
cells from MIEV- or PKCa-KR-HPCs-injected mice, respectively, MACS-sorting 
was carried out: lgD‘" cells from a mixture of spleen and LN of MIEV-HPCs- 
injected mice; lgDVCD23+ cells from a mixture of spleen and LN of PKCa-KR- 
FlPCs-injected mice, and; CD23'*' cells from tumours of PKCa-KR-HPCs-injected 
mice. The results revealed that tumours had a higher percentage of cells 
arrested in the Gq/Gi stage ex vivo (92 %) compared with LN and spleen cells 
(82 %) from the same PKCa-KR mouse, indicating tumour cells did not divide, 
which is another striking feature of CLL (Fig. 4.21, dO). The mature B cells 
from spleen and LN of MIEV-HPCs-injected mouse also arrested at Gq/Gi,
(95 %) as expected due to their quiescence (Fig. 4.21, dO). This is probably
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because cells from spleen and LN are proliferating whereas tumour cells have 
undergone cell cycle arrest.
To determine whether the tumour cells could be induced to proliferate, therefore 
overcoming the cell cycle arrest, all the in vivo derived cells were seeded onto 
0P9 cells in the presence of IL-7 and the cell cycle profile was determined after 
5 days in culture. Of interest, PI analysis revealed that the tumour cells re­
entered cell cycle (GgM/S, 6.0 % to 31.3 %), and the spleen and LN cells from 
PKCa-KR-HPCs-injected mice also proliferated more vigorously compared to 
the day 0 profile (GglVl/S, 17 % to 40 %), suggesting that these cells maintain 
the ability to re-enter the cell cycle when introduced into the proliferative 
conditions of the in vitro cultures (Fig. 4.21 ). Of note, tumour cells and LN cells 
from PKCa-KR-HPCs-injected mice did not apoptose, indicating that these cells 
were protected from apoptosis in the presence of 0P 9 cells and IL-7. On the 
other hand, the spleen and LN cells from MIEV-HPCs-injected mice were prone 
to apoptosis (13 %) and majority of the cells were halted at Gq/Gi (Fig. 4.21).
4.3.13 The impact of pharmacological Inhibitors on PKCa-KR-expressIng 
cells were different depending on their developing stage
P13K-, ERK-MAPK- and PKC-mediated pathways have also been implicated in 
mediating the survival of human CLL cells (Barragan et al, 2002, Ringshausen 
et al, 2006, Ringshausen et al, 2002). Therefore, to address whether these 
signalling pathways play a role in the survival of PKCa-KR-expressing CLL cells, 
PKCa-KR- and MIEV-expressing cells and M-1 cells were treated with 
pharmacological inhibitors (Section 2.2) for 24 h; PKC inhibitors (cheierythrine 
and rottlerin), MARK inhibitors (U0126, SB203580 and PD98059) and P13K 
inhibitors (LY294002 and wortmannin) were used as indicated. HPCs derived 
from wildtype mice were retrovirally infected with MIEV or PKCa-KR and 
cocultured with OP9 for 16 days, therefore the majority of PKCa-KR cocultures 
consisted of the retrovirally infected GFP+ population. Phosphatidylserine 
exposure on the outer PM, which is an early indication of apoptosis, was 
detected using Annexin V and analysed by FCM.
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Our studies revealed that addition of PKC inhibitors did not induce spontaneous 
apoptosis on any of the cell populations tested (Fig. 4.22A). Both U0126 and 
PD98059 (MEK inhibitors) selectively induced a significant increase of 
apoptosis in long-term cultured PKCa-KR expressing cell, M-1 (Fig. 4.22 top 
and middle). Thus a 6.4-fold increase in apoptosis was observed compared to 
MIEV-expressing cells at 10 piM U0126. The p38-MAPK inhibitor, SB203580 
did not affect either MIEV- or PKCa-KR-expressing cells, suggesting that p38- 
MAPK is not involved in CLL-survival. Indeed, M-1 cell survival was enhanced 
upon treatment with 5 p.M SB203580 (Fig. 4.22B bottom). LY294002 appeared 
to induce apoptosis at 10 juM to all the cells, but PKCa-KR-expressing cells 
were most sensitive and thus the apoptosing ratio in PKCa-KR-expressing cells 
is 1.5-fold higher than MIEV-expressing cells (Fig. 4.22C top). Wortmannin 
caused apoptosis in both MIEV- and PKCa-KR-expressing cells, but not in M-1 
cells (Fig. 4.22C bottom). Next, day 10 cocultures were treated with U0126 
and LY294002 and the amount of apoptosis was analysed by FCM. Similar to 
that noted in d17 cocultures, apoptosis was observed in response to U0126 at 
day 10. However, day 10 MIEV-expressing cells were more sensitive than 
PKCa-KR-expressing cells to LY294002, which is opposite to that observed in 
day 17 cultures (Fig. 4.23). Taken together, ERK-MAPK and PI3K pathways 
seem to be key signalling pathways for survival in PKCa-KR-expressing cells 
and the mechanism of regulation by these pathways is different depending on 
the duration of culture.
4.3.14 PI3K and ERK signalling pathways were Involved in PKCa-medlated 
transform
In order to further address the role played by the ERK-MAPK and P13K 
pathways, the phosphorylation status of ERK1/2 and AKT, which is a 
downstream target of P13K, was analysed in retrovirally infected HPCs and M-1 
cells by Western blots. HPCs from wildtype mice FL were retrovirally infected 
with MIEV or PKCa-KR and cocultured with 0P9 for up to 15 days. Whole cell 
lysates were prepared and resolved by SDS-PAGE. The resultant gel was
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transferred to PVDF membrane and probed with anti-pERK1/2 antibody and 
anti-pAKT(T308). Of note, PKCa-KR-expressing cells exhibited an elevation in 
phosphorylation of ERK1/2, with a marked increase in ERK1 phosphorylation 
during the early stages of the coculture, whereas there was weak 
phosphorylation detected on ERK1/2 in MIEV-expressing cells (Fig. 4.24). The 
phosphorylation level of ERK1/2 was sustained in PKCa-KR-expressing cells, 
with stronger phosphorylation of ERK2. However, surprisingly, M-1 cells lost 
the high phosphorylation levels of ERK1/2 during long-term culture. These 
results suggest that ERK1 signal may preferentially mediate proliferation and 
survival in CLL-like cells at proliferative early stage. Phosphorylation on T308 
of AKT, which is necessary for maximal AKT activation (Gold et al, 1999), was 
evident in the ICR-day 8 MIEV cocultures, whereas no signal was detected in 
ICR-day 8 and day 15 PKCa-KR cocultures or at later stages of the cultures.
In samples derived from R a g - 1 m i c e  whose B cells are blocked pro-B cell 
stage, higher phosphorylation of AKT was noted compared with wildtype mice. 
This is possibly because AKT is important at the pro-B cell stage of 
development. Of note, AKT was less phosphorylated in PKCa-KR-expressing 
cells. These results support previous findings that AKT is essential for normal 
B lymphocyte development (Fruman et al, 1999), but may not be responsible for 
the aberrant survival of PKCa-KR cells.
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4.4 Discussion
Collectively, these results indicate that the attenuation of PKCa signalling during 
early B cell development acts as an oncogenic trigger for developing B cells, 
resulting in the spontaneous generation of transformed cells that bear many of 
the hallmarks of CLL both in vitro and in vivo. The subversion of PKCa 
signalling in mouse HPCs generates a leukaemic population that has a striking 
resemblance to human CLL at the level of; (i) phenotype - CD19 '^ CD5^ CD23" 
lglVl'°; (ii) cell cycle phase - halted in Gq/Gi ex vivo, and; (iii) resistance to 
apoptosis - possibly due to an elevation in Bcl-2 and Mcl-1 expression. 
Moreover, PKCa-KR-expressing cells possess an enhanced proliferative 
capacity at the initiation of transformation both in vitro and in vivo. These data 
establish an important link between PKCa and CLL and provide an excellent 
model system to study the cellular and molecular mechanisms that drive the 
induction of CLL as well as role that PKCa specifically plays in the development 
of this disease.
This is to our knowledge the first time that PKCa has been specifically linked to 
the induction of CLL. PKC-mediated signalling pathways have been 
associated with the survival of CLL cells, but the role of individual PKC isoforms 
has not been elucidated (Barragan et al, 2002). As shown in the previous 
chapter, the ability to induce the development of CLL in HPCs only occurs upon 
PKCa, but not PKCô or PKCC subversion, suggesting that this is a unique 
property. This is supported by the fact that only PKCa is phosphorylated in 
early developing B cells (Fig. 4.5). When the PKCa-KR was expressed in 
developing B cells, certainly the reduction of PKCa activity was observed in the 
PKCa-KR early cultures (Fig. 4.2, 4.3 and 4.4), suggesting that the reduction in 
kinase activity at the early stage of B cell development is essential for B cell 
transformation. The different level of reduction in kinase activity was observed 
between non-radioactive ELISA kit (50 %) and radio active ®^ P kit (33 %) (Fig.
4.2 and 4.3). The former is not PKC specific and thus is also able to assess
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the PKA activity, suggesting that the activity of other kinase is reduced in PKCa- 
KR-expressing cells. However, an increased kinase activity was observed in 
the later PKCa-KR cultures, which may be caused by the transformation of B 
cells resulting in induction of enhanced PKCa activity. ®^ P assay kit used is not 
specific for PKCa and may represent an increase in other PKC isoform activity, 
such as PKCÔ, possible molecule for a cross-talk to PKCa (Koivunen et al, 
2006). The growth advantage of PKCa-KR-expressing cells was accompanied 
by an enhanced proliferation and upregulation of p21'^"’ '^^  and p27'''' '^  ^at mRNA 
level (Fig. 4.7 and 4.8). CDK inhibitors, p21' '^*'’  ^and p27'"'^ \  are known as a 
putative tumour suppressor, however, it has recently been suggested that they 
function as an oncogene when they are in cytoplasm not in nucleus 
(Blagosklonny, 2002). Therefore, the involvement of p21'"^ ’^  ^and p27'"’''^  in the 
progression of proliferation, is not counterintuitive.
lL-7 is an essential cytokine for mouse B cell development, survival and 
proliferation (Fry and Mackall, 2002). Murine developing B cells display a low 
threshold for IL-7-induced proliferation at pre-pro B cell stage and early pre-B 
cell stage. This sensitivity is lost at the late-pre B cell stage (Marshall et al, 
1998). Proliferation of MIEV-expressing cells did not appear to be lL-7 
dependent anymore (Fig. 4.13), indicating that MIEV cells had progressed 
beyond the late-pre B cell stage after day 12. However, the PKCa-KR- 
expressing cells exhibited pronounced level of IL-7 response, the transformation 
events may occur at either pre-pro B cell- or early pre-B ce 11-stage. IL-7Ra is 
upregulated as early as CD45R^ CD19' B cell precursor stage and the 
expression is maintained until the early pre-B cell stage and is downregulated 
afterwards (Tudor et al, 2000). The RT-PCR results reveal that normal 
upregulation and downregulation of lL-7Ra occurred in MIEV-expressing cells, 
but PKCa-KR-expressing cells maintained the upregulated IL-7Ra (Fig. 4.14), 
which may be induced by their high response to lL-7. Moreover, lL-7 is known 
as a survival factor that induces anti-apoptotic Bcl-2 protein expression, such as 
Bcl-2 (Marsden and Strasser, 2003) and Mcl-1 (Opferman et al, 2003) in T cells. 
This high response to IL-7 and possible increased sensitivity to lL-7 by elevated
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ÎL-7R expression in these cells may explain the relatively higher expression of 
Bcl-2 and Mcl-1.
It is becoming increasingly evident that CLL cells are resistant to apoptosis and 
arrested at the Gq/G i phase of the cell cycle (Bannerji and Byrd, 2000). In 
keeping with CLL cells, PKCa-KR-expressing cells have resistance to apoptosis 
induced by withdrawal of 0P9 cells and IL-7, and moreover, majority of cells are 
arrested at Gq/G i cell cycle stage (Fig. 4.10). There was more BrdU 
incorporation in PKCa-KR-expressing cells compared to MIEV-expressing cells 
when they were cultured in the absence of 0P9 cells and IL-7, therefore, 
indicating that PKCa-KR-expressing cells were still cycling in the absence of 
stroma and cytokines. The proliferative potential of PKCa-KR-expressing cells 
is reduced 2-fold in the absence of stroma and growth factors (Fig. 4.11) 
compared to normal culture conditions (Fig. 4.7) (58 % vs. 20 %), however, 
PKCa-KR-expressing cells did maintain their cellularity after 2 days in culture in 
the absence of 0P9 cells and lL-7 (Fig. 4.9). Bc/-2fam ily genes in CLL cells
have long been reported to favour the suppression of apoptosis (Bannerji and 
Byrd, 2000), and a member of the Bcl-2 protein family, Mcl-1 was found to 
correlate with failure to undergo apoptosis in response to chemotherapy (Kitada 
et al, 1998). Therefore, the resistance of apoptosis in PKCa-KR-expressing 
cells may be explained by relatively higher level of Bcl-2 and Mcl-1 expression 
in these cells compared to control cells.
While tumours are not a characteristic of CLL, PKCa-KR-expressing cell 
injected mice generate s.c. tumour mass at the injection site in vivo (Fig. 4.18). 
Indeed, similar tumours develop when human CLL cells are s.c. injected into 
severe combined immune deficiency (SCID) mice, suggesting that some PKCa- 
KR-HPCs became trapped s.c. at the time of injection and developed into 
tumours (Mohammad et al, 1996). Although spleen and LN cells from PKCa- 
KR-HPCs-injected mouse were in the GgM/S phase when they were isolated, 
the tumour-derived cells arrested at Gq/Gi stage, which is a hallmark of CLL. 
Presumably, there is no growth factor or stroma at the location where the
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tumour formed, therefore, tumour cells may mirror the in vitro culture condition; 
no stroma or growth factor, which also arrested at Gq/Gi stage. Interestingly, 
culture of these tumour-derived cells fresh ex vivo in the presence of 0P9 cells 
and IL-7 renders them re-enter the cell cycle, which may explain two phases of 
this disease between proliferative and quiescent (Dighiero, 2005). Tumour- 
derived cells resulted in cell death when they were cultured in the absence of 
both 0P9 cells and lL-7, a finding that is common in CLL cells isolated from 
patients (data not shown).
A previous report showed that human CLL samples expressed an increased 
percentage of IgM^ cells intracellularly in spite of low surface IgM expression 
(Payelle-Brogard et al, 2002). This low level of surface expression is probably 
attributable to impairment of the glycosylation and folding of \x and Iga chains, 
leading to defective assembly and the retention of these chains in the ER 
compartment (Vuillier et al, 2005). It was demonstrated that PKCa-KR- 
expressing cells also displayed reduced level of the surface IgM expression, but 
there is a 4.5-fold more p heavy chain in intracellular expression. Moreover, 
the Dh to Jh recombination pattern observed in PKCa-KR-expressing cells was 
similar to the control cells, therefore indicating that subversion of PKCa 
signalling in HPCs stimulates aberrant expansion of oligoclonal or possibly 
polyclonal population of developing B cells that resemble CLL. Further 
analysis is required to confirm this finding.
We have shown that treatment of both PKCa-KR- and MIEV-expressing cells 
with P13K inhibitors induces an increase in apoptosis compared with the DMSO- 
treated control. These results support previous findings that AKT is essential 
for B lymphocyte development (Fruman et al, 1999). Previous studies in 
human CLL cells have demonstrated that while AKT phosphorylation was not 
detected using Western blotting techniques, these cells apoptose upon 
treatment with the P13K inhibitor LY294002 (10 jvM) (Ringshausen et al, 2002), 
this may also be the case in our PKCa-KR-expressing cells. However, as M-1 
cells were not affected by LY294002 (Fig. 4.22C), P13K may not be solely
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responsible for the aberrant survival of PKCa-KR cells. Treatment of M-1 cells 
with MEK1 inhibitors induced a significant increase in apoptosis, while the level 
of apoptosis in MIEV- and PKCa-KR-expressing cells were unaffected upon 
treatment with these inhibitors. Studies assessing the phosphorylation status 
of ERK1/2 in MIEV-, PKCa-KR-expressing cells and M-1 cells reveal that while 
ERK1/2 are weakly phosphorylated in MIEV-expressing cells and M-1 cells, 
ERK1 is strongly phosphorylated in PKCa-KR-expressing cells (Fig. 4.24). In 
contrast, phosphorylation of AKT is evident only in MIEV-expressing cells at the 
early stage of development. The phosphorylation was most pronounced in 
RAG-T^', supporting the notion that this is most important at the early stage. 
Despite of lack of detectable AKT phosphorylation in PKCa-expressing cells, 
these cells were more affected by P13K inhibitors than MIEV-expressing cells. 
This implies that other downstream molecules of PI3K, such as Btk (Marshall et 
al, 2000), may be involved in the survival of PKCa-KR-expressing cells. 
Collectively, these studies suggest that P13K- and ERK-MAPK-signalling 
pathways are differentially-regulated to induce survival during the progression of 
CLL cells. Further investigation of signalling pathways responsible for the 
induction of CLL will be performed using this model system.
In conclusion, this chapter reveals that PKCa-KR-expressing cells display a 
marked resemblance to human CLL at the level of: (i) phenotype - CD 19'^ ' CDS'" 
CD23"' lgM'°; (ii) resistance to apoptosis, possibly supported by elevation of Bcl- 
2 and Mcl-1 ; (iii) intracellular retention of IgM; and (iv) cell cycle phase (halted in 
Gq/Gi ex vivo) coupled with potential for proliferation. Taken together, these 
showed important link between the subversion of PKCa signalling and the 
induction of CLL.
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Figure 4.1 HA expression was confirmed in PKCa-KR-expressing cells
HPC-enriched FL cells were prepared from wildtype mice and retrovirally 
infected with MIEV or PKCa-KR and then seeded on 0P 9 cells in the presence 
of growth factors and cultured for 16 days. Unpermeabilised cells were 
analysed for GFP fluorescence by FCM, after Pi discrimination of dead cells 
(upper plot). PKCa-KR expression was determined by examining HA 
expression. Cells were fixed and permeabilised before staining with an anti- 
HA antibody, to reveal the retrovirally introduced PKCa-KR construct (lower 
plot). These data are from a single experiment, representative of two separate 
experiments.
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Figure 4.2 PKCa-KR-expressing cells display a decrease in PKC activity at 
d10 of coculture
Cell lysates were prepared from MIEV and PKCa-KR retrovirally infected cells 
that were cultured for 10 days, before the determination of PKC activity with 
non-radioactive protein kinase assay kit. The graph shows the average % 
kinase activity (n=3/point) relative to MIEV-expressing control cells (100%);
SEM shown. ***=p<0.0005 MIEV vs. PKCa-KR. The data are from a single 
experiment, representative of two separate experiments.
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Figure 4.3 PKCa-KR-expressing cells display a decrease in PKC activity at 
early culture, but not in the late culture
Cell lysates were prepared from MIEV and PKCa-KR retrovirally infected cells 
that were cultured for either 10 or 17 days, before the determination of PKC 
activity with ®^ P PKC kinase kit. The graph shows the average % kinase 
activity (n=2) relative to MIEV-expressing control cells (100%); SEM shown. 
**=p<0.005 MIEV vs. PKCa-KR. A representative of two separate experiments 
is shown.
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Figure 4.4 Phosphorylation level In PKC substrate was decreased in 
PKCa-KR-expressing cells
MIEV and PKCa-KR retrovirally infected cells cultured up to 10 day were 
incubated in the presence or absence of phorbol ester (0, 20, or 200 nmol/L 
TPA as indicated) for 30 min. Lysates were prepared and resolved by SDS- 
PAGE under reducing conditions and subsequently immunoblotted with a 
specific antibody against phosphoserine PKC substrates. The blot was 
stripped and reprobed with anti-ERK1/2 antibody. The data are from a single 
experiment, representative of two separate experiments.
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Figure 4.5 PKCa is not overexpressed in PKCa-KR expressing cells, but 
PKCa is the only phosphorylated isotype detected
MIEV and PKCa-KR retrovirally infected cells cultured up to 10 day were 
incubated in the presence or absence of phorbol ester (0, 20, or 200 nmol/L 
TPA as indicated) for 30 min. Lysates were prepared and resolved by SDS- 
PAGE under reducing conditions and subsequently immunoblotted with a 
specific antibody against PKCa. The blot was stripped and reprobed with anti- 
pan-phospho-PKC antibody. These data are from a single experiment, 
representative of two separate experiments.
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Figure 4.6 There is no difference in the cell cycle between PKCa-KR- 
expressing and MIEV-expressing cells
MIEV and PKCa-KR retrovirally Infected cells were seeded on 0P 9 cells in the 
presence of growth factors and cultured for 12 days. Then the cells were 
harvested by Lympholyte density gradient centrifugation and cultured in the 
same condition for further 2 days before PI analysis. Top, average ±SEM 
percentage of cells at the indicated cell cycle stage taken from four separate 
experiments. Bottom, histogram of DNA content vs. RCN is a representative 
of these experiments. The cellular data were size gated.
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Figure 4.7 Enhanced proliferation gives PKCa-KR-expressing cells growth 
advantage
MIEV and PKCa-KR retrovirally infected cells were seeded on 0P 9 cells in the 
presence of growth factors and cultured for 12 days. Then, the cells were 
harvested by Lympholyte density gradient centrifugation and cultured on 0P9 
cells in the presence of growth factors for 2 days. BrdU solution was added 23 
h prior to anti-BrdU antibody staining and subsequent FCM analysis. Cells 
were size gated before analysis of percentage of BrdU incorporation. The 
graph shows the average percentage of BrdU incorporated cells of three 
separate experiments; Average ±SEM shown. *=P<0.05, MIEV over PKCa-KR.
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Figure 4.8 p21'^ ^^ ‘^and p27‘"‘^ ’  ^mRNA was relatively higher in PKCa-KR- 
expressing cells to MIEV-expressing cells
MIEV and PKCa-KR retrovirally infected cells were seeded on 0P9 cells in the 
presence of growth factors. Cells were removed at days 3, 8, and 14 of 
coculture and RNA/cDNA was prepared from the samples. Semi-quantitative 
RT-PCR was done with (32m, p21'^^''\ and p27’^ ’^ '^  primers (top). The bottom 
bar graph shows the relative expression of p21'^ ^^ '^  or p27"'P'^normalized to (32m. 
The RNA level of indicated molecule in freshly prepared FL is calculated as 
100 %. The representative is shown from two separate experiments.
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Figure 4.9 Subversion of PKCa signais enable cells to survive in the 
absence of stromal ceils and growth factors
MIEV and PKCa-KR retrovirally infected cells were seeded on 0P 9 cells in the 
presence of growth factors and cultured for 12 days. Then the cells were 
harvested by Lympholyte density gradient centrifugation and cuitured in the 
absence of both 0P 9 ceiis and growth factors (day 0; triplicate welis of a 24-weii 
plate for each day of counting). Cells were then counted on the following 3 
consecutive days by FCM. The graph shows the mean number of GFP+ ceils 
of three separate experiments; Average ± SEM shown. Ceiis were iive and 
size gated.
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Figure 4.10 PKCa-KR-expressing cells were resistant to growth factor 
withdrawal-induced apoptosis
MIEV and PKCa-KR retrovirally infected ceils were seeded on 0P9 cells in the 
presence of growth factors and cuitured for 12 days. Then the ceiis were 
harvested by Lympholyte density gradient centrifugation and cuitured in the 
absence of 0P 9  cells and growth factors for further 2 days before PI analysis. 
Top, average ± SEM percentage of ceils at the indicated ceil cycle stage taken 
from four separate experiments. Bottom, histogram of DNA content vs. RCN is 
a representative of these experiments. The cellular data were size gated.
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Figure 4.11 More PKCa-KR-expressing ceiis were cycling in the absence 
of 0P9 cells and growth factors
MIEV and PKCa-KR retrovirally infected cells were seeded on 0P 9 cells in the 
presence of growth factors and cultured for 12 days. Then the cells were 
harvested by Lympholyte density gradient centrifugation and cultured on 0P9 
cells in the absence of growth factors for 2 days. BrdU solution was added 23 
h prior to anti-BrdU antibody staining and subsequent FCM analysis. Cells 
were size gated before analysis of percentage of BrdU incorporation. The 
graph shows average percentage of BrdU incorporated cells of three separate 
experiments; Average ± SEM shown. *=P<0.05, MIEV over PKCa-KR.
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Figure 4.12 Bcl-2 and Mci-1 mRNA was relatively higher in PKCa-KR- 
expressing ceiis to MiEV-expressing ceiis
MIEV and PKCa-KR retrovirally infected cells were seeded on 0P9 cells in the 
presence of growth factors. Cells were removed at days 3, 8, and 14 of 
coculture and RNA/cDNA was prepared from the samples. Semi-quantitative 
RT-PCR was done with [32m, Bcl-2, Mcl-1 and Bcl-xL primers (top). The 
bottom bar graph shows the relative expression of Bcl-2, Mcl-1 and Bcl-xL 
normalized to (32m. The RNA level of indicated molecule in freshly prepared 
FL is calculated as 100 %. The representative is shown from two separate 
experiments.
135
dO
FL
d3 d8 d14
MIEV PKCa-KR MIEV PKCa-KR MIEV PKCa-KR
Bcl-2
Mcl-1
Bcl-xL
120
§  90
2
*= 30 1“(Q 0)
^  0
Bcl-2 level (%) normalised 
by p2m
Mcl-1 level (%) normalised 
^  by p2m
^00
dO d3 d8 d14
Co'150 c
I  120 I 90
s-
I  60
§  30 0)
^  0
Bcl-xL level (%) normalised 
by p2m
dO d3 d8 d14
Figure 4.13 IL-7 induces PKCa-KR-expressing celis proliferate explosively
MIEV and PKCa-KR retrovirally infected cells were seeded on 0P 9 cells in the 
presence of growth factors and cultured for 12 days. Then the cells were 
harvested by Lympholyte density gradient centrifugation and cultured in the 
absence of 0P 9 cells and in the presence of IL-7 (day 0; triplicate wells of a 24- 
well plate for each day of counting). Cells were then counted on the following 
3 consecutive days by FCM. The graph shows the mean number of GFP+ cells 
of three separate experiments ±SEM. Cells were live and size gated. 
***=P<0.0005, MIEV vs. PKCa-KR; **=P<0.005, MIEV vs. PKCa-KR.
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Figure 4.14 IL-7Ra mRNA was upregulated in PKCa-KR-expressing ceils
MIEV and PKCa-KR retrovirally infected cells were seeded on 0P9 cells in the 
presence of growth factors. Cells were removed at days 3, 8, and 14 of 
coculture and RNA/cDNA was prepared from the samples. Semi-quantitative 
RT-PCR was done with (52m, lL-7Ra primers (top). The bottom bar graph 
shows the relative expression of IL-7Ra normalized to (52m. The RNA level of 
indicated molecule in freshly prepared FL is calculated as 100 %. The 
representative is shown from two separate experiments.
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Figure 4.15 Phenotype analysis of M-1 ceiis
PKCa-KR retrovirally infected cells were cultured in the presence of OP9 cells 
and growth factors for 2 weeks, and cultured in the absence of 0P9 cells and 
IL-7 as described in Section 2.4.10. M-1 cells were established by sorting out 
GPP'" and CD5'° population. FCM analysis was carried out on established M-1 
cells, CD5-APC vs. CD45R-PE and CD19-APC vs. CD23-PE; percentages are 
indicated. All FCM plots were live and size gated. These data are from a 
single experiment, representative of two separate experiments.
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Figure 4.16 IgM is expressed intracellularly, but not on the surface In 
PKCa-KR-expressing ceiis
MIEV and PKCa-KR retrovirally infected cells were seeded on OP9 cells In the 
presence of growth factors and cultured for 19 days. Half of the cells were 
analysed for surface IgM expression (top). Half of the culture was fixed and 
permeabilised before staining with an anti-IgM antibody or isotype-matched 
antibody, to reveal the intracellular IgM level (bottom). An isotype-matched 
antibody was utilised for the control staining. Cells were size gated for both 
surface and intracellular staining, and dead cells were discriminated by gating 
out PI positive cells in surface staining. These data are from a single 
experiment, representative of three separate experiments.
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Figure 4.17 IgM in PKCa-KR-expressing cells was D to J recombined
MIEV and PKCa-KR retrovirally infected cells were seeded on OP9 cells in the 
presence of growth factors and cultured for 15 days. Half of the cells were 
cultured under the same condition for further 4 days and the other half were 
cultured in the absence of 0P9 cells and IL-7 for 4 days. Splenocytes from 
wildtype mouse and RAG-T^‘ were obtained by crushing spleens followed by 
Lympholyte density graduation centrifugation. PCR was performed for the 
analysis of DNA rearrangements by amplifying DNA with specific primers 
flanking Dhi and Jh4 of BCR locus. Amplifying the same DNA samples with 
primers specific for |32m. These data are from a single experiment, 
representative of two separate experiments.
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Figure 4.18 A s.c. tumour mass was formed in PK-KR-HPCs-injected mice 
at the injection site and these mice could not survive more than 6 weeks
HPC-enriched FL cells were prepared from wildtype mice, retrovirally infected 
with PKCa-KR and were injected i.p. into neonatal RAG-T^' mice ( 1X10® per 
mouse) (top). Analysis of the mice 3 weeks after injection revealed that GFP^ 
tumour cell masses developed s.c. at the point of injection. Survival curve for 
PKCa-KR infected cell-adoptive transferred mice (bottom). * Include 2 mice 
sacrificed for the analysis. Both of them borne s.c. tumours. ** Include 3 mice 
sacrificed for the analysis. All of them borne s.c. tumours. *** Include 2 mice 
sacrificed for the analysis. One of them borne s.c. tumours. **** Include 1 
mouse sacrificed for the analysis, which borne s.c. tumours. None of MIEV- 
HPCs-injected-mice died during the course of the experiments.
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Figure 4.19 PKCa-KR-HPCs-injected mouse accompanied splenomegaly 
and the spleen enriched GFP^ PKCa-KR-expressIng cells
FL cells was prepared from wildtype mice, retrovirally infected with MIEV or 
PKCa-KR, and were injected i.p. into neonatal R A G - 1 m i c e  (1 X 10® or 1 X 
10® and 1 X 1 0 ®  per mouse, MIEV or PKCa-KR, respectively). The photo of 
the spleen was taken immediately after removal (top). Splenocytes were 
extracted from each mouse and analysed GFP intensity by FCM (bottom). The 
graph shows mean percentage of GFP'" cells of three separate tubes. Average 
±SEM shown. Cells were live and size gated. These data are from a single 
experiment, representative of three separate experiments.
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Figure 4.20 A tumour cell mass phenotyplcally resembling CLL
Tumour mass was removed from PKCa-KR-HPCs-lnjected mouse and a single 
cell suspension was prepared. FCM analysis was carried out on GFP'™ and 
GFP"" populations, IgM-APCvs. CD45R-PE, IgD-APC vs. CD45-PE, CD19-APC 
vs. CD23-PE, and CD5-PE vs. CD45R; percentages are indicated. All FACS 
plots were live and size gated. These data are from a single experiment, 
representative of at least five separate experiments.
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Figure 4.21 Freshly prepared tumour ceils arrested at G /G i, but re-entered 
cell cycle upon culture In the presence of OP9 cells and IL-7
PI analysis was carried out on cell suspensions of isolated tumour, spleen and 
LN cells from PKCa-KR-HPCs-injected mouse and spleen and LN cells from 
MIEV-HPCS“injected mouse at day 0. The rest of the cells were seeded onto 
0P9 cells in the presence of IL-7 and samples as PI analysis (day 5). Top, 
value at the indicated cell cycle stage; bottom, histogram of DNA content vs. 
RCN. The cellular data were size gated. This is a representative result of two 
separate experiments.
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Figure 4.22A Effect of pharmacological inhibitors on apoptosis in mouse 
CLL-like cells
Retrovirally infected HPCs with MIEV or PKCa-KR were cocultured with OP9 for 
16 days. Thereafter, 1 X1 0 ® cells (MIEV- and PKCa-KR-expressing cells and 
M-1 cells) were plated and incubated in the absence or presence of 
pharmacological inhibitors for 24 h as indicated before Annexin V/7-AAD 
staining and subsequent PCM analysis was performed. The average ratio 
(n=5) against the control (DMSO-treated) ±SEM is shown. The concentration 
of pharmacological inhibitor is presented in a log scale. PKC inhibitors: 0.2, 2 
f-iM cheierythrine (total PKC inhibitor); 2, 20 \iN\, rottlerin (nPKC inhibitor).
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Figure 4.22B Effect of pharmacological inhibitors on apoptosis in mouse 
CLL-like ceils
Retrovirally infected HPCs with MIEV or PKCa-KR were cocultured with 0P9 for 
16 days. Thereafter, 1 X1 0 ® cells (MIEV- and PKCa-KR-expressing cells and 
M-1 cells) were plated and incubated in the absence or presence of 
pharmacological inhibitors for 24 h as indicated before Annexin V/7-AAD 
staining and subsequent PCM analysis was performed. The average ratio 
(n-5) against the control (DMSO-treated) ±SEM is shown. The concentration 
of pharmacological inhibitor is presented in a log scale. MAPK inhibitors: 1,10 
nM, U0126 (MEK1/2 inhibitor); 2, 20 pM, PD98059 (MEK1 inhibitor); 0.5, 5 \xW\, 
SB203580 (p38 inhibitor).
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Figure 4.22C Effect of pharmacological inhibitors on apoptosis in mouse 
CLL-like cells
Retrovirally infected HPCs with MIEV or PKCa-KR were cocultured with 0P9 for 
16 days. Thereafter, 1 X1 0 ® cells (MIEV- and PKCa-KR-expressing cells and 
M-1 cells) were plated and incubated in the absence or presence of 
pharmacological Inhibitors for 24 h as indicated before Annexin V/7-AAD 
staining and subsequent PCM analysis was performed. The average ratio 
(n=5) against the control (DMSO-treated) ±SEM is shown. The concentration 
of pharmacological inhibitor is presented in a iog scale. PI3K inhibitors: 1, 3,
10 |.xM, LY294002; 1,10 [.iM, wortmannin.
147
PI3K inhibitors
LY2940024
i rO (C
0
1000.1 101
ICRd17-MIEV 
iCRd17-aKR 
M-1 ceii
jLVM
Wortmannin
iCRd17-MIEV 
ICRd17-aKR 
M-1 ceii
100
Figure 4.23 Effect of pharmacological inhibitors on apoptosis in eariy 
cocultures
Retrovirally infected HPCs with MIEV or PKCa-KR were cocultured with OP9 for 
9 days. Thereafter, 1 X1 0 ® cells were plated and incubated in the absence or 
presence of pharmacological inhibitors for 24 h as indicated before Annexin 
V/7-AAD staining and subsequent FCM analysis was performed. The ratio 
against the control (DMSO-treated) is shown. The concentration of 
pharmacological inhibitor is presented in a log scale. 1,10 ^iM, U0126 
(MEK1/2 inhibitor): 1 , 3 , 1 0  piM, LY294002 (PI3K inhibitor). This is a 
representative of two separate experiments.
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Figure 4.24 Western blots showed the activation/phosphorylation status 
of AKT and ERK1/2 In B-CLL-llke cells
HPCs derived from wiidtype mice FL or R A G - 1 m i c e  FL were cocultured with 
0P9 and removed from the culture at day 8 and day 15 or day 6, respectively. 
The phosphorylation levels of AKT at the threonine residue 308 and ERK 1 and 
2 were analysed by Western blotting. These are representative blots of three 
separate experiments.
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Chapter 5:
Which stage in the B-cell development does the 
tumourigenesis happen?
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5.1 Introduction
5.1.1 T cell development
T ceil progenitors are derived from BM or FL progenitors. Their development 
is dependent on the thymic organ. Developing thymocytes can be 
phenotypically characterised by expression of CD4 and CD8. When cells enter 
the thymus they lack the expression of CD4 and CD8, therefore being called 
CD4' CDS' double negative (DN) thymocytes. As development progresses, 
they become CD4^ CD8^ double positive (DP), and mature into single positive 
(SP) CD4+ or CD8+ T cells (Zûniga-Pflücker, 2004) (Fig. 5.1). The DN stage Is 
further subdivided based on CD25, CD44 and CD117 surface expression (Fig. 
5.1). The earliest progenitors termed DN1 (CD25' CD44+ CD117^) maintain 
pluripotency, and thus can differentiate into T celis, B cells, NK cells, and DCs 
(Pear et al, 2004). The differentiation potential of DN2 (CD25^ CD44'" CD117^) 
cells is limited to T cells and DCs (Pear et al, 2004). DN3 (CD25'*' CD44'
CD117 ) cells are fully committed to the T cell lineage and start rearranging the 
TCR(3 gene iocus. DN4 (CD25' CD44' CD11T) cells are the product of DN3 
cells that have successfully rearranged TCRp gene locus and express a 
functional TCRp chain it in the context of the pre-TCR complex on cell surface 
(Schmitt et al, 2004).
5.1.2 Notch and T cell commitment
Notch, a gene that was originally identified in Drosophila melanogaster, is 
involved in binary cell fate decisions (Radtke et al, 2004). Mammals have 
four receptors (Notch 1-4) and five ligands (Jagged 1 and 2, and Delta-like 1, 3 
and 4), which are widely expressed in the haematopoietic system (Radtke et al, 
2004). Notch signalling is initiated through ligand-receptor interactions, leading 
to proteolytic cleavage of the receptor, which results in the release of 
cytoplasmic domain of Notch (NIC). NIC translocates to the nucleus and 
heterodimerises with the transcription factor CSL (CBF-1 [c-promoter binding 
factor 1] for humans, Su(H) [suppressor of hairiess] for drosophiia, Lag-2 [Lin- 
12 and Glp-1 phenotype 2] for Caenorhabditis elegans), also known as RBP-Jk
151
[recombining binding protein-J kappa] in the mouse, leading to de­
repression/activation of CSL-dependent downstream targets, such as Hes 
(Hairy enhancer of split) 1 and Hes 5 (Radtke et al, 2004).
The inhibition of Notch 1 signalling in thymus by Lunatic Fringe, a modulator of 
Notch 1, promoted the development of lymphoid progenitors towards the B cell 
lineage instead of T cell commitment (Koch et al, 2001 ). In contrast, the 
expression of activated Notch 1 in haemato-lymphoid progenitors resulted in the 
emergence of a popuiation of thymic-independent T cells in BM, concomitant 
with a biock of B cell maturation (Pui et al, 1999). Altogether, compelling 
evidence is provided that Notch 1 signalling is essential and sufficient to induce 
T ceii iineage commitment in eariy iymphoid progenitors with a simultaneous 
block in B cell development, thus, the function of Notch 1 is vital in T cell versus 
B cell fate specification (Pear and Radtke, 2003). On the other hand. Notch 
signalling must be switched off during B ceil development in BM despite the fact 
that Notch receptors and ligands are expressed on BM progenitors and stroma 
(Radtke et ai, 2004). There are several reports that may explain this paradox. 
The expression of Pax5 represses transcription of Notch 1 in B cell progenitors 
thus facilitating B lineage commitment (Souabni et al, 2002). Although a high 
density of Notch 1 molecules promotes T cell fate and inhibit B cell fate, the 
lower density of DL-1 enhances B220' cells to an early T lymphoid generation 
and B220+ cells to B lymphoid generation (Dalias et al, 2005). Alternatively, B 
cell progenitors can be protected in the specific niches of the BM (Tokoyoda et 
al, 2004). In order to understand the Notch signalling in T cell versus B cell 
fate, further investigations are required.
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5.2 Aims and Objectives
The aims of this chapter were:
i. To examine if leukaemiagenesis can occur in other HPC sources.
ii. To define the developmental stage susceptible to PKCa-KR-mediated 
transformation by retrovirally infecting HPCs from RAG-T^' mice.
iii. To examine the impact of Notch ligand DL1 on PKCa driven 
leukaemiagenesis.
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5.3 Results
5.3.1 GFP+ PKCa-KR-expressing FT and BM celis from wiidtype mice 
exhibited the CLL-like phenotype
In order to elucidate whether cellular sources other than FL could lead to 
spontaneous tumourigenesis upon expression of PKCa-KR, FT and BM cells 
from wiidtype mice were retrovirally infected with PKCa-KR or MIEV, and 
cultured in our in vitro B cell generation system. FCM analysis of cultures 
immediately after retroviral infection revealed a GFP'" population in both sets of 
cocultures (FT: Fig. 5.2 top, day 1 MIEV 16 %, PKCa-KR 6.1 %; BM: Fig. 5.2 
bottom, day 1 MIEV 17 %, PKCa-KR 11 %). As the BM cell coculture 
progressed, it became clear that PKCa-KR-expressing (GFP^) cells displayed a 
growth advantage over the untransduced (GFP ) cells as shown by a 8.4-fold 
increase in the percentage of GFP^ PKCa-KR-expressing cells from days 1 to 
16(11 % vs. 93 %; Fig. 5.2 bottom). Although PKCa-KR-expressing GFP'' FT 
exhibited growth advantage (PKCa-KR: day 1 to day 16, 16-fold increase; Fig.
5.2 top), it was clear that MIEV-expressing GFP" FT also exhibited an 
expansion growth (MIEV: day 1 to day 16, 5.0-fold increase; Fig. 5.2 top). The 
reason for this is not known and needs to be elucidated. When the growth 
speed was compared between PKCa-KR-expressing GFP" FL and BM, FL 
proliferated faster than BM (FL: 21-fold increase from day 2 to day 14, BM: 8.4- 
fold increase from day 1 to day 16). Next, the infected ceils were analysed for 
CLL-markers; IgM, CD2, CD5, CD19 and CD23. The majority of the FT and 
BM cells retrovirally infected with MIEV committed towards the B cell lineage 
(FT: 99 % CD19" and BM: 97 % CD19", Fig. 5.3 top and bottom, respectively), 
and appeared to reach normal immature/mature B cell stage expressing ic and 
IgM molecules (Fig. 5.3 top and bottom). On the other hand, both FT and BM 
cells expressing PKCa-KR displayed CLL-like phenotype; lgM'°, CD5" and 
CD23" (Fig. 5.3 top and bottom). These findings suggest that CLL cells may 
not only be generated from B cell committed cells as a result of PKCa 
subversion, but may also be generated from the pluripotent DN1 population, as 
these celis still retain the ability to commit to B cell lineage (Schmitt et al, 2004).
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Of note, the subversion of PKCa also transformed BM cells, suggesting that this 
transformation process occurs in the adult system.
5.3.2 GFP" PKCa-KR-expressing celis derived from RAG-T^-FL also 
exhibited growth advantage over GFP ceils and CLL-like phenotype
In order to identify how PKC mutants affect B ceil development in R AG- 1 mi ce ,  
HPCs derived from RAG-1'^'-FL were retrovirally infected. As B cells in RAG-T 
mice are arrested in development at the pro-B cell stage (Mombaerts et al, 
1992), transformation of RAG- 1der i ved  lymphoid progenitors by subversion of 
PKCa, wouid suggest that this leukaemic event occurs before the pre-B cell 
stage. The infected PKC mutant expressing celis were cultured in our in vitro 
B cell generation system and analysed by FCM as indicated in the figure legend. 
As noted in wiidtype mice (Fig. 3.9A), the percentage of GFP" population was 
reiatively constant in PKCô-KR- and MIEV-expressing cells from day 2 to day 
18 (PKCÔ-KR: day 2, 22 %, day 18, 26 %; MIEV: day 2, 83 %, day 18, 99 %; Fig. 
5.4). PKC^-KR expression in RAG-T^' FL cells induced a decrease of GFP" 
population (2.7-foid reduction, day 2, 19 %; day 18, 6.9 %; Fig. 5.4) as observed 
in wiidtype FL cells (Fig. 3.9A). Notably, the GFP" population in PKCa-KR- 
expressing cells reached 6.8-fold higher at day 18 compared to day 2 (day 2,
9.7 %, day 18, 67 %; Fig. 5.4), with major expansion noted after day 6 as 
noticed with wiidtype cells (Fig. 3.9A). Therefore, GFP" PKCa-KR-expressing 
HPCs from RAG-T^' aiso exhibited a growth advantage over GFP' population.
Of note, the GFP" dominance over GFP' in RAG-T^' PKCa-KR expressing FL 
ceils progressed slower than that of wiidtype FL (RAG-T^': day 18, GFP"=67 %; 
ICR, day 14, GFP"=98 %, Fig. 5.4 and Fig. 3.9A). This may be due to the fact 
that developing B cells in RAG-T^' mice can not express the pre-BCR complex, 
suggesting that the stimuli from pre-BCR might be required for more rapid 
transformation, although further studies are required to test this. Next, CLL 
marker expression (CD2, CDS, CD23 and CD19) on these PKC mutant 
expressing RAG-T^' ceiis was analysed by FCM. In PKCô-KR-, PKC^-KR- and 
MIEV-expressing RAG-1'^' FL celis, >95 % cells became CD19" B cells and no 
CD23 expression was observed on surface (Fig. 5.5). PKCa-KR-expressing
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R AG - 1 c e l l s  upregulated CD2, GD23 and CDS as observed in PKCa-KR- 
expressing wiidtype derived FL (Fig. 3.1 OA). Analysis of the MFi of CD19 in 
MIEV-, PKCa-KR-, PKCÔ-KR- and PKC^-KR-expressing RAG-r"' FL cells 
revealed an upregulation of CD19 on GFP" PKCa-KR expressing B lineage 
cells as indicated: in the order of MiEV, PKCa-KR-, PKCô-KR- and PKC^-KR; 
67, 164, 115 and 88 (Fig. 5.5). Therefore, these results suggest that this 
leukaemic event occurs at or before the early pre-B cell stage.
5.3.3 Subversion of PKCa initiated transformation in aduit RAG-T^ derived 
BM celis
In order to test whether this transformation can be initiated in cells derived from 
adult RAG-T^' mice, BM cells were retrovirally infected. In agreement with 
wiidtype mice (Fig. 5.2 bottom), GFP" PKCa-KR-BM cells from adult RAG-T^' 
mice also showed a growth advantage over the GFP' cells (PKCa-KR: day 1, 
4.9 %, day 8, 66 %; MIEV: day 1, 32 %, day 12, 46 %, Fig. 5.6). Of note, the 
growth advantage of GFP" PKCa-KR-expressing cells from RAG-1'^' mouse 
lymphoid progenitors compared with those of wiidtype mice in the eariier phase 
was similar in adult system ( RAG- 1 6 . 3 - fo ld  increase in GFP"(%) from day 1 
to 8; ICR, 2.7-fold increase in GFP"(%) from day 1 to 8), thus, an earlier 
expansion was observed. FCM analysis on CLL markers (CD2, CDS, CD23 
and CD19) revealed that >92 % cells became CD19" B cells in both PKCa-KR- 
and MIEV-expressing RAG-T^' BM cells and PKCa-KR-expressing celis showed 
CLL-like phenotype, upreguiated CD2, CD23, CDS and CD19 (Fig. 5.7). 
Therefore, these results suggest that transformation aiso occurs in RAG-1'^' 
adult system in a similar fashion to that in adult wiidtype BM cells.
5.3.4 CLL-iike phenotype developed in vivo by adoptive transfer of 
RAG-T^'-FL-derived PKCa-KR-expressing-HPGs into RAG-T^ mice
To assess whether the population of cells observed in vitro culture (Fig. 5.5) 
could also be generated in vivo, MIEV- or PKCa-KR-retroviratly infected FL- 
HPCs derived from RAG-1'^' mice were injected into RAG-T^' mice and the 
lymphocyte populations of the mice were analysed from 2 to 6 weeks post
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injection. The GFP" popuiation in LN celis from MIEV- and PKCa-KR-HPCs- 
injected mice was 0.76 % and 29 %, respectively, suggesting cells from GFP" 
PKCa-KR-HPCs-injected mice had growth advantage over GFP' and host 
derived cells compared with the GFP" population at day 2 (MIEV, 83 %; PKCa- 
KR, 9.7 %, Fig. 5.4). As observed in wiidtype PKCa-KR-HPCs adoptive 
transfer mice (Fig. 4.18), some mice bore a s.c. tumour mass at the injection 
site. Representative data of reconstituted LN cells from either PKCa-KR or 
MIEV-HPCs injected RAG-T^' mice and tumour are presented in Figure 5.8. 
Phenotypic analysis revealed that no GFP" CD19" B cells were present in either 
LN or spleen from MIEV-injected mice, and 20 % and 19 % was observed in LN 
cells and spleen, respectively, from PKCa-KR-injected mice (Fig. 5.8 and data 
not shown). Of interest, 37 % GFP" CD19" B cells were found in thymus 
(GFP"=6.0 %) from PKCa-KR-HPCs injected RAG-T^' mice, whereas none 
found in MIEV-HPCs injected RAG-T^' mice (data not shown), indicating that 
these CLL-like cells are invasive. In contrast, >60 % HPCs became B cell in 
splenocytes from both MIEV- and PKCa-KR-wildtype HPCs-injected mice (Fig. 
5.8), suggesting that the reconstituted B lineage population in RAG-T^'-HPCs- 
injected mice was either much lower or reconstituted cells die faster. The 
phenotype of LN cells from PKCa-KR HPC-injected mice resembied that of ceiis 
generated in in v/fro cuitures for RAG-T^' FL cells in Figure 5.4 (GFP", CD23" 
and CD5"; Fig. 5.8), representing a hallmark of human CLL. Overall, 
subversion of PKCa causes transformation in RAG-T^ derived FL ceils in vivo 
that are phenotypically similar to wiidtype mouse PKCa-KR expressing FL, 
therefore, human CLL cells.
5.3.5 CLL-like phenotype was developed from retrovirally infected PKCa- 
KR-expressing splenocytes derived from adult wiidtype mice
In order to test whether this transformation event could be initiated post pre-B 
ceii stage, CD19" B cells-derived from splenocytes of a wiidtype mouse were 
infected with MIEV- and PKCa-KR whilst being stimulated with 50 jug/ml LPS for 
48 h to enhance retrovirus incorporation into genome of normally unproliferative 
mature CD19" B cells. Analysis of cells at day 3 revealed that there were
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GFP" cells, indicating that retroviral infection was successful. GFP" PKCa-KR 
B cells showed growth advantage over the GFP cells (PKCa-KR: day 3, 15 %, 
day 11,94 %; MIEV: day 3, 51 %, day 11, 79 %, Fig. 5.9). FCM analysis on B 
ceil marker expression (IgD vs. CD45, CDS vs. CD45R, IgM vs. CD45R and 
CD23 vs. CD19) revealed a gradual upregulation of CDS and CD23, and 
downregulation of IgM in PKCa-KR-expressing cells, thus displaying a CLL-like 
phenotype (Fig. 5.10). CD45R" CDS" celis reached 45 % in PKCa-KR- 
expressing cells, whereas only 6.0 % in MIEV-expressing cells (Fig. 5.10). 
Therefore, these results suggest that transformation can aiso occur in IgM 
expressing mature B cells.
5.3.6 Association with Notch ligand attenuates PKCa-KR-expressing ceiis 
to generate leukaemic cells
0P9-DL1 cells express Notch ligand, DL-1, and induce T cell differentiation of 
lymphoid progenitors in the absence of thymus (Schmitt and Zûhiga-Pflücker, 
2002). 0P9-DL1 cells can support normal B cell development if B cells are 
beyond the pre-B cell stage (Schmitt and Zûhiga-Pflücker, 2002). PKCa plays 
an important role in early T cell development from DN to DP stage (Mtchie et al, 
2001 ). This paper shows that PKCa-KR blocks T ceil development at the DN 
stage in the thymic environment, however, the potential that PKCa-KR- 
expressing DN subsets develop into B lineage cells was not assessed. Due to 
my findings showing PKCa-KR expression in HPCs generates CLL-like cells, 
the capacity of B ceil commitment in PKCa-KR expressing DN and the 
possibility that this transformation event can occur in an in v itroT  cell 
development system was tested. HPCs derived from wiidtype FL were 
retrovirally infected with PKCa-CAT, PKCa-KR and MIEV and cocultured with 
0P9-DL1. FCM analysis of HPC cocultures revealed a shift in GFP" 
population within each retroviral condition (Fig. 5.11). There were 2.0 % GFP" 
cells at day 1 PKCa-CAT-expressing cells, but the number was decreased to 
0.57 % at day 15. The same effect was observed when PKCa-CAT- 
expressing cells were cultured in 0P9 (Fig. 3.9B), suggesting that the 
expression of PKCa-CAT is detrimental to HPCs. GFP" PKCa-KR-expressing
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cells showed growth advantage, exhibiting 7.9-fold growth increase (day 1,
8.8 %: day 15, 69 %), whereas MiEV-expressing cells did not (day 1, 27 %; day 
15, 56 %). Interestingly, while PKCa-KR showed a growth advantage 
compared to the MIEV- and PKCa-CAT cocultures, the increase of GFP" cells 
was milder in 0P9-DL1 cocultures, 7.9-fold increase from day 4 to 15 (Fig. 5.11), 
compared with 0P9 cocultures, 21-fold increase from day 2 to 14 (Fig. 3.9A).
Analysis of T cell maturation markers (CD25 vs. CD117 and CD4 vs. CD8) and 
B cell markers (CD23 vs. CD19) revealed that none of the MIEV-expressing 
cells became CD19" expressing B cells (Fig. 5.12A). More than 47 % of the 
cells committed to CD25" CD117" T cell lineage, and among them 7 % reaching 
DP stage in MIEV-expressing cells (Fig. 5.12A). Thus, confirming that T cell 
development occurred by co-culturing HPCs with 0P9-D L1. In PKCa-CAT- 
expressing cells, T lineage cells developed as evidenced by the presence of DN 
and DP celis, but no B cells were observed. In the PKCa-KR GFP" cocultures, 
T cell development appeared to be severely blocked and as expected (Michie et 
al, 2001), and no DP cells were present (Fig. 5.12A). Moreover, 34 % of the 
cells were CD117" CD25', suggesting PKCa-KR-expressing cells were trapped 
at the pluripotent DNI stage. Interestingly, only a small number of PKCa-KR- 
expressing cells became B cells (2.5 %), and they did not express CD23 (Fig. 
5.12A), suggesting that they were not leukaemic. When celluiarity was 
examined in the same coculture, the percentage in PKCa-KR-expressing cells 
was nearly half that of GFP" MIEV-expressing cells (Fig. 5.12B), despite the fact 
that more cells were GFP" in PKCa-KR-expressing cells (Fig. 5.11). This may 
suggest that PKCa-KR expression keeps HPCs from proliferating in the 
presence of DL1.
5.3.7 Notch signalling suppressed transformation of PKCa-KR-expressing 
cells
To define whether cells maintain their leukaemic potential when cultured on 
0P9-DL1, HPCs from wiidtype FL were infected with MIEV and PKCa-KR and 
cocultured with either 0P9 or 0P9-DL1 up to day 6. Then the coculture was
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divided into two, half was cultured with 0P9 and the other half was cultured with 
0P9-DL1 until day 13 (step 1: 0P9-DL1 to 0P9-DL1, step 2: 0P9-DL1 to 0P9, 
step 3: 0P9 to 0P9, step 4: OP9 to 0P9-DL1). In MIEV-expressing cells, B 
cell development was not observed in the day 13 0P9-DL1 culture (step 1), but 
when cells were transferred to 0P9 cells (step 2), the B cells expanded, 
resulting in 34 % B celis observed at the day 13 (Fig. 5.13A). This may be due 
to expansion of existing B lineage cells present in culture and/or commitment of 
HPCs to the B lineage possibly from the DNI stage of thymocyte development. 
As expected, 97 % cells became CD19" B cells in the day 13 OP9 culture (step 
3), which was reduced to 44 % B cells in the day 13 0P 9 to 0P9-DL1 culture 
(step 4). This is supported by a previous report showing that 0P9-DL1 cells 
are able to support B cell development after pre-B cell stage (Schmitt and 
Zûhiga-Pflücker, 2002) (Fig. 5.13A). In PKCa-KR-expressing cells, not many 
B cells appeared in the day 13 0P9-DL1 culture although more B cells 
observed than in MIEV culture (MIEV; 4.8 %, PKCa-KR; 15 %) (step 1). Of 
interest, B cells explosively proliferated in the day 13 step 2 culture and indeed 
0.4 % cells exhibited the CLL-like phenotype (CD19" CD23"). As described in 
Section 3.3.6, most of PKCa-KR-expressing cells became B cells (98 %: Fig.
5.13B) and some of them expressed CLL phenotype when they were kept in 
culture on 0P9, however, B cell growth was suppressed when they were 
cultured on OP9-DL1. Indeed only 3.3 % CD19" B cells were present in the 
cultures at day 13, these results suggest that Notch signalling functions as 
tumour suppressor for our CLL-like cells, compared with 85 % at the number of 
transfer at day 6 (Fig. 5.13B). PKCa-KR-expressing cells were not cancerous 
while they were cocultured with 0P9-DL1, but tumourigenesis was reversible 
depending on the growing condition, suggesting that Notch signalling inhibits 
leukaemiagenesis in B lineage ceiis.
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5.4 Discussion
In this chapter, other HPC sources were tested for their transformation potential 
and it was showed that stable PKCa-KR expression generated CLL-like cells in 
HPCs derived from wiidtype BM and FT, and RAG-1^' FL and BM. The 
mechanisms that underlie the leukaemiagenesis remain not unclear, however, 
ERK pathway is involved and the signals for transformation appears to be 
inhibited by Notch signalling.
CLL is commonly considered to arise from an outgrowth of a mature subset of B 
lymphocytes (Stevenson and Caligaris-Cappio, 2004). However, as B cell 
development is blocked at the pro-B cell stage in RAG'^' mice due to an inability 
to initiate recombination at the IgH chain gene iocus, these results indicate that 
PKCa-mediated development of CLL occurs at an early stage of B cell 
development in this system.
MIEV-FT derived from wiidtype mice successfully committed to CD19" B cells 
(Fig. 5.3 top), thus it was confirmed B ceils can be generated from thymocytes. 
The subversion of PKCa-KR in thymocytes generated CLL-like cells with the 
distinct phenotype, CD23" CD5" lgM'°, indicating that B cell committed cells are 
not necessarily a target of transformation. Previously, it was shown that 
thymocytes at DN1 stage can give rise to B cells with reiatively low frequency, 
but no later than DN1 stage (Schmitt et ai, 2004). Therefore, it is most 
plausible that the both normal and leukaemic B cells were given rise from MIEV- 
and PKCa-KR-infected DN1 cells, respectively. In order to test until which 
stage of thymocytes can generate CLL-like celis by PKCa-KR expression, 
PKCa-KR infected cells will be separated into either DN1 or DN2 celis by virtue 
of CD25 and CD44 expression by cell sorting, and cultured in the B cell 
generation system, and analysed by FCM for CLL markers. Thymocytes seem 
to proliferate more than HPCs derived from FL, which increases chances for 
retroviral infection, and thus growth advantage was not observed in PKCa-KR- 
FT because both MIEV- and PKCa-KR-cocultures completely occupied with
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GFP" cells (Fig. 5.2 top). We could generate CLL-like cells using BM cells 
derived from adult wiidtype mice, suggesting that this transforming event is not 
limited to foetai system. Although recent study showed that adult BM contains 
CD5" B-1 ceii progenitor (Montecino-Rodriguez et al, 2006), the CD5" BM cells 
that generated in our in vitro culture are different from B-1 ceils due to lack of 
IgM expression (Fig. 5.10).
The origin of CLL is unknown, however, it is thought that mature B cells, such 
as naïve B ceils and memory B cells, are candidates due to their mature 
phenotype (Stevenson and Caiigaris-Cappio, 2004). Curiously, PKCa- 
expressing RAG-T^' cells also exhibited CLL-like phenotype (Fig. 5.5) that we 
observed in wiidtype mice. This suggests that this transformation is induced 
before pre-B stage, where B ceils in RAG-T^' mice stop development.
However, when aduit CD 19" splenocytes were infected with PKCa-KR upon 
LPS stimuiation and were cocultured with 0P9, they also displayed the CLL- 
phenotype. This is odd because adult CD19" splenocytes consist of 
populations of post immature B cells stage that express IgM on surface and 
thus, no late-pro-B cells (Martensson et al, 2002). To explain this controversy, 
there are two hypotheses. First, CLL is a heterogeneous leukaemia and thus 
PKCa-KR may target different developmental stages. For example, ALL is a 
heterogeneous disease with regard to clinical treatment response and 
prognosis, genetic changes resulted from chromosomal translocation and the 
involved causative proteins (Faded et al, 1998). Recently, clinically and 
genetically different ALL subtypes have been shown to originate and transform 
at distinct stages of haematopoietic development. p210 BCR/ABL1 fusions 
originated in HPCs, whereas p i 90 BCR/ABL1 positive leukaemic cells were 
derived from committed B ceil progenitors (Castor et al, 2005). Therefore, it 
may be plausible that PKCa mediated transformation result in different 
consequences depending which stage of cells PKCa targets. As another 
possibility, there may be two transformation points for CLL induction, one before 
late-pro-B cell stage and the other after immature B cell stage. If so, it may 
explain why the growth speed of PKCa-KR-expressing RAG-T^' FL cells was
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slower than that of wildtype FL cells, the latter can fully bear both signals for 
transformation. This may also describe why there were less CLL-like B cells in 
the PKCa-KR-RAG“T^"-HPCs injected mice compared to PKCa-KR-wildtype 
MFCs injected mice even though GPP'' population in the reconstituted mice was 
higher (PKCa-KR-RAG-T'-HPCs injected mice, GD19-*- B cell=20 %,
GFP^=29 %: PKCa-KR-wildtype-HPCs injected mice, GD19^ B cel!=70 %, 
GFP+=7.5 %; Fig. 5.8 and Fig. 3,13, respectively). The GFP' population in 
R A G - 1 m i c e  may not have developed as well as that in wildtype mice, which 
makes the GFP+ population look elevated. Thus, the GLL-like cells without 
BGR, such as PKGa-KR-RAG-1 '^expressing cells may not survive as long as 
the GLL-like cells with BGR. As a future study to define the specific 
transformation stage and establish the cellular population targeted for 
transformation by PKGa, distinct populations of developing B cells will be 
isolated using PGM sorting, and thus the ability of cells to be transformed by 
PKGa-KR will be examined. First, HPGs derived from wildtype mice FL will be 
infected with PKGa-KR and discrete developmental stages of GFP"^ B cell will 
be isolated based on the expression of multiple cell surface markers, as follows; 
HSG (GD117% S ca~r): pre-pro-B cells (GD19‘, Sca-TGD117%; pro-B cells 
(GD45R% GDI 9% GD24'"), and; pre-B cells (GD45R% GDI 9% GD24"') (Hardy 
and Hayakawa, 2001, Kondo et al, 1997). The subsequent population will be 
stained with GLL markers, such as GD5, GD23 and IgM, and will be analysed 
by PGM. This experiment will elucidate which stage of haemopoiesis has a 
potential to be transformed by subversion of PKGa.
The 0P9-DL1 cell line was generated by ectopicaliy expressing the Notch 
ligand DL-1 in the 0P 9 cell line, thus enabling the 0P 9 cell line to support the 
induction of T cell differentiation (Schmitt and Zûhiga-Pflücker, 2002). The 
results gained from 0P9-DL1 coculture showed that GFP^ PKGa-GAT- 
cocultures express GD4 and GD8 on surface larger percentage than MIEV 
control, in contrast, PKGa-KR-cocultures did not express GD4 or GD8. This is 
consistent with a previous report showing that PKGa-GAT expression in FT 
facilitated T cell differentiation, while PKGa-KR expression blocked T cell
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development (Michie et al, 2001 ). As we expected, 0P9-DL1 did not support B 
cell development, which is consistent with the findings that Notch 1 signalling 
blocks B cell development before or during pre-pro-B cell stage (Pui et al, 1999). 
Yet, as it was observed that B cells that have matured beyond the pre-B cell 
stage are able to grow in the coculture with 0P9 (Schmitt and Zûhiga-Pflücker, 
2002), it is not surprising to see a population of B cells in MIEV-0P9-DL1 
culture. B cell population in MIEV-0P9 culture started from 27 % at day 6, and 
it was slightly increased till 44 % at day 13. Whereas the leukaemic population 
of B cells generated by culturing PKCa-KR-expressing FL with 0P9 started 
85 % at day 6, and it was drastically decreased to 3.3 % at day 13 by co- 
culturing with OP9-DL1. Recently, it has been shown that Notch signalling 
induces growth arrest and apoptosis in malignant B cell via Hesi (Zweidler- 
McKay et al, 2005). Our results support this data, and thus the level of Hesi 
expression is of Interest for a further study.
Considering the previous study showed that high density of DL-1 facilitates T 
cell development and inhibits B cell development (Dallas et al, 2005), and 
constitutively active Notch 1 expression leads to T cell development fate and 
blocks B cell development at pre-pro-B cell stage (Pui et al, 1999), it is expected 
that 0P9-DL1 cells which express DL1 with high density on surface Interfere B 
lymphopoiesis and the B cell development is hindered at pre-pro-B cell stage. 
Thus, PKCa-KR-expressIng HPCs that committed to B cells before 
transformation events would not proliferate in T cell environment unless they 
are transformed early enough to escape from Notch-mediated B cell block, 
which support the early transformation by PKGa-KR expression.
Aitogether, it was shown that transformation events can occur before pre-B cells 
and possibly in an even earlier stage of B cell development. The progression 
of leukaemiagenesis could be hindered by Notch signalling. Further 
investigations are required to elucidate the origin of leukaemic cells as well as 
mechanisms of PKGa-KR mediated transformation.
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Figure 5.1 T cell development
Thymocyte differentiation is characterised by the expression of well-defined cell- 
surface markers, including CD4, CD8, CD44, CD25 and CD117 as well as the 
expression of either pre-TCR or TCR.
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Figure 5.2 Wildtype FT/BM-derived HPCs retrovlrally Infected with PKGa- 
KR display a growth advantage over GFP
Wildtype FT (top) and HPCs derived from adult BM (bottom) of ICR mice were 
retrovirally infected with MIEV and PKGa-KR and then cultured in our in vitro B 
cell generation system. During this period, the cultures were sampled and 
analysed by PGM for relative amounts of GFP expression, percentages as 
indicated. Histogram plots were live and size gated. These data are from a 
single experiment, representative of three separate experiments.
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Figure 5.3 Stable expression of PKCa-KR in wildtype FT and BM results in 
the development of CLL-like cells
Wildtype FT (top) and HPCs derived from adult BM (bottom) of ICR mice were 
retrovirally infected with MIEV or PKCa-KR and cultured in our in vitro B cell 
generation system, and then phenotyplcally characterised by FCM. The 
cocultures were harvested at day 15 (top) or at day 16 (bottom). Analysis of 
IgM vs. K ,  IgD vs. k , GD5 vs. GD2 and GD23 vs. GDI 9 expression are shown 
for GFP^ gated cells, percentages as Indicated. Contour plots were live and 
size gated. These data are from a single experiment, representative of three 
separate experiments.
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Figure 5.4 RAG-T^' FL-derived HPCs retrovirally Infected with PKCa-KR 
display a growth advantage over GFP cells
HPCs derived from R A G - 1 m o u s e  FL were retrovirally infected with MIEV, 
PKCa-KR, PKCÔ-KR or PKC^-KR and then cultured in our in vitro B cell 
generation system. During this period, the cultures were sampled and 
analysed by FCM for relative amounts of GFP expression, percentages as 
indicated. Histogram plots were live and size gated. These data are from a 
single experiment, representative of five separate experiments.
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Figure 5.5 Stable expression of PKCa-KR also renders CLL-like phenotype 
In HPCs derived from RAG-T^
HPCs derived from FL of RAG-T^' mice infected with MIEV, PKCa-KR, PKC5- 
KR and PKCÇ-KR were phenotyplcally characterised by FCM. The cocultures 
were harvested at day 18. Analysis of CDS vs. CD2 and CD23 vs. CD19 
expression are shown for GFP^ gated cells, percentages as indicated.
Contour plots were live and size gated. These data are from a single 
experiment, representative of five separate experiments.
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Figure 5.6 RAG-T^ BM cells retrovirally infected with PKCa-KR also 
display a growth advantage over GFP cells
RAG-1 mice BM cells were retrovirally infected with MIEV or PKCa-KR and 
then cultured In our in vitro B cell generation system. During this period, the 
cultures were sampled and analysed by FCM for relative amounts of GFP 
expression, percentages as Indicated. Histogram plots were live and size 
gated. These data are from a single experiment, representative of three 
separate experiments.
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Figure 5.7 Stable expression of PKCa-KR renders CLL-like phenotype in 
RAG-1  ^ ceils
RAG-1 derived BM cells Infected with MIEV or PKCa-KR were phenotyplcally 
characterised by FCM. The cocultures were harvested at day 16. Analysis of 
CDS vs. CD2 and CD23 vs. CD19 expression are shown for GFP+ gated cells, 
percentages as indicated. Contour plots were live and size gated. These 
data are from a single experiment, representative of three separate experiments.
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Figure 5.8 LN cells from PKCa-KR-Infected RAG-1'^-HPC-infected RAG-T^ 
mouse displayed a CLL-like phenotype
1 X 10® of either PKCa-KR- or MIEV-infected RAG-T^'-HPCs were I.p. Injected 
into RAG-T^' mouse. LN cells and tumour mass from reconstituted mice were 
analysed 6 week after the Injection. FCM was carried out on GFP and GFP"" 
populations, CD23 vs. CD19 and CD45R vs. CDS percentages as Indicated. 
Plots were live and size gated. This Is a representative experiment from three 
separate adoptive transfers.
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Figure 5.9 PKCa-KR-expressing-CD19^ splénocytes from adult wildtype 
mice showed growth advantage
CD19^ population in splenocytes derived from adult wildtype mice was enriched 
by MACS. CD19'" splenocytes were retrovirally infected with MIEV or PKCa- 
KR under stimulation with 50 |ig/ml LPS stimulation for 48 h and infected cells 
were cocultured with 0P9. During this period, the cultures were sampled and 
analysed by FCM for relative amounts of GFP expression, percentages as 
indicated. Histogram plots were live and size gated. These data are from a 
single experiment, representative of two separate experiments.
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Figure 5.10 Stable expression of PKCa-KR in CD19^ splenocytes from 
adult wildtype mice revealed CLL-like phenotype
CD19^ splenocytes were infected with MIEV or PKCa-KR whilst being 
stimulated with 50 ^.ig/ml LPS stimulation for 48 h and were phenotypically 
characterised by FCM. The cultures were sampled and analysed by FCM. 
Analysis of CD45 vs. IgD, CD45R vs. CD5, CD45R vs. IgM and CD23 vs. CD19 
expressions are shown for GFP^ gated cells, percentages as indicated.
Contour plots were live and size gated. These data are from a single 
experiment, representative of two separate experiments.
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Figure 5.11 Coculture with 0P9-DL1 inhibited growth of PKCa-CAT- 
expressing cells
Wildtype HPCs derived from FL of ICR mice were retrovirally infected with MIEV, 
PKCa-KR, and PKCa-CAT, and then cocultured with 0P9-DL1 cells that 
support T cell development. During this period, the cultures were sampled and 
analysed by FCM for relative amounts of GFP expression, percentages as 
indicated. Histogram plots were live and size gated. These data are from a 
single experiment, representative of three separate experiments.
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Figure 5.12A Notch iigation inhibited leukaemic ceiis' growth
Wildtype HPCs derived from ICR mice were retrovirally infected with MIEV, 
PKCa-KR, and PKCa-CAT, and then cocuitured with 0P9-DL1 ceils. The 
cocuitures were harvested at day 15 and phenotyplcally characterised by FCM. 
Analysis of CD23 vs. CD19, CD25 vs. CD117, and CD4 vs. CD8 expressions 
are shown for GFP+ gated cells, percentages as indicated. Contour plots were 
live and size gated. These data are from a single experiment, representative 
of three separate experiments.
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Figure 5.12B Notch ligation inhibited ieukaemic cells' growth
Wildtype HPCs derived from ICR mice were retrovirally infected with MIEV, 
PKCa-KR, and PKCa-CAT, and then cocultured with OP9-DL1 cells. The 
GFP^ cell number from the day 15 coculture was counted by PCM. The 
percentage was calculated against the number of MIEV coculture. The data 
are from a single experiment, representative of three separate experiments.
177
100 -
75 -
3  50 h
O
25 I-
0
PKCa- PKCa- MIEV 
CAT KR
** p < 0.0001 against MIEV 
p < 0.01 against MIEV
Figure 5.13A Leukaemic ceiis do not show CLL-iike phenotype upon 
cocuiture with 0P9-DL1, but they remain aberrant
Wildtype HPCs derived from ICR mice infected with MIEV were cocultured in 
either 0P 9 or 0P9-DL1 for 6 day. At day 6, haif of each coculture was 
exchanged into different feeder ceiis: step 1 : OP9-DL1 to 0P9-DL1 ; step 2: 
0P9-DL1 to OP9; step 3: OP9 to 0P9; step 4: 0P 9 to OP9-DL-1. The 
cocultures were phenotypically characterised by PCM at day 10 and day 13. 
Analysis of CD23 vs. CD19 expressions are shown for GPP+ gated cells, 
percentages as indicated. Contour plots were live and size gated. These 
data are from a single experiment, representative of three separate experiments.
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Figure 5.13B Leukaemic cells do not show CLL-iike phenotype upon 
cocuiture with 0P9-DL1, but they remain aberrant
Wildtype HPCs derived from ICR mice infected with PKCa-KR were cocultured 
in either 0P 9 or 0P9-DL1 for 6 day. At day 6, half of each coculture was 
exchanged into different feeder cells; step 1 : OP9-DL1 to 0P9-DL1 ; step 2: 
0P9-DL1 to 0P9; step 3: 0P9 to 0P9; step 4: 0P 9 to 0P9-DL-1. The 
cocultures were phenotypically characterised by PCM at day 10 and day 13. 
Analysis of CD23 vs. CD19 expressions are shown for GPP+ gated cells, 
percentages as indicated. Contour plots were live and size gated. These 
data are from a singie experiment, representative of three separate experiments.
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Chapter 6: 
General discussion
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6.1 What mechanisms underly the subversion of PKCa generating CLL- 
llke cells?
PKCa-KR-expression generated CLL-iike cells with a reduction in PKC activity, 
which may occur as a consequence of discretely targeting PKCa activity. The 
ability to induce the development of CLL in HPCs appears to be a unique 
property of this isoform, PKCa, as subversion of PKCô or PKC^ did not induce 
leukaemiagenesis. PKCa activation has generally been associated with the 
generation of anti-apoptotic cell responses (Jiffar et al, 2004, Ruvolo et al,
1998), however it is becoming apparent that the biological outcome of PKCa 
activation, whether it is survival or apoptosis is dependent on the cell type being 
studied (Michie and Nakagawa, 2005). As there is growing evidence that 
PKCa and PKCô antagonise each other in order to regulate survival or 
apoptosis in a number of cell types (Hornia et al, 1999, Mandil et al, 2001 ) these 
studies, coupled with those of Ringshausen et a i, suggest that upsetting the 
balance of either of these isoforms may enable apoptosis of CLL cells 
(Nakagawa et al, 2006, Ringshausen et al, 2006).
BAFF and APRIL are IN F  family ligands that are critical cytokines for 
maintenance of normal B cell development and homeostasis (Schiemann et al, 
2001, Schneider et al, 2001, Thompson et al, 2000). Recent reports showed 
that BAFF and APRIL are expressed in CLL cells (He et al, 2004, Kern et al, 
2004) and moreover, BAFF-R and receptors for both BAFF and APRIL, BCMA 
and TACI (Schneider, 2005) are expressed on CLL cells (He et al, 2004). The 
soluble forms of BAFF and APRIL prevented spontaneous/drug-induced 
apoptosis (Kern et al, 2004, Novak et al, 2002), suggesting autocrine secretion 
of these cytokines rescue CLL cells from apoptosis. To understand the 
mechanism of how PKCa-KR expressing cells evade apoptosis, it could be 
determined whether BAFF/APRIL and their receptors are expressed in our CLL- 
iike cells by FCM. If expression of either BAFF or APRIL or both is determined, 
then anti-BAFF and -APRIL antibody could be added to the serum to block the 
autocrine survival action of BAFF/APRIL, and the apoptosis rate of CLL cells 
could be examined.
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It is unknown how PKCa mediates transformation. A possible explanation is 
that PKCa phosphorylates and activates tumour suppressor downstream and 
therefore, the reduction of PKCa activity diminishes the tumour suppressing 
function. For example, the rasGTPase activating protein-associated docking 
proteins, Dok-1 and Dok-2 act as tumour suppressors of CIVIL, as demonstrated 
by the development of CIVIL in Dok-T^ Dok-2'^' mice (Niki et al, 2004, Yasuda et 
al, 2004). In addition, reports establish that the signalling molecules SLP-65 
(also known as BLNK/BASH) and Btk act as tumour suppressors in B 
lymphocytes, as evidenced by the observation that SLP-65'^' and SLP-65'^'Btk'^' 
mouse models display a high incidence of pre-B cell lymphomas (Flemming et 
al, 2003, Jumaa et al, 2003, Kersseboom et al, 2003). Detailed mechanisms 
remain unknown and need further examination.
6.2 Do CLL cells proliferate?
Two hallmarks of CLL is a defect in apoptosis and cell cycle arrest in the Gq/G  ^
phase (Bannerji and Byrd, 2000). Yet, some studies showed that CLL cells are 
able to proliferate in the proliferating compartment (Ghia et al, 2002, Schmid 
and Isaacson, 1994) and the turnover between birth and death of the leukaemic 
cells is more vigorous than previously thought (Messmer et al, 2005). 
Proliferating CLL cells are KI67 positive (Ghia et al, 2002, Granziero et al, 2001) 
and a member of the lAP family, survivin positive (Granziero et al, 2001 ). In 
addition, it seems that the stimulation provided by CD40L, which is mainly 
expressed on CD4'*' T cells, causes proliferation of CLL cells (Caligaris-Cappio, 
2003, Fluckiger et al, 1992), and induces RNA expression of T cell attracting 
chemokines, CCL17 and CCL22 (Ghia et al, 2002). Thus, CLL does not 
appear to be a static disease that results of accumulation of long-lived 
lymphocytes, but rather consists of two phases, an accumulation and a 
proliferation phase (Caligaris-Cappio, 2003). The results in this thesis showed 
that our CLL-iike cells exhibited prominent proliferation capacity in vitro and in 
vivo, but the cell cycle of tumour cells in vivo are arrested at the Gq/Gi stage, 
thereby presenting two different phases. In order to understand what
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mechanisms control proliferation, it would be interesting to determine the 
expression level of molecules that regulate proliferation, such as survivin, 
CCL22, CCL17, CD40, at the protein or transcript level by Western or RT-PCR, 
respectively. Although IL-4 is often examined for its role for CLL cell survival 
and proliferation, the results are still controversial (Fluckiger et al, 1992, Luo et 
al, 1991) in human CLL. The importance of IL-7 in CLL is not highlighted.
This is probably because IL-7 in human B cell development is less essential 
than murine system (Fry and Mackall, 2002), therefore our murine CLL system 
may be substantially different from human CLL system regarding the 
dependence on cytokines. In our murine CLL system, IL-7 is a crucial cytokine 
for proliferation. IL-7 is secreted from multiple stromal tissues including spleen 
(Jiang et al, 2005), therefore, splenocytes and LN cells in PKCa-KR-injected 
mice access IL-7 and proliferate under the physiological concentration of IL-7. 
However, the cells from i.p. tumour mass probably could not obtain IL-7, thus, 
arresting the cell cycle at the Gq/G i stage.
6.3 Do CLL cells need stromal cells?
CLL cells die spontaneously in vitro, however, survival of CLL cells is promoted 
when stromal cells are added to cultures (Lagneaux et al, 1998). Tsukada et 
al., have described that a subset of CDM"" blood mononuclear cells can 
differentiate in vitro into large, round, adherent cells that contact with leukaemic 
cells and protect them from undergoing apoptosis in vitro and called these cells 
NLCs (Tsukada et al, 2002). The phenotypic characterization of NLCs 
suggests that they are related to stromal cells and NLCs prevent CLL cells from 
apoptosis by producing SDF-1, the chemokine that regulates B lymphopoiesis 
(Burger et al, 2000). Indeed, our CLL-iike cells survived and even proliferated 
when they cultured with stromal cell line, 0P9, in the presence of IL-7.
Moreover, adherent, bigger CD5^ cells were identified during the culture of M-1 
cells (data not shown). These adherent cells may be NLCs in our system and 
help survival of long cultured M-1 cells. As a future direction, NLCs from M-1 
cell culture will be isolated and phenotypically characterised, and assessed for 
their ability to secrete any chemokines or cytokines.
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6.4 What is the role of BCR in CLL?
The BCR includes membrane Ig homodimer and the noncovalently bound 
disulphide-linked Iga and lg(3, which forms oligomeric complexes Inside to 
process and amplify signals. Both Iga and lg|3 play a key role in receptor 
expression and signal transduction through their ITAMs, and engagement of 
BCR induces phosphorylation on ITAMs, leading to recruitment of Src tyrosine 
kinase family including Syk and activation of intracellular signalling cascade 
(Gauld et al, 2002b). Signals delivered through the BCR may have different 
consequences depending on the stage of maturation of the cells, and thus BCR 
ligation results in apoptosis for immature cells or in proliferation for mature cells 
(Carey et al, 2000). Previously, Zupo et al., reported that anti-IgM treatment of 
CD38+ CLL cells causes apoptosis (Zupo et al, 1996), but Bernal et ah, reported 
that IgM ligation causes survival of CLL cells in the PI3K dependent way (Bernal 
et al, 2001 ). Nédellec et al., examined 41 cases of CLL and categorised the 
cells on the basis of Ca^^ mobilisation upon surface IgM cross-linking: Group I; 
not respond. Group Ha; responded and proliferated, Group lib; responded and 
apoptosed (Nédellec et al, 2005). Group Ha proliferated in a PI3K- and PKC- 
dependent manner, and ERK and PI3K were activated upon IgM ligation. In 
contrast, ERK and PI3K were inactive, but p38 is activated upon IgM 
engagement in Group Hb (Nédellec et al, 2005). CLL consist of heterogeneous 
cells, thereby it is not surprising that the response was varied.
ZAP-70, which is a receptor associated protein tyrosine kinase, is detected in 
most unmutated CLL cells (Rosenwald et al, 2001, Wiestner et al, 2003) and 
the ZAP-70 expression status is mostly correlated to clinically poor prognosis 
(Crespo et al, 2003, Orchard et al, 2004), thus ZAP-70 is an important clinical 
marker. Recent reports demonstrated that the level of Syk phosphorylation 
upon IgM cross-linking is greater in ZAP-70 positive CLL cells (Chen et al,
2002) and unmutated CLL cells (Lanham et al, 2003). Moreover, there are 
reports that CLL cells expressing CD38, a CLL clinical marker for poor 
prognosis, are more sensitive to IgM stimulation (Lanham et al, 2003, Zupo et al, 
1996). This suggests that the expression of ZAP-70 and CD38 in CLL allows
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more effective IgM signalling in CLL cells, which could contribute to the more 
aggressive course observed in ZAP-70 and CD38 positive CLL cells, mostly 
consisting of unmutated forms. The results presented in this thesis 
demonstrated that subversion of PKCa generates CLL-iike cells, however, the 
expression levels of relevant clinical markers, such as ZAP-70 and CD38 
remain undetermined. ZAP-70 is found abundantly in both human and murine 
T cells. Surprisingly, recent studies established that a subset of normal human 
B cells (Nolz et al, 2005) and normal murine B cells at the most stages of 
development (Schweighoffer et al, 2003) expressed ZAP-70 although there 
seems a difference in the expression level and cell type between human and 
murine system. Interestingly, murine ZAP-70 appears to be inducible by IL-7 
(Meade et al, 2004), which is a proliferation inducing cytokine in our system. 
Analysis of ZAP-70 expression level by FCM in the presence/absence of IL-7 
using our CLL system and comparison with that of MIEV may be useful for 
further understanding how our CLL-iike cells transduce survival/proliferation 
signal to sustain malignancy. The amount of apoptosis/proliferation and the 
levels of Syk phosphorylation upon IgM engagement would also be interesting 
to be assessed. The outcome of IgM ligation will be linked to the expression 
level of either ZAP-70 or CD38 or both, thereby further characterising our CLL- 
iike cells.
Although the survival of our CLL-iike cells appears to depend on ERK and/or 
PI3K pathway, the response to IgM ligation or the signals involved have not 
examined. Therefore, further studies will investigate how PI3K-, ERK- and 
PKC-pathway are modulated when our CLL-iike cells are treated with those 
pathway inhibitors upon IgM ligation by looking at expression level of particular 
signalling molecules, such as pAKT and pERK.
6.5 What stage do CLL cells mature at?
Somatic mutations in the Ig genes occur at GC during maturation of the B cells 
en route to production of high-affinity antibody. CLL can be divided into 2 
subsets distinguished by the incidence of somatic mutations in the Ig Vh genes
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(Stevenson and Caligaris-Cappio, 2004), and patients bearing unmutated 
genes have a poorer clinical outcome compared to those with mutated V genes 
(Hamblin et al, 1999). If the development of IgV^ gene mutations requires 
BCR crosslinking/antigen stimulation, CLL cases with mutated V gene must 
have arisen from previously stimulated B cells, which is considered as memory 
B cells by similarity in phenotypical analysis (Klein et al, 2001, Rosenwald et al, 
2001 ). Un mutated CLL is believed to be derived from a naïve B cell before 
entering a GC, or alternatively, from cells that did encounter antigen but it may 
have not been sufficient to induce antigen-stimulated maturation in a GC, 
thereby carrying germline IgV (Damle et al, 2002, Stevenson and Caligaris- 
Cappio, 2004). It has not been resolved whether this lack of mutations is 
either a consequence of the type of antigenic stimulation or a result of the timing 
of the transformation event. However, considering the results presented In this 
thesis regarding the transformation in R A G - 1 m i c e  and CD19^ adult BM cells, 
it is suggested that transformation can be initiated at different stages of B cell 
development, prior to the pro-B stage or post immature B cells stage. Thus 
PKCa-KR may target different population of cells and result in CLL with similar 
phenotype. A malignant cancer stem cell population has been identified in 
other leukaemias, such as AML (Bonnet and Dick, 1997), ALL (Cobaleda et al, 
2000) and chronic myeloid leukaemia (CML) (Holyoake et al, 1999). The 
cellular origin of cancer stem cells has not been clarified, but they have a self­
renewal ability to generate additional cancer stem cells and can differentiate to 
generate phenotypically diverse cancer cells. Therefore, a possibility cannot 
be excluded that CLL originates from cancer stem cells at least in our system, 
and thus, PKCa-KR may target the HPC population. In order to define the 
origin of CLL, HPCs will be retrovirally infected with PKCa-KR, and distinct 
populations of developing B cells will be isolated using FCM sorting with the 
virtue of GFP+and the expression of surface markers: HPC (CD117^, Sca-T); 
pre-pro-B cells (CD19', S ca -rC D 1 17"); pro-B cells (CD45R", CD19", CD24'°), 
and; pre-B cells (CD45R", CD19", CD24'’’) (Hardy and Hayakawa, 2001, Kondo 
et al, 1997). The developed population will be stained with CLL marker, such 
as CDS, CD23 and IgM, and will be analysed by FCM. This experiment will
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elucidate which stage(s) of B haematopoiesis has a potential to be transformed 
by subversion of PKCa. Furthermore, a limiting dilution analysis will be 
performed to determine the frequency of transformation into CLL cells from 
each developmental stage.
6.6 Concluding remarks
These studies provide vital information regarding a unique oncogenic trigger for 
the development of a CLL-iike disease resulting from the subversion of PKCa 
signalling. Further investigation will uncover novel avenues not only for the 
study of the induction and maintenance of CLL, but also for the development of 
potential diagnostic tools and therapeutic drugs to identify and combat CLL.
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